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Abstract
Background
Over the past few years, Genome Wide Association Studies (GWAS) have identified thousands of genetic
variants that are associated with a wide range of complex traits, and have provided valuable insights
as far as their genetic architectures are concerned. In malaria studies too, GWAS has been successful
and a number of genetic variants have been identified. Despite the success, the complete aetiology of
malaria, and many complex traits in general, remains poorly understood. A key concern is that the missing
heritability remains too large, with some of the variants identified in some populations failing to replicate
using independent study populations. Indeed comparable sources have revealed that the statistical power of
association studies can be improved either via genotypes imputation approaches or by treating the whole
genome of an individual as a risk predictor using Polygenic Risk Scores (PRS). However, imputation
remains at modest in Africa populations with few (or no) studies (study) have evaluated the potential of
imputation tools in African populations. On the other hand, although the utility of PRS has been shown in
other studies, it has neither been assessed in African population nor applied in an infectious disease, like
malaria.
Methodology
We evaluated the performance of five popular genotypes imputation methods (IMPUTE4, minimac 4,
IMPUTE2, minimac3 and BEAGLE4) using case control datasets that mimics African populations,
European populations and the admixed populations simulated with FractalSIM. We assessed imputation
performance based on internal imputation quality metrics and the genotypes concordance. We applied the
best imputation tool based on the assessment results to impute raw genotypes data of severe malaria case
control studies from MalariaGEN of three African populations: Kenya, The Gambia and Malawi. Similarly,
we obtained summary statistics of the same datasets, and imputed the summary statistics with ImpG. We
performed an association on the imputed raw genotypes, and compared the association results with that of
ImpG based imputation. Additionally, we performed meta-analysis with METASOFT, and compared the
meta-analysis result of ImpG based imputation and that from imputed raw genotypes associations. Finally,
we assessed five PRS methods (PRSice, LDpred(p+t), PRSoS, PLINK and PRScS) in predicting genetic
x
risk in African population, and applied the best PRS method to predict the genetic risk of severe malaria.
Results
IMPUTE2 recorded the best performance based on imputation accuracy and concordance for the African
(accuracy=80.21% and concordance=99.2%) and the admixed samples (accuracy=69.46% and concor-
dance=90.92%) for variants with MAF>0.05. Other tools recorded similar accuracy and concordance
although BEAGLE 4 recorded the lowest concordance and accuracy across all the African and admixed
datasets. For the real genotypes data, no SNP attained the genome wide significant threshold of 5.0× 10−8
for Malawi and the Gambia datasets. However, for the Kenyan dataset, 9 SNPs on chromosome 11 were
significantly associated with severe malaria. 3 of these SNPS were located on the HBG2 genes and the
remaining 6 had not been reviewed. No SNP attained the genome wide threshold for the ImpG imputed
summary statistics for all the populations. For IMPUTE2 based meta-analysis, only one SNP rs12295158
located on the HBB region was significant across all the meta-analysis model (with P-value of 2.88× 10−12
for fixed (FE), 2.88× 10−12 random (RE) and 9.64× 10−12 binary effect (BE) respectively). On the other
hand ImpG based meta-analysis, two SNPs were signicant across all the meta-analysis model (rs183731078
located on RFX3 with P-values of 8.40× 10−9, 8.40× 10−9, 4.47× 10−8 for FE, RE and BE respectively,
and rs8096513 located on DLGAP1 1.43× 10−9, 1.43× 10−9, 1.01× 10−8 with P-value for FE, RE and
BE respectively). Pathway enrichment and analysis of these genes revealed that both of these genes are
associated with malaria. Finally, for the PRS, PRSoS recorded the best performance based on Nargalkerke’s
R2 (0.01736) and area under curve (AUC) (0.511). Other PRS methods recorded slightly similar results
with PLINK recording the least. The odds of having severe malaria was estimated as 2.869, and a unit
change of PRS scores was associated with -5.143 change in odds of having severe malaria with P-value of
0.0193 at α = 0.05. However, the scores could only explain 1.28% of the phenotypic variance.
Conclusion
Our results provide foundation for future studies in genetics, especially in African population, where the
best performing imputation tool remains a mystery. Moreover, our results have demonstrated the potential
of application of PRS in infectious diseases.
xi
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Chapter 1
Introduction
1.1 Overview
Malaria is one of the oldest infectious diseases that continues to be among the leading causes
of morbidity and mortality across the world. Characteristics symptoms of malaria were first
described by Neu ching, the Chinese medical canon [1], and were first edited by emperor Huang
Ti, and can be traced back to as early as 2700 BC. It was also documented by most of early
civilized societies like Greek, Roman, Indian and Arabs [1]. The characteristic symptoms are
manifested inform of fevers, chills, general malaise, headaches, nausea and vomiting, body aches
among others [2].
Malaria infection in human is caused by a protozoan parasite of genus Plasmodium [3]. It is
transmitted to human being by a bite from a female anopheles mosquito [2]. Five known species
of plasmodium parasites cause malaria in human i.e Plasmodium falciparum, Plasmodium vivax,
Plasmodium ovale, Plasmodium malariae and Plasmodium knowlesi [4, 5]. Of the five known species of
Plasmodium genus, Plasmodium vivax is the most widespread and Plasmodium falciparum is the
most virulent, and is the cause of high morbidity and mortality, especially in Africa [4, 6].
Despite the fact that malaria can be prevented by mosquito vector controls through use of
mosquito nets, removal of breeding sites of mosquitoes and use of insecticides, among other
effective case managements that have been advocated by World Health Organization (WHO), it is
only drugs that can cure an infection from malaria [1]. While malaria continue to claim more
lives with death toll rising every year, attempts to reduce this burden in most cases are thwarted
by the fact that malaria parasites keep on developing resistance to the anti malarial drugs that
are being invented [4, 6]. This has presented a serious health challenge and has consequently
made its elimination and control very difficult [7]. Although efforts have been made to come up
1
with an effective vaccine that can prevent an infection from falciparum malaria, which is the most
common and the most dangerous form of malaria in Africa, none has so far materialized [3]
One challenge in eliminating malaria is the understanding complex interaction that emanates
from the parasite and the host [3]. These complex interactions have made the organisms to
evolve strategies that have resulted into signatures of selections being exerted on the parasite
genomes by the human host, and parasite too exerting footprints of malaria selection on the
human genomes [3]. Other factors that adds more complexities to these interactions include
environmental factors, parasite virulence, transmission intensity, different genetic background of
the host among others [8]. It is therefore very important to understand the molecular basis or
mechanism of these interactions, and a comprehensive understanding of the host and parasite
factors [3]. Such understanding can inform the development of effective antimalarial drugs,
effective vaccines and can also be applied in the risk prediction strategies [9].
On the other hand, Genome Wide Association Studies (GWAS) has been applied in the identi-
fication of variants associated with susceptibility or risks in complex traits, and for understanding
the genetic architecture of complex traits [9]. Similarly, in malaria studies too, GWAS has been
successful and a number of genes that confer susceptibility and protection against malaria have
been identified [10]. Nevertheless, the overall contribution of the human genetics factors on
malaria risk remains very low. Mackinnon et al. [11] for example used a pedigree data and
estimated the overall host genetic factors to be approximately 25% [11]. This is similar to a recent
study in Tanzania which reported that approximately 22% of the total variation in malaria risk
can be explained by the genetics factors of the host [12]. While cognizant of the fact that it is
difficult to generalize the overall estimate of the host genetic factors that contribute to a disease
like malaria that involves the interaction of both genetic and environmental factors, which are
inseparable in most study designs [11], and with the implicated variants being population or
location specific [12] , it is clear that these estimates are still very low. Furthermore, most of
these associations never replicated in different populations and several conflicting findings have
been reported as well [13, 14]. By the fact most of the studies have failed to replicate or showed
conflicting results implies that either the current studies are underpowered and much of the
variation is still unexplained or missing [10], or the study approaches that have been applied so
far do not address the overall picture. For this reason, more research is still needed to unravel
these unexplained genetic variations. The question is then whether several association signals
across the genome, whose effect sizes are too small to attain the stringent genome wide threshold
could explain the remaining source of the genetic variation [15] or can more power be gained by
including more variants into the study using different approaches?
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One way of utilizing the variants that have small effect sizes, that in most cases do not meet
the stringent GWAS threshold, is by treating the whole genome as a risk predictor [16], a concept
that is well implemented in polygenic risk scoring methods [16, 17, 18] and linear mixed models
[15]. Yang et al. for example used linear mixed model software (GCTA [15]) and illustrated
that much of heritability of a trait can be accounted for by evaluating the effect of all SNPs [15].
Similarly, Ripke et al. [19] applied PRS in schizophrenia and showed that a large number of
markers, actually up-to half of the total markers, were jointly associated with schizophrenia as
opposed to the initial study which only identified a few of the variants. Indeed both polygenic
score and linear models have been used to infer a wide range of complex traits to the extent that
it is now generally accepted that all complex traits are polygenic [16]. Malaria being a complex
trait [11, 13] trait is therefore no exception.
Another way of accounting for the remaining unexplained genetic variation in a disease like
malaria is through imputation approaches. By including the variants that are not typed into
the study, imputation increases the likelihood of finding the true causal signal of a disease [20].
Moreover, imputation can combine several studies through meta-analysis thus increasing the
power [20]. Although imputation has been applied in genetics studies of African populations,
up-to date no study has evaluated and hence recommended the most appropriate tool that
can accurately handle African populations, that is known to have high genetic diversity and
sub-structure.
Here in this project, we will focus on how the power of GWAS can be improved: first via
imputation approaches and second using Polygenic Risk Score methods, in estimating the risk
of malaria in African populations. We therefore evaluate the potential of genotypes imputation
tools and present a recommendation of the most accurate tool that will guide future studies,
particularly for the African populations. We moreover review and evaluate the polygenic risk
score methods and finally, we apply the best PRS method in genetic prediction of malaria.
1.2 Key Concepts in Genetic Variation
1.2.1 Polymorphism
Polymorphisms are the variations in the human DNA sequences. These variations are what
makes individuals unique and also determines an individual risk or susceptibility to a given
trait or disease. The most common form of variations are the Single Nucleotide Polymorphisms
(SNPs), that are popularly referred to as modern unit of genetic variation [21]. These variations
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occur at specific loci of the genome, and can occur during DNA replication in which a single base
pair may be left out, replaced or a single base pair might be added. In most cases, SNPs have two
alleles and the frequency of a SNP in a population is given in terms of the frequency of the less
common allele. This frequency is referred as the minor allele frequency [21].
1.2.2 Hardy Weinberg Equilibrium
Hardy Weinberg Equilibrium (HWE) describes how alleles/genotypes frequencies in a given
population are inherited from generation to generation. It assumes that in the absence of
migration, natural selection, mutation, and assortative mating the genotypes frequency tend to
remain constant in a diploid population [22, 23]. Therefore, the genotypes frequencies under
HWE can be estimated from the allele frequencies [22, 23]. It is very important to check if the
observed genotypes of the target sample deviates from HWE [24]. Deviations from HWE raises
a signal and could imply either genotyping error or problems with the population structure or
it could also indicate the presence of selection [24]. Samples that deviates from HWE must be
corrected or excluded from further analysis to avoid spurious associations [21].
To illustrate the concept of HWE, let N be the number of unrelated subjects of diploid
populations. Suppose 0 is the reference allele and 1 is the alternate allele. Denote the frequency of 0
as f0 and that of 1 as f1. By diploid, there are 2N alleles so that the frequency of f0 =
2N00+N01
2N = p
and, f1 = 1− f0 = 1− p = q. For the first generation,
p + q = 1 (1.1)
And for the second and subsequent generations,
p2 + 2pq + q2 = 1. (1.2)
Thus by HWE, the expected genotype frequencies of 00, 01 and 11 are given by the following.
f00 = p2
f01 = 2pq
f11 = q2
Observed genotype frequencies and the expected genotype frequencies from HWE can be com-
pared using Pearson Chi-Square test for goodness of fit, Fisher exact test among others [24].
However, Fisher exact test is more preferred since it does not rely on the chi-square approximation,
which can be poor when the genotypes counts are low [25]
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Results from HWE can well be interpreted using qq plot of the log of p-values. Deviations
from the y = x line signifies deviations from HWE.
1.2.3 Linkage of Disequilibrium
Linkage of Disequilibrium, abbreviated as LD, is the correlation of alleles at one SNP to alleles at
another SNP within a population [22]. Typically, it describes the degree with which allele at one
SNP is inherited or correlated with an allele at another SNP within a population [26]. Thus, LD is
used by the geneticist to describe changes in genetic variation within a population over time [27].
In a population of fixed size, LD decays over time due to random mating. This in particular
leads to repeated random recombination of events which breaks away segments of contiguous
stretches of chromosomes from founder generation sequentially until all the alleles in the contigu-
ous chromosome segments are independent or are in linkage equilibrium [21, 27]. The rate of LD
decay depends on population size, number of founder chromosomes in the population and the
number of generations the population has existed [26].
Different populations have different patterns of LD [21]. African descent population in
particular have smaller regions of contiguous chromosomal stretches hence smaller regions of
LD [22]. This is due to the fact that African population is the most ancestral thus has undergone
more recombination of events than any other population [21].
LD can be quantified by many measures although D
′
and r2, which have been showed to be
highly correlated, are commonly used [21]. However, LD is mostly reported in terms of r2 as
explained by [21]. To illustrate how D
′
and r2 measures LD, let AB and ab be two SNPs at two
loci. Denote the frequency of AB as fAB and fab, fAb, faB to be the frequency of ab, Ab and aB
respectively. Then,
D
′
=

fAB fab− fAb faB
min ( fA fb, fa fB)
if fAB fab − fAb faB > 0
fAB fab− fAb faB
min ( fA fB, fa fb)
if fAB fab − fAb faB < 0
(1.3)
D
′
= 0 implies complete linkage of equilibrium between two SNPs/markers [21]. This signifies
frequent combinations between two SNPs and statistical independence under HWE. D
′
= 1
means complete LD thus indicates no recombination between the two markers.
r2 =
( fAB fab − fAb faB)2
fA fB fa fb
(1.4)
The interpretation of r2 is similar to the interpretation of D
′
[21].
When two SNPs are in LD, then only one SNP needs to be genotyped to capture the variation
at nearby sites in the genome, hence preventing genotyping of SNPs that are redundant [21].
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The SNPs that are selected to capture the variations in the nearby regions of LD are called tag
SNPs. It is important to note that tag SNPs selected for a given population may not work well for
another population since LD is population specific [21]. The tag SNPs are particularly useful in
the design of custom genotype array for a specific population.
1.2.4 Genome Wide Association Studies
Overview
Genome Wide Association Studies (GWAS) are studies that examine SNPs or genetic variations of
thousands of individuals to identify the genetic variants which are associated with a particular
trait or risk of a disease [27]. GWAS can be conducted at either family-based level or at a
population-based level or both. However, the most common study design in GWAS are those
that involve case/control study design. The main objective of GWAS is to identify the genetic
variants that cause common diseases, and to understand how these genetic variants contribute to
a particular trait or risk of a disease, with the assumption of common disease common variant
hypothesis [21]. The understanding can be applied in predicting those who are at risk in a
population [21, 27].
GWAS is actually the most efficient way to discover the genetic variants associated with a
disease when we have very little molecular knowledge of the disease and has been applied in
developing better treatment and prevention strategies, using results from the GWAS findings
[21, 24]. Association analysis in GWAS is done by comparing the frequencies of genotypes or
alleles between cases and controls [21, 24]. There are many strategies for performing association
analysis in GWAS. However, Single SNP scan, which sequentially examines each SNP with the
null hypothesis that there is no association, is more popular hence most commonly used [24].
GWAS association tests, that are used especially if the phenotypes are quantitative includes linear
regression, analysis of variance, and for binary traits, logistic regression is preferred [24].
Despite successfully identifying thousands of SNPs that are associated with complex traits or
diseases, most of results from GWAS have only accounted for a small proportion of the phenotypic
variation. Below, we discuss current challenges in GWAS particularly in African populations.
Current Challenges in GWAS
Advancement in technology has made it possible to measure millions of SNPs at a cheaper
cost, thus making studies utilizing GWAS common. This has indeed revolutionized the field of
genetics with thousands of alleles that influence disease risk being discovered and replicated
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across studies. However, despite the success, just a few of the loci identified via GWAS are
associated with large or moderate disease risk, with some of the well known disease risk being
missed by these associations. As a matter of fact, the genetic variance explained by GWAS
findings is disappointingly low which has raised questions as far as their relevance or utility
in risk assessment is concerned, and application in personal genetics, or their suitability in
genetics testing [28]. Below, we give current challenges in GWAS studies, especially in a resource
constrained continent like Africa.
African studies have lower levels linkage of disequilibrium, hence require denser genotyping
arrays than the ones that are currently available. For example, based on HapMap from a single
ethnic groups, it is estimated that 1.5 million SNPs from African populations have the same
statistical power as 0.6 millions SNPs of European study [10]. This implies that larger number of
SNPs are needed to achieve adequate statistical power across different ethnic groups in Africa
[10].
Despite the fact that large sample sizes are possible to obtain, the greatest limitation is
obtaining well characterized samples [29]. African samples, in particular, are characterized by
high levels of ethnic diversity. This again, may lead to false positive association due to population
structure. For example, Jallow et al. examined the possibility of false positive findings using
402,814 SNPs from 958 cases and 1,382 controls from The Gambian [10]. Interestingly, they found
a high false positive association test statistics of λ = 1.23 in the raw data, which reduced to
λ = 1.07 after accounting for the self reported ethnicity [10]. Additionally, variation of haplotype
structure (which is common in African populations) among groups may reduce the power of
association especially when data across multiple study sites are combined [10]. For example,
band et el. [30] showed how the patterns of association of HbS differs across different populations
in Africa.
Another challenge is handling large datasets [31]. GWAS datasets are typically very huge and
are computationally intensive to analyze [31]. Thus, successful GWAS analysis require powerful
computers with very many processors and high storage capacity. Although efficient strategies
using distributed architectures, like clusters, cloud based systems, and super computers, have
been proposed, these resources are very expensive and are not within reach to some of the
institutions in the developing countries [32], like in Africa. This therefore makes it impossible for
them to conduct such studies.
Disappointing results from GWAS also presents a very big challenge to researchers. So far,
variants that have been identified to be significantly associated with a trait have weak relative
risk ranging from 1.0 to 1.2, which is too weak to be applied in genetics testing [33]. Moreover,
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missing heritability is still very large for most of the traits. In height for example, which is known
to be highly heritable trait, 40 variants were found to be significantly associated with height for
tens of thousands of individuals. However, these loci accounted for only 5% of the phenotypic
variation , which is far much below the theoretical estimate of heritability, which is approximately
80% [34]. This therefore, raises questions about the utility of GWAS as disease classifier and their
usefulness in risk assessment in personal genetics [35]
Finally, another challenge in GWAS is that results from GWAS cannot be directly translated
into an immediate clinical use. As Du et al. [31] put it, that the cost of conducting quality GWAS
is very high and the end result will actually attract high impact journal however translation to
immediate clinical use is still lacking. This therefore raises the question whether GWAS researches
are just for publication or health oriented or the chip companies are intended beneficiaries for
GWAS [31].
1.3 Overview of Polygenic Risk Scores (PRS)
Polygenic Risk Score (PRS) analysis is one of the most popular and current methods for sum-
marizing the effect of a collection of variants [36]. Using a single score for each individual in
the study, PRS sums the risk alleles corresponding to a given trait or disease for an individual,
weighted by the estimates of the effect sizes from GWAS published result or meta-analysis [17].
Typically, PRS summarizes the whole genome wide data of each individual in the study into a
single variable which can then be tested for the association with a trait of interest, and can used
as a measure of an individual liability or tendencies to a trait or phenotype of interest [36].
Polygenic methods uses two datasets; the first dataset is referred to as the training or the
discovery dataset [16]. This dataset is used to estimate the effect sizes for each SNP, which are
then selected according to some P-Value threshold [16]. The second dataset is called the target
dataset, from which the PRS are calculated for each subject by calculating the weighted sum of
the risk alleles using only the SNPS selected from the training sample [16].
To illustrate how PRS works, let y to be a vector of phenotypes of n unrelated or independent
individuals in the target sample and G to be an n× q matrix of genotypes, where Gi is a vector of
genotypes dosages for individual i in the target sample.
PRS of an individual is defined by the following [18].
PRSi =
M
∑
j=1
βˆ jGij (1.5)
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Where βˆ j in 1.5 is the effect size estimate for SNP j from the training sample and Gij is the
genotype dosage of the target sample, j ∈ {1, . . . , M} and i ∈ {1, . . . N} and N is the number of
individuals in the training sample.
There are several PRS methods but the basic idea is the same. Figure 1.1 illustrates how PRS
scores can be obtained and applied in association analysis.
Figure 1.1: An illustration of how PRS scores are obtained and applied in the association analysis.
Here in this thesis, We will give a brief review of some of the popular PRS methods, discussing
various aspects of their implementation.
PRS has been applied in studies like Schizophrenia, cancer, continuous traits like height among
others [19, 37, 38]. Despite the fact that evidence from malaria GWAS suggests that malaria
could be polygenic [10]. To date, no literature has been published that illustrates the potential
of PRS application in malaria, and in infectious diseases in general. By the fact that genetic
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factors identified to date only explain a small proportion of the malaria risk, and that most of the
variants identified had effect sizes that did not meet the stringent GWAS threshold implies that
more insights can be gained by evaluating the overall effect of all the variants in each individual.
Indeed, comparable sources have suggested the existence of polygenic inheritance in malaria in
some of the early publications [11, 13]. In the preceding chapters, we will discuss malaria and the
genetic susceptibility, and attempt to answer the question whether malaria is polygenic or not.
We will finally attempt to predict the risk of malaria using the PRS.
1.4 Malaria and The Human Genetic Susceptibility
1.4.1 Overview
Early findings suggests that in Africa alone, P. falciparum records approximately 500 million
cases [39], killing in the order of a million African children every year [10, 40]. P. falciparum is
considered the deadliest due to the fact that it can attack all red blood cells of all ages, while the
other species like P. vivax and P. Ovale for instance can only invade the young red blood cells, and
P. malaria on the other hand can only attack aging red blood cells [41].
If the interventions for Malaria controls are correctly implemented, then malaria is not only
treatable but preventable as well [42]. However, to prevent malaria, we need to understand
different life stages of the plasmodium parasite and their mechanism of adaptation in different
hosts. This understanding in particular facilitated the development of different vector control
programs that were applied in the 20th century and were very instrumental in controlling malaria
[5]. In the next section, we give an overview of plasmodium parasite life cycle, that was very
instrumental in controlling malaria in 20th century. Nevertheless, to fully eliminate malaria,
we need to understand the genetic basis of severe malaria. It is estimated that human genetic
factors accounts for approximately 25% of the risk of severe malaria in areas where p. falciparum
malaria infection is common. Additionally, hemoglobin S (HbS) is known as the strongest
determinant of malaria risk and contributes approximately 2% of the total malaria variation
[10]. Understanding these factors can provide valuable insights of molecular mechanisms of
pathogenesis and protective immunity that can be applied in the development effective treatment
options and vaccines [10, 30].
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1.4.2 Plasmodium Parasite Life Cycle
Plasmodium has a complex life cycle with two distinct phases of life that involves two hosts,
vertebrate and the invertebrate [2, 43]. The first phase is the asexual cycle, which takes place
inside the human host and the second phase is the sexual phase which takes place inside the
mosquito (invertebrate) [43].
Asexual phase begins when an infected mosquito, with the infection acquired from the
previous blood meal, inject sporozoites into the human host during the blood meal [2, 39]. The
injected sporozoites takes approximately 30-60 minutes to reach the liver via the blood stream
[39]. Inside the human host, the parasite undergoes two stages; the exo-erythrocytic stage and
the erythrocytic stage of the cycle [2]. Exo-erythrocytic stage takes place in the liver during which
the sporozoites multiplies asexually [2, 5]. During this time, the sporozoites undergo many cell
divisions producing 10,000 to 30,000 descendants for each sporozoite [39]. These descendants
sporozoites matures in the hepatocytes to become schizonts [2, 5, 39]. Typically, the cell division
for the sporozoites and the maturity of the descendants of the sporozoites into schizonts lasts
for about 6 to 15 days and after which the schizonts bursts or raptures releasing thousands of
merozoites into the blood stream for circulation [39]. This marks the end of exoerythrocytic
stage, and the beginning of the erythrocytic stage [39]. The merozoites then invade the red blood
cells, mature and multiply asexually producing descendants merozoites [2]. The descendants
merozoites then develop into immature trophozoites and finally into mature trophozoites, which
then develop into schizonts [2]. Erythrocytic stage lasts for about 44 -72 hours and terminates
when the infected red blood cell burst releasing the merozoites [2]. The released merozoites can
either begin the erythrocytic cycle again by infecting the new red blood cells or can develop into
gametocyte, then infect the mosquito during the blood meal [2].
Sexual cycle, also known as sporogonic cycle, similarly begins during the blood meal when a
feeding mosquito takes blood from an infected person [2, 39]. During the blood meal, the male
gametocyte (known as microgametocyte) or the female gametocyte (macrogametocyte) may be
injested, or both [2]. Inside the mosquito, microgametocye and macrogametocyte matures to
become microgametes and macrogametes [2]. Microgamete then fertilizes the macrogamete in
the midgut of the mosquito forming what is known as a zygote, which then matures to become
ookinete [2, 39]. The ookinete develops into oocyst while invading the midgut of the mosquito at
the same time. Finally, the oocyst matures and then raptures to release sporozoites, which can
make their way to the human host through blood meal hence completing the life cycle [2, 39].
Figure 1.2 illustrates the schematic life circle of the plasmodium parasite that causes malaria in
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human.
Figure 1.2: schematic life circle of the plasmodium parasite that causes malaria in human [39].
1.4.3 Human Genetic Susceptibility and Malaria
Studies suggest that malaria prevalence and incidence increased between 5,000 to 10,000 years
ago [13]. It is during this period that there was massive expansion of agriculture, forest clearing
and animal domestication, that are said to have enhanced the success of anopheles mosquito
[1]. Human haplotypes studies have also shown that alleles that offer protection against malaria
have undergone selection the same time frame [13]. Consequently, genetic mutations that offer
protection against malaria varies in different populations due to difference in environmental
factors, population structure, transmission intensity, effects of specific variant on a given host
genotypes, and many more [3].
Malaria, the strongest force of the evolutionary selection on the human genome, is known to be
the source of hematological disorders like hemoglobinopathies ( HbS, HbC and HbE), quantitative
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hemoglobinopathies ( like the thalassamias ), membrane mutations ( like spherocytosis, ellipto-
cytosis, ovalocytosis ) and enzymopathies ( like glucose-6-phosphate dehydrogenase deficiency
( GD6P )) [3, 11]. These genetics disorders have risen to high frequencies in malaria endemic
regions and thus suggests that malaria selective pressure is very strong [3]. A typical example
is thelassaemia, which causes mild anaemia and is common in Mediterraneans, reached and
maintained the high frequency due to selective advantage against P. falciparum and not as a
result high mutation rate [44]. Moreover, these disorders vary with different populations having
independent evolutionary response to malaria as can be witnessed from both global and local
malaria levels [3, 13].
Table 1.1: Common red blood cell variants that affect resistance to malaria [13].
Gene Protein Function Reported Genetic Associations with Malaria
FY Duffy antigen Chemokine receptor FY*O allele completely protects against P. vivax
infection.
G6PD Glucose-6-
phosphatase
dehydogenase
Enzyme that protects against
oxidative stress
G6PD deficiency protects against severe malaria.
GYPA Glycophorin A Sialoglycoprotein GYPA-deficient erythrocytes are resistant to in-
vasion by P. falciparum.
GYPB Glycophorin B Sialoglycoprotein GYPB-deficient erythrocytes are resistant to inva-
sion by P. falciparum.
GYPC Glycophorin C Sialoglycoprotein GYPC-deficient erythrocytes are resistant to in-
vasion by P. falciparum.
HBA α-Globin Component of hemoglobin α+Thalassemia protects against severe malaria
but appears to enhance mild malaria episodes in
some environments.
HBB β-Globin Component of hemoglobin HbS and HbC alleles protect against severe
malaria. HbE allele reduces parasite invasion.
HP Haptoglobin Hemoglobin-binding protein
present in plasma (not ery-
throcyte)
Haptoglobin 1-1 genotype is associated with sus-
ceptibility to severe malaria in Sudan and Ghana.
SCL4A1 CD233, erythro-
cyte band 3 pro-
tein
Chloride/bicarbonate ex-
changer
Deletion causes ovalocytosis but protects against
cerebral malaria.
Infectious diseases in general are considered as complex traits, that involves the interplay of
host genetic factors, environmental factors and the pathogen genome [45]. As such, approaches
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that works in the identification of variants that underlies complex trait can also be applied in
infectious diseases. Prior to GWAS, linkage studies and candidate gene studies were applied
in the identification of variants that are involved in the predisposition of complex disease [45],
malaria inclusive. However,these studies had limited power, and in most cases the associations
that were identified never replicated [45].
1.4.4 Malaria-Specific GWAS
The first GWAS malaria in Africa was done with a study data from The Gambia in 2009, using
958 cases and 1,382 controls with 402,814 SNPs after quality control. A total of 139 SNPs were
identified to be nominally associated with malaria at a threshold of P-value < 10−4, of which
six had a P-value of P < 10−6 [10]. However, only one SNP rs11036238 OR = 0.61, P-value
= 3.9× 10−7, located on the HBB region, replicated in an independent sample. The replication
samples had 1,087 cases and 2,376 controls. Surprisingly, even the authentic loci like the ABO
gene, G6PD, HBA1-HBA2 also failed to reach the level of association even after genotyping of
these regions. However, the authors argued that some of these variants have reached fixation
in the Gambian population, while others are rare in the Gambia [10] hence could not attain the
significance level. Additionally, low tagging efficiency by the Affymetrix array was also implicated
as the reason why some of the known loci failed to attain the association threshold. Interestingly,
imputation resulted to an increase in power as was observed from the HbS variant that had
a P-value of 3.9 × 10−7 in the initial GWAS before imputation and a P-value of 4.5 × 10−14
after imputation. This study, despite highlighting the potential of imputation, they did not
apply a guided choice for the imputation tool, a gap that we present in the current study. The
study moreover recommended that different methodological approaches for GWAS in Africa.
Genotypes imputation is the most cost effective approach of improving the power of GWAS, even
as researchers are working on different approaches to entangle Africa population GWAS data,
which present a lot of challenges during the GWAS analysis.
Another notable GWAS study on malaria was done by Timmann et al. [46] that identified
two novel resistance loci for severe malaria using Ghanian study sample. Although this study
moderately identified 41 loci that were associated with severe malaria, only four loci had a
threshold of P < 5× 10−8, of which two were novel and other two had been identified by other
studies [13]. The two novel loci were ATP2B4 on chromosome 1q32.1 under recessive model
and MARVELD3 on chromosome 16q22.2 using additive model. Other loci are summarized in
the table below. Recently, Ravenhall et al. [47] conducted a GWAS in the North Easter part of
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Tanzania using 449 cases and 465 typed at 15.2 million SNPs. This study again, despite small
sample size, discovered novel loci that had not been identified before. Among the novel regions
identified includes IL-23R and IL-12RBR2, KLHL3 among othes [47].
In other GWAS studies, Band et al. [30] did a meta-analysis of African population from
Kenya, The Gambia and Malawi. The study had a total of 5,425 cases and 6,891 controls with 1.3
million common SNPs. Although the potential of using the same methodology for meta-analysis
in Africa is not clear, Band et al. [30] tried different methodologies for associations. Notably,
two regions (HBB on chromosome 11 and ABO on chromosome 9), that are among the known
authentic loci for malaria susceptibility and protection had numerious SNPs with association
(P-value) value less than < 5× 10−8. Although other regions showed significant associations with
P-value < 1× 10−6, their associations were not conclusive as they have never been replicated [30].
This study in particular highlighted the potential of imputation based meta-analysis in African
population. That despite the challenges in Africans genetic make up, convincing results can be
obtained when larger samples sizes and correct methodologies are applied [30]. In Table 1.2
below, we list the variants that have been identified and replicated through GWAS to be associated
with malaria.
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Table 1.2: List of genes that have been reported to be associated with malaria through GWAS and have been replicated in some studies.
Near Gene CHR SNP Model MAF OR P-Value POPULATION Reference
ATP2B4 1q32.1 rs10900585 (T/G) Recessive 0.38(0.43) 0.60 [0.47-0.76] 2.0× 10−5 Ghana GWAS [46]
0.38(0.44) 0.69 [0.57-0.84] 1.9× 10−4 Ghanian Replication
0.65 [0.56-0.75] 6.1× 10−9 Ghanian GWAS Combined
0.33(0.37) 0.58 [0.40-0.85] 5.3 ∗ 10−3 Gambia Population
0.61 1.9× 10−10 Meta-analysis (Ghana+Gambia)
rs2365860 (A/C) Recessive 0.33(0.39) 0.58 [0.45-0.74] 2.5× 10−5 Ghana GWAS
0.33(0.39) 0.68 [0.55-0.84] 3.9× 10−4 Ghanian Replication
0.63 [0.55-0.74] 1.5× 10−8 Ghanian GWAS Combined
0.27(0.30) 0.54 [0.36-0.81] 2.7× 10−3 Gambia Population
0.61 1.9× 10−10 Meta-analysis (Ghana+Gambia)
rs10900589 (T/A) Recessive 0.33(0.39) 0.57 [0.44-0.74] 2.4× 10−5 Ghana GWAS
0.33(0.39) 0.69 [0.55-0.85] 5.1× 10−4 Ghanian Replication
0.63 [0.54-0.74] 2.1× 10−8 Ghanian GWAS Combined
0.27(0.29) 0.54 [0.36-0.81] 2.8× 10−3 Gambia Population
0.62 2.8× 10−10 Meta-analysis (Ghana+Gambia)
rs2365858 (C/G) Recessive 0.33(0.39) 0.56 [0.43-0.73] 1.1× 10−5 Ghana GWAS
0.33(0.38) 0.68 [0.55-0.85] 5.9× 10−4 Ghanian Replication
0.63 [0.54-0.74] 5.1× 10−8 Ghanian GWAS Combined
0.27(0.29) 0.56 [0.37-0.83] 4.4 ∗ 10−3 Gambia Population
0.62 9.5× 10−10 Meta-analysis (Ghana+Gambia)
ABO 9q34.2 rs8176719 (delG/G) Dominant 0.36(0.29) 1.62 [1.35âA˘S¸1.96] 1.2× 10−7 Ghana GWAS [46]
Continued on next page
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Near Gene CHR SNP Model MAF OR P-Value POPULATION Reference
0.37(0.28) 1.70 [1.48-1.96] 2.9× 10−13 Ghanian Replication
1.67 [1.50-1.86] 1.1× 10−20 Ghanian GWAS Combined
NA(0.16) 1.26 [1.11-1.44] 5× 10−4 Gambia Population
1.48 4.3× 10−21 Meta-analysis (Ghana+Gambia)
rs8176703 (C/A) Dominant 0.093(0.057) 1.84 [1.42-2.39] = 5.1× 10−6 Ghana GWAS
0.091(0.056) 1.72 [1.41-2.10] 5.1× 10−6 Ghanian Replication
1.73 [1.48âA˘S¸2.02] 4.0× 10−12 Ghanian GWAS Combined
NA(0.16) 1.26 [1.11-1.44] 5× 10−4 Gambia Population
1.48 4.3× 10−21 Meta-analysis (Ghana+Gambia)
HBB 11p15.5 rs334 (A/T) Heterozygous0.053(0.072)0.06 [0.038âA˘S¸0.12] 2.5× 10−21 Ghana GWAS [46]
0.010(0.059) 0.15 [0.10-0.23] 1.6× 10−18 Ghanian Replication
0.011 [0.079-0.015] 1.6× 10−18 Ghanian GWAS Combined
NA NA 1.3× 10−28 Gambia Population
rs372091 (C/T) Heterozygous0.029(0.068) 0.38 [0.028-0.52] 1.4× 10−9 Ghana GWAS [46]
0.028(0.058) 0.45 [0.34-0.59] 3.6 ∗ 10−8 Ghanian Replication
0.44 [0.36-0.54] 1.1× 10−14 Ghanian GWAS Combined
0.012(0.018) 0.63 [0.38-1.07] 0.085 Gambia Population
0.46 5.6× 10−14 Meta-analysis (Ghana+Gambia)
MARVELD3116q22.2 rs2334880 (T/C) Additive 0.47(0.40) 1.31 [1.16-1.49] 2.3 ∗ 10−5 Ghana GWAS [46]
0.45(0.41) 1.20 [1.08-1.32] 4.3 ∗ 10−4 Ghanian Replication
1.24 [1.15-1.34] 3.9× 10−8 Ghanian GWAS Combined
0.40(0.38) 0.96 [0.81-1.13] 0.60 Gambia Population
Continued on next page
17
Table 1.2 – continued from previous page
Near Gene CHR SNP Model MAF OR P-Value POPULATION Reference
1.19 1.9× 10−6 Meta-analysis (Ghana+Gambia)
SPATA3 2q37.1 rs6750230 (T/C) Additive 0.37(0.43) 0.65 1.6 ∗ 10−5 Gambia GWAS [10]
0.38(0.40) 0.83 1.0× 10−1 Gambian Replication
0.74 [0.64-0.85] 3.2× 10−5 Ghanian GWAS Combined
DDC 7p12.2 rs1451375 (A/C) Dominant 0.18(0.21) 0.69 3.0 ∗ 10−4 Gambia GWAS [10]
0.19(0.22)) 0.81 1.4× 10−2 Gambian Replication
0.75 [0.66-0.85] 6.1× 10−6 Ghanian GWAS Combined
HBB 11p15.4 rs11036238 (C/G) Trend 0.09(0.04) 0.65 3.9 ∗ 10−7 Gambia GWAS [10]
0.10(0.14) 0.81 6.8× 10−6 Gambian Replication
0.63 [0.66-0.72] 3.7× 10−11 Ghanian GWAS Combined
SCOI 17p13.1 rs6503319 (T/C) Trend 0.51(0.45) 1.28 6.6 ∗ 10−5 Gambia GWAS [10]
0.49(0.45) 1.14 2.1× 10−2 Gambian Replication
1.21 [1.12-1.31] 7.2× 10−7 Ghanian GWAS Combined
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1.5 Genotypes Imputation
1.5.1 Overview
Genotypes imputation is the process of estimating genotypes that are not directly measured in
a sample of individuals under study. Through this, the evidence of the association of genetic
markers that are not genotyped directly can be examined [48]. Imputation applies the knowledge
of linkage of disequilibrium (LD) structure in the reference panel and the GWAS datasets to
combine the data from the reference panel with the data from the study dataset thus predicting
the untyped or missing genotypes in the target dataset [48, 49]. Genotypes imputation has two
practical applications: In Genome Wide Association Studies (GWAS) and in fine mapping studies.
In context of GWAS, genotype imputation is carried out across the whole genomes to predict
the SNPs that are not typed into the study [20]. In fine mapping on the other hand, genotypes
imputation is carried out in a more focused region of the genome to find the true causal variant.
In either way, the baseline is to estimate variants that have not been typed into the study [48].
1.5.2 Application and Challenges in Genotypes Imputation
Genotypes imputation is not a new concept and its potential applications can be traced as early as
the era of haplotypes phase inference methods [50]. During phasing, sporadic missing genotypes
are imputed hence genotypes imputation is as old as phasing. However, genotypes imputation
gained popularity in the era of GWAS , that saw emergence of larger and denser samples than
before, thus allowing accurate imputation of missing genotypes [51]. Genotypes imputation
presents a lot of benefits in genetics. Despite several application and success, challenges are
inherent in genotypes imputation. Below, we give some of the popular applications of genotypes
imputation, and challenges in genotypes imputation.
Application of Genotypes Imputation
Application in GWAS: Genotypes Imputation improves power in Genome Wide Association
Studies by including into the study SNPs that were not typed. Usually, a high proportion of
individuals have missing data at one or more markers, and thus removing these individuals
in downstream analysis can substantially reduce the sample size of the data [51]. Again, many
markers may fail to pass quality control hence are supposed to be removed in downstream
analysis. Genotypes imputation presents a powerful technique for recovering SNPs that have
failed to pass quality control, and also can be be used to estimates the SNPs that are not typed
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into the study. This therefore maintains or improves the power of association studies [51]. A
popular example of the power of imputation on GWAS is highlighted by the study by Zeggini et
al. [52], where two novel associations (PPARG and CDC123-CAMK1D) were identified from the
imputed SNPs. These associations, moreover, were confirmed via replication and genotyping
[52].
Application in Fine Mapping: Fine mapping studies are studies that assess the genetic variations
at a known GWAS risk locations with the aim of identifying the variants that have direct effect
on the trait [53]. Genotypes imputation can be carried out in a specific region of the Genome
to provide high resolution view of the associated region hence increasing the likelihood of
identifying the true causal SNP. One of the best illustration of potential of imputation on
fine mapping is from a study by Jallow et al. [10]. Using HbS, which is known as the best
polymorphism for evaluating GWAS, Jallow et al. [10] sequenced 111kb region at the center
of the GWAS signal on chromosome 11p15 using 62 individuals as a reference panel. They
then applied IMPUTE program to impute approximately 2,500 samples from the GWAS and
applied association test at each of the imputed SNPs. From their result, three imputed SNPs
had stronger association than any of the SNPs genotyped on the initial GWAS. Moreover, the
known polymorphism rs334 showed the strongest association with p value of 4.5× 10−14, which
was far much stronger than the signal of association from the genotyped SNPs alone, which had
a P-value of 3.9× 10−7 [10]. Although this association signal was weaker than the association
signal of genotyping the region directly (P-value= 1.3× 10−28), one of the possible explanation
for this is due LD patterns of African population, which strongly affects imputation.
Application in Meta-Analysis: As most GWAS susceptibility loci have small to moderate effects,
sufficient statistical power can only be obtained when large sample sizes or densely typed
markers are for associations [30]. Such statistical power is beyond the capacity of a single GWAS
study, and perhaps, can be obtained from combining multiple GWAS studies [51]. Meta-analysis
is the statistical procedure of integrating or combining data from several independent studies or
studies from different genotyping platforms [54]. Through imputation, a homogeneous datasets
from different study cohorts can be created [55], and a statistical test is conducted at each
SNP, and across the collection using different meta-analysis models [30] . First application of
imputation based meta-analysis was done in 2008, which identified novel associations that had
been missed by previous GWAS based on single studies [56]. Since then, meta-analysis has been
on the rise with many risk loci identified [54].
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Current Challenges in Genotypes Imputation
Imputation accuracy decreases with minor alleles frequency. Consequently, imputation of rare and
low frequency variants remains a very big challenge. Africa for example, which has the greatest
diversity worldwide and the lowest LD patterns, has the lowest imputation accuracy worldwide
[20]. To improve imputation accuracy for the low frequency variants, studies have suggested
the use of diverse reference panels that contains more samples from diverse populations. This
has seen reference panels like 1000 genomes being extended to contain more samples from
Africa. Although slight improvement has been reported with this kind approach, the imputation
accuracy for diverse population still remain at modest. Recently, there is so much hype about
the development of a reference panel for African population, in which are near completion, and
are expected to improve the power of association studies and imputation in particular. However,
the benefits of these developments are yet to be seen. In one of the studies, Liu et al. [57] used
whole genome data of 90 individuals from European populations to assess and compare the
performance of three popular imputation tools( BEAGLE, IMPUTE2 [58] , and minimac [59])
using two reference panels: a European population specific reference panel and 1000 Genomes
reference panel. Interestingly, the 1000G reference panel outperformed the populations European
specific reference panel [57]. The question then is whether the African specific reference panel will
improve the imputation performance in African population, and in diverse populations like the
African Americans, or will it give similar experiences that have been reported by using specific
reference panel in the European populations?
By the fact that imputation accuracy increases with increase in the size of the reference
panels, there have been efforts of increasing the sizes of reference panels. As a result, reference
panels are steadily increasing in sizes with the current largest reference panel having tens of
thousands of samples. Moreover, this is set to increase to include hundreds of thousands of
samples [60]. However, even though this would definitely improve the accuracy of imputed
variants, the computation cost is also expected to increase. Increase in computation cost is
a big challenge that current imputation tools must be able to deal with. As a consequence,
imputation tools have devised several techniques for reducing the computational complexities
like the use of pre-phasing which succeeded in reducing quadratic complexity, use of identity
by descent, haplotype clustering and linear interpolation, use of specialized formats (like m3vcf,
bref2, bref3) of reference panels to reduce file size and memory requirement and many more [60].
Nonetheless, total computation cost is still higher for most of the tools. Recently, Browning et
al. [60] implemented a new imputation algorithm that has been shown to reduce the imputation
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computation costs to less than a penny, and has been shown to be 100 times faster than the
current imputation tools.
In malaria, as in most complex traits, imputation has been applied to improve the power of
the association studies. To date, a number of studies have implemented various imputation tools
and a lot of success have been reported [10, 30]. By the fact that malaria is the strongest force of
evolutionary selection that has shaped the human genome, applying the best imputation tool in
malaria studies can elucidate the potential of imputation and can be generalized in other traits.
1.6 Motivation of the Thesis
Malaria continues to be one of the leading causes of death globally; affecting more than 91
countries worldwide [61]. The global tally of malaria in 2015 was 212 million cases and 429,000
deaths [61]. It is estimated that over 90% of malaria related mortalities are reported in sub-Saharan
Africa with the hardest hit group being pregnant women and children below the age of five
[62]. Moreover on global scale, under-five years child death in sub-Saharan Africa is over 10%
compared to developed countries where it is less than 1% [63]. This is primarily due to malaria
and other infectious diseases [63]. Recently, a report of World Malaria Day 2017 approximated
that over 70% of infants death is as a result malaria, killing a child every two minutes [61].
One of the interesting finding is that P. falciparum mainly kills children before reproductive
age because it has the capacity to select emerging polymorphisms that offers protection against
the severe form of the disease and death [64]. Thus a comprehensive understanding of the
genetic basis of resistance/susceptibility to severe malaria can shed more lights into molecular
mechanisms of drug resistance and protection, and can be applied in the development of effective
treatments options and vaccines [30, 65]. An example of how genetic discoveries may be translated
into the development of vaccines and treatments is about Plasmodium vivax [13]. The realization
that Africans lack the Duffy blood group, caused by chemokine receptor gene popularly known
as DARC, led to the molecular characterization of the crucial parasite protein that binds to the
Duffy erythrocyte receptor [3]. Consequently, this led to the identification of a vaccine against P.
vivax [66]. By the fact that malaria is known to be the strongest selection force that has shaped
the human genomes, the genetic discovery on P. falciparum can not only revolutionize malaria
research but also genetics research as a whole [13].
To date, the known genetic factors explains only a small proportion of host genetic resistance
to malaria, an indication that most genetic factors are yet to be identified. GWA studies have been
proven to be powerful tools for investigating the genetic architecture of human diseases including
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Malaria [67]. However, the methods have been hugely suffering from different challenges
including 1) the lack of translation of associated loci into suitable biological hypotheses [68],
2) the well-known problem of missing heritability [68], 3) the lack of understanding of how
multiple modestly associated loci within genes interact to influence a phenotype [69], accuracy of
genotypes imputation tools, and many more.
One way of improving the power of Genome Wide Association Studies is by increasing the
sample size and by using a dense set of SNPs in the study [20]. Conrad et al. estimates that
typically, 1.5 million SNPs in African populations have equivalent power of 0.6 million SNPs of
HapMap phase 1 dataset of European descents [70]. This implies that African studies require
more markers for GWAS to achieve adequate power than the European samples. Imputation has
been shown to be the most cost effective way of including variants that are not typed into the
study [20]. In malaria, imputation is not a new concept and has been applied in many studies
with the first in Africa being by Jallow et al. [10]. This studies, Jallow et al. applied imputation
with IMPUTE [71] program on the HbS locus using 62 individuals from Gambian population
[10]. Their results showed that the imputation has the potential of boosting the GWAS signals. In
particular, their GWAS signal improved from a signal of association value of 4× 10−7 to 4× 10−14
[10]. However, despite the successful results that have been obtained through imputation in
African populations, with different genotypes imputation tools used in different studies, little is
known as to which imputation tool is most appropriate when dealing with data from African
ancestry. This therefore suggests that there is an urgent need of the assessment of the imputation
tools in African populations to guide future researches. Given a rich source of information on
both malaria GWAS and reference panels, it is now an intriguing time to evaluate the potential of
imputation tools in imputing genetic data from African populations. Table 1.3 highlights some
of the Malaria GWAS that have implemented imputation.
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Table 1.3: Example of malaria GWAS in Africa that have used imputation
Authors Journal Publication Date Tool Title Reference
Jallow et al. Nature Genetics 2007 IMPUTE1 Genome-wide and fine-
resolution association analysis
of malaria in West Africa
[10]
Band et al. PloS Genetics 2013 IMPUTE2 [58] Imputation-Based Meta-
Analysis of Severe Malaria
in Three African Populations
[30]
Ravenhall et al. PloS Genetics 2018 IMPUTE2 [58] Novel genetic polymorphisms
associated with severe malaria
and under selective pressure in
North-eastern Tanzania
[47]
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Further, results from GWAS findings shows that much of the genetic basis for most of the
complex traits is indeed a combination of hundreds or thousands of genetic variants with small
effects [17]. This realization points to the fact that Single SNP analyses alone do not address the
overall genomic architecture for most of the complex diseases [72]. Therefore, other methods
that treats the entire genome as a unit or explores the overall effects of SNPs that fails to reach
genome wide significance should be applied when analyzing complex traits. Moreover, it has
been illustrated that much of the heritability of complex traits can be explained by analyzing the
common variants that fail to reach genome wide significance threshold. Yang et al. for example
used linear mixed model software (GCTA [73]) and illustrated that much of heritability of a trait
can be explained by evaluating the effect of all SNPs [15]. Similarly, in malaria the estimated
heritability is approximately 25% [11], with the replicated associations accounting for only a
fraction of this estimate [74]. This implies that, just as in height, more insights can be gained by
analyzing the variants that do not reach the GWAS significance threshold. We therefore propose
to exploit this by using polygenic risk score analysis, which sums the risk alleles corresponding
to a given trait or disease for an individual, weighted by the estimates of the effect sizes from
GWAS published result or meta-analysis [17].
1.7 Objectives of the Thesis
We hypothesize that, malaria resistance is a complex trait that is under polygenic control as
suggested by Mackinnon et al. [11]. We further suggest that in as much as genotypes imputation
tools have been applied in studies of African ancestries, and in malaria studies in particular,
better results can obtained if appropriate tool is used. This is only possible when the tools are
properly evaluated using African genetic data and a recommendation given thereof. We therefore
propose to asses the power of the genotypes imputation tools using whole genome data of African
ancestry versus European ancestry individuals and admixed population. We apply two separate
reference panels, 1000 genomes reference panel and an extended 1000 genomes reference panel
that has more African samples, and finally give a recommendation of the best tool that has the
highest imputation accuracy when dealing with genetic data from African populations. Also, by
the fact that missing heritability is still large in most of diseases, and GWAS has not been able to
account for this large “dark side of the genome", it is time to explore other approaches. So far,
PRS has presented promising results in explaining the heritability that has never been accounted
for by standard GWAS approaches. Nonetheless, this powerful technique has never been applied
in any infectious disease. We thus explore the possible application of PRS in malaria and give
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recommendations for future studies.
The following are the objectives of our study.
I) We propose to review the current tools used in imputation.
II) Compare the performance of genotypes imputation tools using the simulated datasets that
mimic African and European genetics structure.
III) Access all malaria genome-wide associations studies (GWAS) data in African populations
from MalariaGEN.
IV) Compare GWAS from genotypes imputation using the best tool identified in (ii) verses
summary statistics imputed by ImpG.
V) Perform a meta-analysis of results in IV.
VI) Perform pathway enrichment from the results in V).
VII) Review PRS methods and compare the performance of different PRS methods using simu-
lated datasets that mimic Africa populations.
VII) Apply the best PRS method from VII in genome-wide association study(GWAS) summary
statistics of malaria to predict Malaria risk/resistance in order to understand Malaria-specific
genetic architecture.
1.8 Outline of the Thesis
In Chapter 2, we discuss different mathematical approaches of genotypes imputation and some of
the concepts that have revolutionized genotypes imputation. We also review some of the popular
imputation tools and discuss different imputation quality metrics, and their comparison. In
Chapter 3, we evaluate some of the popular imputation tools discussed in Chapter 2. We begin by
first reviewing literature of previous studies that have compared different imputation approaches.
We then describe our datasets and the simulation framework we applied in obtaining the datasets
and finally present imputation results and the discussion. In Chapter 4, we apply the best tool
identified from the evaluation in Chapter 3 in imputing Malaria GWAS data from three African
populations obtained from MalariaGEN. Also impute the summary statistics from the same
populations with ImpG. We then compare the association result from imputed summary statistics
data by ImpG and the summary statistics of GWAS from raw genotypes data imputed by the best
imputation tool identified in Chapter 3. We conclude the chapter by performing a meta-analysis
and pathway enrichment of the meta-analysis results. In Chapter 5, we review different PRS
methods, classification and challenges in calculation of PRS. We review previous studies that have
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compared different PRS methods, and finally compare different PRS methods using a simulated
dataset that mimics Africa population. We then recommend the best PRS method based on the
result. We finally apply the best performing PRS method based on the evaluation in predicting
genetic liability/risk of severe malaria. In Chapter 6, we present conclusion and future work,
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Chapter 2
Mathematical Review of Genotypes
Imputation Approaches
2.1 Overview
A number of statistical methods have been proposed for genotypes imputation of GWAS data.
However, the ultimate classification of these algorithms is difficult due to the fact that the
implemented algorithms are often modified and combined in the newer versions of the imputation
programs or implemented in completely new programs. Nonetheless, genotypes imputation
tools can be broadly classified into four categories: the first category are tools that are based on
standard statistical method like Multinomial models, linear regression with variable selection,
Regression tree, Singular Value Decomposition, k-Nearest Neighbor (k-NN) method and many
others. These tools, despite the fact that they can estimate the missing genotypes, they do not
model the key features of the genetic data like recombination and linkage of disequilibrium (LD)
[75]. As result, they have lower imputation accuracy as compared to the tools that incorporate the
key characteristics of the genetic data. Schaid et al. [76] for example compared the performance of
seven of these standard statistical methods (linear regression with variable selection, Regression
tree, Singular Value Decomposition, k-Nearest Neighbor (k-NN)) with fastPHASE [77], which
is based on population genetics principle. Their result showed that fastPHASE [77] had the
lowest error rate, hence highest accuracy and outperformed all the other seven tools. The second
category of tools that employs SNPs tagging approach in performing imputation. These tools
includes PLINK [78], SNPMStat [79], TUNA [80], and UNPHASED [81]. Although these tools are
very computationally efficient in carrying out imputation, they are less accurate since they do not
utilize information across the entire chromosome in performing imputation. The third class of
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genotypes imputation tools are tools based on haplotype matching. Here, a popular example
is PWBT, which was developed recently by Durbin et al. [82]. Again, these tools, despite being
computationally efficient, do not integrate across all possible mosaic haplotypes configurations
hence giving less accurate estimates [83]. The fourth, and the last category of tools are those that
are based on population genetics principle. Tools under this category includes BEAGLE, IMPUTE,
MaCH, minimac [59] and many more. These tools apply hidden Markov Models (HMM) in
imputing the missing genotypes and have been applied as the gold standard for performing
genotypes imputation [84].
Here in this thesis, we will focus on the computational tools that are developed explicitly
for genotypes imputation in GWAS, and employs Hidden Markov Model using Li and Stephen
framework.
2.1.1 Li and Stephens HMM framework
Li and Stephens model offers a spectacular approach for analyzing LD patterns and modeling
recombination hotspots [26]. This model, popularly known as Li and Stephens framework, has
several advantages including ability to analyze LD patterns across multiple loci, can handle long
chromosome stretches using the fact that haplotypes share contiguous stretches with each other
despite individuals haplotypes being unique [26]. Moreover, it models the historical events, like
mutations and recombination rates, hence offers an efficient application in the imputation of
genotypes, and forms the underpinning of genotypes imputations [26].
In Li and Stephens framework, a subset of haplotypes are selected and used as reference
set. This has since then been replaced with a reference panel like the 1000 Genome Project
and the HapMap. Each marker in the reference panel represents a hidden state of the Hidden
Markov Model (HMM). Observed genotypes are assumed to be imperfect mosaic of the reference
haplotypes [26]. The state space of the HMM by Li and Stephens can be visualized as a matrix,
where the columns are the markers in the reference panel and the rows are the individual
haplotypes in the reference panel [54]. Each allele in the reference panel represents a state and the
study haplotype, or genotypes are assumed to trace unobserved path through the matrix from the
first reference marker to the last reference marker [54]. The study haplotype can thus be viewed
as a combination of segments in the mosaic template, in which switching from one segment to
another segment follows a Markov Chain [51]. This Markov chain incorporates the recombination
event and therefore, a new haplotype can copy from different haplotypes from two consecutive
loci. This simplifies the switching probabilities from one marker to the next, and the transition
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probability does not depend on the haplotype being copied from. Alleles of the new haplotype
can be different or close to the haplotypes they are copied from and this reflects the mutation or
the genotyping error [26, 51]. Recombination and mutation parameters are determined as part of
model fitting process [51].
Figure 2.1: Li and Stephens Hidden Markov Model framework for performing geneotypes imputation. The ovals
represents the hidden state, defined by the reference markers. Bold arrows represent paths with the highest
transition probabilities. Thin arrows allows for recombination between markers [51].
To illustrate how Li and Stephens model is applied in imputation, Let H to be the set of
reference haplotypes typed at M markers and h to denote the set of the target haplotypes. Denote
the hidden states of the HMM by S and assume that each individual haplotype is independent
of other individuals’ haplotypes. The four elements of HMM includes: state space, initial state
probabilities, transition probabilities and emission probabilities. Most imputation tools have
similar initial, transition and emission probabilities. However, the only difference is how each
tool defines the state space of the HMM. The general form of a hidden Markov model can be
given as follows:
P(s|h, H, θ, ρ) = P(S1)
M
∏
m=2
P(Sm|Sm−1, ρ)
M
∏
m=1
P(hm|SM, H, θ) (2.1)
Where P(S1) in Equation 2.1 denotes the initial probabilities, P(Sm|Sm−1, ρ) are the transition
probabilities and P(hm|Sm, H, θ) are the emission probabilities, ρ and θ represent recombination
and error/mutation parameters. The initial probability for most tools is equaprobable in all
configuration and is given by the following:
P(S1) =
1
R
, (2.2)
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Where R in Equation 2.2 is the number of haplotypes in the reference panel.
Transition probabilities on the other hand are defined by the following:
P(Sm = i|Sm−1 = j) =
(1− θm−1) +
θm−1
R if i = j
θm−1
R , Otherwise
(2.3)
In Li and Stephens framework, the transition probabilities are defined based on the number of
haplotypes in the reference panel, effective population size and the genetic distance between
markers. Thus θm−1 in Equation 2.3 is defined as follows according to Li and Stephens framework:
θm−1 = 1− e
−4Nedm−1
R , (2.4)
where Ne in Equation 2.4 is the effective population size, dm−1 is the genetic distance between
the markers m and m− 1, and R is the number of reference haplotypes in the reference panel.
Therefore, any given state (m− 1, h) can be on the reference panel h with probability θm−1 =
1− e−4Nedm−1R or it can be on the same reference haplotype h due to recombination with probability
θm−1
R . Also, a state (m− 1, h) on reference haplotype h can transition to (m, hˆ) -where h 6= hˆ- with
probability θm−1R
Emission probabilities on the other hand are given by the following:
P(hm|Sm) =
1− em, if hm = himem, Otherwise (2.5)
Emission probabilities generally take into account the genotyping errors and mutations, modelled
by the mutation parameter em. Equation 2.5 therefore implies that a state (m, h) emits allele
carried by haplotype h at marker m with probability 1− em otherwise, it emits a different allele.
IMPUTE1 [85], IMPUTE2 [71] and IMPUTE4 [86] provides estimates of the fine recombination
map, which can be downloaded from the program webpage. However, the user must specify
effective population parameter which by default is 20,000 [71]. Emission parameter on the other
hand is fixed internally by the program [71]. For BEAGLE tools, emission probabilities are defined
in terms of error rate. By default, the tool uses em = 0.0001. MaCH, minimac [59], minimac 2 [87],
minimac 3 [83] and minimac 4 [54] on the other hand estimate the parameters and are updated in
each iteration. While this approach is flexible in that it can adopt to each data being analyzed, the
parameters may not be estimated well which may consequently reduce the imputation accuracy
[20].
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2.2 Concepts Revolutionizing Genotypes Imputation
2.2.1 Pre-phasing
Early genotypes imputation methods like MaCH [88], IMPUTE [85], BEAGLE [89] and fasPHASE
[77] were based on unphased geneotypes. These tools were very computationally intensive due
to quadratic complexity. Typically, phasing of the target genotypes and subsequently imputation
were done simultaneously on the same run of the algorithm. The realization that alleles can be
imputed directly into phased target haplotypes motivated the separation of phasing step from the
imputation step. This then has motivated the development of tools that can specifically require
the target genotypes to be phased prior to the imputation, and has greatly reduced the imputation
time and has motivated the implementation of additional computational optimizations.
2.2.2 Specialized Reference Panel Format and Clustering
Reading and storing large reference panel is a great challenge in imputation, and in genetics
studies in general. The Variant Call Format (VCF) for example requires 4 byte for storage for
every genotypes and can require several terabytes for millions of samples in the reference panel
[90]. Although compressing the reference panel is an option that can greatly reduce the size of
the reference panel, it does not address the issue of storage in memory during analysis. Moreover,
time for decompressing large reference panel can sometimes exceed even the time required to
perform imputation. Among the early reference formats that have been developed in imputation
to reduce the size of reference panel are the Minimac3 VCF (M3VCF) [83], bref [60, 91]. M3VCF
are created to adopt with the imputation algorithm implemented in minimac 3 [83]. Here, only
unique haplotypes in each segment in the reference panel are stores as opposed to storing all the
haplotypes for each segment. Bref (Binary reference format) on the other hand stores genotypes
data in terms of blocks where each block contains a marker and genotype information for a set of
subsequent markers. A marker can either be index coded (stores indices of haplotypes with non
major alleles and specifically suited for low frequency markers) or sequence coded (stores the
sequence of distinct alleles present in a given data block).
In short regions, identical haplotypes can be clustered together in which each cluster has a
unique marker. HMM forward backward algorithm can then be applied to a unique cluster rather
than all the markers of the reference panel. Some of the popular tools implementing clustering
includes minimac 3 [83] [83], minimac4 [54], beagle 3 [89], beagle 4 [91] and beagle 5.0 [60]. The
clustering in minimac is exclusively based on the reference panel and in precomputed prior to
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imputation [83]. Clustering in BEAGLE on the other hand is based local clustering, which is
applied on the genotyped markers of the target sample, and is implemented during imputation
run [92].
2.2.3 Imputation via Linear Interpolation
Linear interpolation applies a two stage approach when calculating the HMM state probabilities.
In the first stage, HMM forward backward algorithm is restricted on the genotyped markers
[54, 91]. In the second stage, the HMM state probabilities for the missing markers are estimated
via linear interpolation based on the genetic distance. Linear interpolation assumes that the
genetic map position of markers are real numbers and applies the fact that over short distances
between typed markers, HMM state probabilities changes smoothly from one marker to next
bounding marker, and that HMM state probability of the missing marker can be estimated by
a straight line [91]. More specifically, let x to be an untyped marker between two genotyped
markers m and m + 1. Suppose marker m carries allele a and marker m + 1 carried allele b, then
by linear interpolation, the probability that the imputed marker, x, carries allele a is given by the
following:
Pa = ∑
h∈H
(λm,xP(sm = (m, h)) + (1− λm,x)P(sm+1 = (m + 1, h))) (2.6)
Where λm,x =
g(m)−g(x)
g(m+1)−g(m) , and g(.) denotes the genetic marker position [91].
Minimac4 [54] forms the real line interval by using the midpoints of the non overlapping
marker intervals and applies the posterior probabilities of the genotyped marker within a given
flunking region to impute the missing markers. Linear interpolation is currently implemented in
BEAGELE4.1 [91], BEAGLE 5.0 [60] and minimac4 [54].
2.2.4 Imputation Via the Web Service
Imputation servers allows users to upload phased or unphased GWAS data and receive a
downloadable output of phased and imputed data. Imputation servers offers a number of
advantages to researchers including: enabling researcher to spend much time focusing on their
research rather than learning how each tool of the imputation works, offers a platform for
researcher to share and consolidate their research and allows access to reference panel that are
very restrictive and cannot be made publicly available by storing the reference panel data behind
the firewall. Currently, there are two imputation servers: the University of Michigan Imputation
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server which uses minimac3 [83] for imputation and Wellcome Sanger Institute imputation server
that uses PBWT for imputation.
2.3 Review of Population Genetics Imputation Tools
Imputation tools based on population genetics principle can be classified into two classes: Tools
before the pre-phasing era and tools after the pre-phasing era. We discuss each category below.
2.3.1 Imputation Tools Before the Pre-phasing Era
Impute v1 [85] uses Li and Stephens HMM framework in which each individuals HMM is
conditioned on the set of reference haplotypes and a set of parameters. Let i be an individual’s
genotype in the target GWAS. Then the HMM used by IMPUTE v1 [85] is given by the following:
P(Gi|H, θ, ρ) =∑
S
P(Gi|S, θ)P(S|H, ρ) (2.7)
Where S = {S1, . . . , SM} with each Sm = (Sm1, Sm2) and Smk = {1, . . . , R}. P(Gi|S, θ) is the
emission probability and depends on the mutation parameter θ. On the other hand, P(S|H, ρ)
is the transition probability and is dependent on the recombination parameter ρ. MaCH uses
a similar HMM framework to that of IMPUTE [85] except that in MaCH [88], the HMM of an
individual is conditioned on the current haplotype estimate of other individuals. Transmission
and emission probabilities are similar to that of IMPUTE v1 [85].
FastPHASE [77] is the earliest tool that implemented the population genetics approach based
on Li and Stephens model, and can carry out both phasing and imputation. Here, the HMM
model is based on the assumption that over tightly linked regions, haplotypes tends to cluster
into groups of similar patterns. It employs a similar transition probabilities as IMPUTE v1 [85].
However, emission probabilities are derived based on the allele frequencies of each cluster rather
the mutation rate as in IMPUTE v1 [85]. Moreover, fastPHASE [77] uses Expectation Maximization
(EM) algorithm approach in estimating the parameters rather than Markov Chain Mornte Carlo
(MCMC) approach employed in IMPUTE v1 [85].
BEAGLE [89] uses a similar clustering algorithm as that of fastPHASE [77]. However, BEAGLE
does not use Li and Stephens model but instead uses a BEAGLE [93] algorithm that is similar to
Li and Stephens model. HMM model under BEAGLE [93] algorithm is a directed cyclic graph
with variable number of hidden states at each marker. Hidden states are represented as clusters
34
at each node of the graph [89]. BEAGLE algorithm has fewer states at each marker hence speeds
up computation [93]. To achieve fewer number of states, BEAGLE implement a two step running
procedure: the bifurcation step and the pruning step [93]. In the bifurcation step, a bifurcation
tree is constructed that describes how the set of haplotypes are constructed across the entire
set of haplotypes. A weighting is then implemented on each edge of the tree by the number of
haplotypes that goes through the edge. In the pruning step, the tree is pruned whereby at each
level of the tree pairs of nodes are compared in terms of their downstream haplotype frequencies.
Nodes that are similar are merged hence resulting to a more parsimonious characterization of the
dataset [93].
IMPUTE2 [58] is an improved version of IMPUTEv1 [85]. It uses both phased and unphased
study data as input hence referred as a flexible approach. The algorithm first partitions the SNPs
into two sets: a set T that is typed both in the study sample and the reference panel, and a
set U that is missing in the study sample but typed in the reference panel. Imputation is then
performed in two steps. In the first step, genotypes in the set T are phased using equation 2.7 of
IMPUTE v1 [85]. It then applies equation 2.1 in the second step to impute alleles in the set U.
This way, much computational effort is applied on the first step and the second step is typically
very first since its haploid [58]. The algorithm alternates between phasing and imputation using
a MCMC framework [58]. The difference between IMPUTE2 [71] and IMPUTE1 [85] is that
IMPUTE1 [85] is analytical and it integrates over all possible possible haplotype configuration
for each study individual and can only be implemented when the study individuals are treated
independently. This therefore sacrifices LD information in the target data and the computational
burden increases with the increase in the size of the reference panel. IMPUTE2 [71] implements
haplotype sampling strategy in a MCMC framework which scales down with the size of the
reference panel.
2.3.2 Imputation Tools After the Pre-phasing Era
Prephasing was first introduced by Howie et al. [59] in 2012 after an observation that imputation
tools spend more computational effort to account for the phases of unknown GWAS genotypes.
Both analytical and sampling strategies employed by the imputation programs are very computa-
tionally intensive, and the computational cost for each approach increases with increase in the
size of the reference panel.
Minimac [59] is the first stand alone imputation tool to work with only phased genotypes
data. It was developed as part of MaCH algorithm, and relies on the phased output from
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MaCH, although it could also accept phased data from other tools as well. Minimac is based on
the assumption that the haplotypes underlying GWAS datasets have been estimated correctly.
Nonetheless, the accuracy of imputation depends on how well the haplotypes are estimated. It
then applies a standard HMM to estimate the marginal probabilities of the missing alleles in each
GWAS haplotype using the reference haplotypes as the template. The advantages that come with
prephasing is that the haplotypes are estimated once and can be re-used many times during the
program runs as opposed to standard imputation tools where the most likely haplotype for each
individual is estimated each time imputation is done with an updated reference panel or new
reference panel.
Minimac2 [87] is the second tool to be released after pre-phasing era. It’s an improvement of
minimac [59] to reduce imputation computation time and memory requirement through software
engineering approaches. It implements a manual loop vectorization as opposed to the automatic
loop vectorization which is implemented in modern compilers by default. This is motivated from
the observation that the default automatic vectorization may fail in some instances, especially
when the optimization is complex. Minimac2 [87] also implements parallel processing through
OpenMP and improves on data locality access.
Minimac3 [83] applies the state space reduction, which is similar to that implemented in
BEAGLE3 [89]. Here, the genome is first subdivided into consecutive haplotypes blocks, such
that each block contains similar haplotypes. While BEAGLE 3 [89] uses a fixed number of
markers per segment/block, minimac 3 [83] applies dynamic programming algorithm to select an
optimal number of markers in each block. HMM iteration is then performed only on the unique
haplotypes in each block. To achieve the same state space as that of IMPUTE2 [58] and minimac
[59], it applies a reversible function that maps the reduced space to the original space.
BEAGLE4 [91] is an improvement of BEAGLE 3 [89] and is the first BEAGLE algorithm to
implement Li and Stephens HMM framework. It applies a state space reduction in which markers
are aggragated using a fixed 0.005 cM into a single aggregate marker. The allele frequency of the
aggragate marker is given in terms of the observed allele frequencies of the constituent markers
and the HMM state space is defined in terms of the state space of the aggregate marker. This
distinguishes BEAGLE4 [91] from other methods, since the state space are in terms of aggregate
markers rather than in terms of all the markers in the reference panel [91]. The forward backward
algorithm of the HMM is then performed on the aggregate markers and the missing genotypes are
imputed via linear interpolation. BEAGLE 4 [91] is the first imputation algorithm to implement
linear interpolation strategy. This is motivated by the fact that over short distances, changes
in state probability of a given allele within the short distance changes smoothly and can be
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approximated by a straight line.
Minimac4 [90] builds from minimac 3 [83] and applies further a state space reduction approach
to reduce the computational complexity experienced from minimac 3 [83] and to increase speed.
Developers refers to this as an aggressive state space reduction [90]. Here, state space reduction
is applied only on the genotyped markers as opposed to all markers in a genomic segment as
was the case in minimac 3 [83], hence referred to as an aggressive state space reduction. It then
applies a reversible function that maps reduced space to an aggressive reduced space. To impute
the missing markers, a non overlapping flanking region of each genotyped marker is defined
based on the midpoint of the genotyped markers. For each flanking region, ungenotyped markers
are imputed using the posterior probabilities of the genotyped markers. To reduce computation
time, the algorithm only transforms haplotype templates with high posterior probabilities in each
flanking region other than using all the haplotypes in the flunking region when imputing the
missing markers.
BEAGLE 5.0 [60] presents a slight improvement of BEAGLE 4 [91]. It however presents three
computation improvement on BEAGLE 4 [91]. First, instead of using full reference panel like
in BEAGLE 4 [91] to impute the missing alleles, BEAGLE 5.0 [60] conditions the HMM on a
composite reference panel whose composite reference haplotypes comprise of regions that share
Identity by State (IBS) with both the reference panel and the target sample. The composite
reference haplotype is generated in a preprocessing step in which the full reference panel is
reduced to a small composite reference panel, which is mosaic of the reference haplotypes. While
previous versions of BEAGLE were based on short fixed window, based on the hamming distance
which had to be specified (e.g ≤ 0.5), this approach had issues for example the window size
could too small hence imputation accuracy will be reduced as the segments are truncated by
the window boundaries. Composite reference panel allows for the imputation of both long and
short Identity by Descent (IBD )segments, and moreover the composite haplotype segments are
mosaic of the haplotypes in the reference panel, with all reference panels haplotypes that are
associated with the IBS segments are included in the composite reference panel. Second, the
posterior probabilities are obtained via linear interpolation just like in BEAGLE4.1 [89], with
the only difference being that the posterior probabilities are calculated when the VCF file is
being created not like in BEAGLE 4[89] where the probabilities of each individual marker is
calculated immediately after every state iteration. Third, BEAGLE 5.0 [60] process the reference
panel in Bref3 (Binary Reference 3) format which breaks the chromosome into consecutive non
overlapping intervals, and alleles are stored in form of distinct sequences with a pointer for each
haplotype that carries a given marker for major alleles and for the non major allele, the index of
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the haplotype that carries the allele is stored. This format reduces memory requirement since the
number of distinct allele sequence is less than the number of haplotypes [60]. Table 2.1 shows
the summary of population genotyoes imputation tools.
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Table 2.1: Summary of popular genotypes imputation tools, their underlying methods (Hidden Markov Models (HMM) parameters), publication year
and citations.
Tool HMM state space HMM Parameter
Functions
Author Year Title of publication Number of
citations as
at May 2019
fastPHASE Composed of all
genotype configura-
tions from a fixed
number of localized
haplotype clusters
Depends on recom-
bination and muta-
tion parameters. The
parameters estimated
using EM algorithm
Scheet et al. [77] 2006 A fast and flexible
statistical model
for large-scale pop-
ulation genotype
data: applications
to inferring miss-
ing genotypes and
haplotypic phase
1682
IMPUTE
v1
Uses all genotype
configurations from
all the reference hap-
lotypes
Uses a fine scale
recombination map
that is fixed and pro-
vided internally by
the program
Marchini et al
[85]
2007 A new multipoint
method for genome-
wide association stud-
ies by imputation of
genotypes
2247
Continued on next page
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Table 2.1 – continued from previous page
Tool HMM state space HMM Parameter
Functions
Author Year Title of publication Number of
citations as
at May 2019
IMPUTE
v2
Uses all possible ref-
erence haplotypes
Depends on fine scale
recombination map
that is fixed and pro-
vided internally by
the program
Howie et al [71] 2009 A Flexible and Ac-
curate Genotype Im-
putation Method for
the Next Generation
of Genome-Wide As-
sociation Studies
2801
BEAGLE 3
[89]
All genotype config-
urations from a vari-
able number of local-
ized haplotye clusters
Empirical model with
no explicit parameter
functions
Browning et al.
[89]
2009 A Unified Approach
to Genotype Imputa-
tion and Haplotype-
Phase Inference for
Large Data Sets of
Trios and Unrelated
Individuals
1299
Continued on next page
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Table 2.1 – continued from previous page
Tool HMM state space HMM Parameter
Functions
Author Year Title of publication Number of
citations as
at May 2019
MaCH Uses all genotype
configurations from
all the reference hap-
lotypes
Depends on recombi-
nation rate, mutation
rate and genotyping
error. Parameters are
fit using MCMC or
EM algorithm
Li et al. [48] 2010 MaCH: Using Se-
quence and Genotype
Data to Estimate
Haplotypes and Un-
observed Genotypes
1717
minimac
v1
Use all possible refer-
ence haplotypes
Similar to MaCH Howie et al.[59] 2012 Fast and accurate
genotype imputation
in genome-wide
association studies
through pre-phasing
1156
minimac 2 Uses all possible ref-
erence haplotypes
Similar to MaCH Fuchsberger et
al. [87]
2014 minimac2: faster
genotype imputation
216
minimac 3
[83]
Uses all unique allele
sequences observed
in reference data in
a small genomic seg-
ment
Similar to MaCH.
However,the param-
eter estimates are
pre-calculated and
fixed
Das et al.[83] 2016 Next-generation
genotype imputation
service and methods
385
Continued on next page
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Table 2.1 – continued from previous page
Tool HMM state space HMM Parameter
Functions
Author Year Title of publication Number of
citations as
at May 2019
BEAGLE 4
[91]
Uses all unique allele
sequences observed
in reference and tar-
get data at each of
aggregate genotyped
marker
Depends on recombi-
nation rates and er-
ror rates that are fixed
and pre-calculated
Brian L. Brown-
ing and Sharon
R. Browning
[91]
2015 Genotype Imputation
with Millions of Ref-
erence Samples
282
minimac 4
[90]
Collapsed allele se-
quences from refer-
ence data that match
at genotyped posi-
tions in small ge-
nomic segments
Similar to minimac3 Das et al [90] 2017 Minimac4 - Faster Im-
putation through Ag-
gressive State Space
Reduction of Hidden
Markov Models
BEAGLE 5
[60]
Similar to BEAGLE 4
[91]
Similar to BEA-
GLE4.1
Browning et al.
[60]
2018 A One-Penny Im-
puted Genome from
Next-Generation
Reference Panels
11
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2.4 Measure of Imputation Quality and Accuracy
Imputation quality metrics allows the evaluation and assessment of the imputation outputs.
Weakness in genotypes imputation has a potential bias in meta-analysis and Genome Wide
Association Studies (GWAS) [55], thus must be properly evaluated. Each software implements
their own quality metric for evaluating the quality of imputation outputs. Below, we present a
discussion of the quality metrics from some of the popular imputation tools.
2.4.1 Beagle Allelic R2
BEAGLE allelic R2 is an estimate of the squared correlation between the imputed allele dosage
and the true allele dosage [89]. Although the true allele dosage is not known, it can be estimated
from posterior genotypes probabilities. Let X represents the true genotype, Y imputed posterior
probabilities, and Z be the genotype with the highest probability. Also, suppose X and Z are
inform of genotype dosages (x ∈ X, z ∈ Z can take values in {0, 1, 2}). Then, R2 is given as
follows:
R2 =
COV(X, Z)2
Var(X)Var(Z)
=
(
1
N ∑
j
(
ziE[X|yj]
)− 1
N2 ∑j
(
E[X|yj]
)
∑
j
zj
)2
 1
N ∑
j
z2j −
1
N2
(
∑
j
zj
)2 1
N ∑
j
E[X2|yj]− 1N2
(
∑
j
E[X|yj]
)2 (2.8)
To estimate E[X|yj] and E[X2|yj], BEAGLE makes an assumption that the posterior probabilities
are correctly calibrated and P(X = k|Y = yj) = yj(k). Hence E[X|yj] = yj(1) + 2yj(2) and
E[X2|yj] = yj(1) + 4yj(2)
R2 =
[
N
∑
j=1
zjej − 1N
N
∑
j=1
zj
N
∑
j=1
ej
]2
 N∑
j=1
f j − 1N
(
N
∑
j=1
ej
)2 N∑
j=1
zj − 1N
(
N
∑
j=1
zj
)2 (2.9)
Where ej = pj + 2pj, i.e the allele dose of the jth SNP, f j = pj + 4pj
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2.4.2 Impute Info
Impute info is based on measuring the relative statistical information of the population allele
frequency. By assuming that all the genotypes data are observed, then the full likelihood is given
as follows:
L(θj) =
N
∏
i=1
θ
Gij
j (1− θj)(2−Gij)
U(θ) =
d log L(θ)
dθ
=
(
N
∑
i=1
Gij
)
− 2Nθj
θj
(
1− θj
)
I(θ) =
dU(θ)
dθ
=
(
N
∑
i=1
Gij
)
θ2j
+
2N −
(
N
∑
i=1
Gij
)
(1− θj)2
(2.10)
Info measure is thus given by the following [71]:
IA =
E[I(θˆ)]−Var(U(θˆ))
E[I(θˆ)]
=

1− fij−e
2
ij
2Nθˆ(1−θˆ) if θˆ ∈ (0, 1)
1, if θˆ = 0, θˆ = 1
(2.11)
Where N is the total number of individuals in the study, θˆ is the sample allele frequency, eij is the
expected allele frequency and fij = Pn,1 + 4Pn,2, where P is the imputed genotypes probability
[71].
2.4.3 minimac rˆ2
Refers to an estimate of the correlation between imputed and the true/unoberved genotype [83].
Let pˆ to denote the alternate allele frequency and Di to denote the imputed allele probability for
the ith haplotype and n to denote the number of haplotypes. Then,
rˆ2 =
1
2n ×∑2ni=1 (Di − pˆ)2
pˆ(1− pˆ) (2.12)
Minimac rˆ2 is based on the assumption that poorly imputed genotypes counts will tends towards
the expectation of population allele frequencies. Particularly, if p is the frequency of the imputed
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allele, then the genotype counts is estimated as 2p. The genotype dosage on the other hand is
estimated by summing the posterior probability of the alternate ellele. For example, suppose the
posterior probability of allele at each haplotype is 0.94 and 0.97. Then the genotype dose will be
just 0.94+ 0.97 = 1.91.
2.4.4 Comparing the Quality Metric for Different Imputation Tools
To determine whether the imputation quality metric for different imputation are similar, Marchini
et al. [20] used a simulated a case-control data with 2000 samples on chromosome 22 based on
HapMap 2 haplotypes. Their results shows that the information measure are highly correlated
and thus can be compared directly without the need of further conversion [20].
Besides the built in accuracy statistics, other popular measures for assessing the imputation
accuracy includes Imputation Quality Score (IQS), corncordance rate and the squared correlation
(Rsq). While concordance rate measure the proportion of chance agreement between the imputed
and true genotypes, IQS on the other hand adjusts on the chance agreement and is generally based
on Cohen’s Kappa statatistics of chance agreement [94]. Both the measures compares the imputed
and genotyped data via masking approach. In contrast, concordance rate is less preffered since it
regards most variants as well imputed even if that is not the case [94]. Ramnarine et al. further
observed that for the common variants, Imputation Quality Score (IQS) and the BEAGLE R2
provided a similar assessment accuracy, and that they can differ considerably for the rare variants.
Nevertheless, the choice of accuracy statistics matters most for the rare variants more than the
common variants, and that for the common variants IMPUTE2 info, BEAGLE Rsq and squared
correlation (Rsq) between the true and imputed genotypes produce similar assessment for the
imputation accuracy [94]. This is similar to an evaluation by Marchini et al. [20], who showed that
the internal imputation metric from the tools are highly correlated. However, for low frequency
variants, neither BEAGLE Rsq, nor squared correlation nor IMPUTE info is recommended for
evaluation but instead, IQS should be considered [94].
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Chapter 3
Evaluation of Current Genotypes
Imputation Tools Through Data Simulation
3.1 Introduction
Genotypes imputation has led to the discovery of thousands of genetic associations which would
have been missed from the initial studies [60, 95]. Africa is believed to be the ancestral home
for human population and is characterized with the greatest recombination events, leading to
high diversity. Indeed studies have demonstrated that Africa has the highest genetic diversity
worldwide [96]. Consequently, high diversity reduces the accuracy with which the missing
genotypes can be imputed thus making GWA studies in African populations difficult [96]. Further,
Africa is known to be leading in the burden of disease, ranging from communicable diseases
to non communicable diseases worldwide [97]. To address this burden, proper assessment of
imputation tools need to be done in African populations to give guideline for the choice of tool
that is more appropriate when dealing with genotypes data from African descent. This will
definitely improve the power for association studies in African populations and populations with
high genetic diversity.
We assessed the performance of IMPUTE2 [58] and minimac3 [83], minimac4 [90], and BEA-
GLE 4 [91] in imputing simulated data both from African and European population. IMPUTE4
[86] , BEAGLE 5 [60] and minimac4 [90] are among the most current tools that were developed
recently. Although they have been shown to produce superior results in most studies [60], no
study has ever evaluated their performances, including the previous versions, using African
population study data as the point of reference.
In this chapter, we use data from African and European populations to assess the performance
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of the popular and current tools used in imputation to estimate the missing genotypes in simulated
dataset both from African and European populations. We then present a comparison of these
tools, between and within the population. Finally, we give a recommendation of the tool that is
appropriate when dealing with data, especially from African origin.
3.2 Review of Literature
Advancement of high throughput genotyping technologies and a comprehensive catalogue of
human genetic variants have been very instrumental to researchers in finding the genetic variants
that are associated with complex traits [79]. However, missing data is inevitable in any studies
and in genetics in particular. Even with well designed high quality genotyping platforms, some
SNPs will be missing at some sites either due to failures by the assays or missing by design
[79]. If the missing data are not accounted for or are even excluded from association studies, the
genetic studies will suffer from loss of power. Genotypes imputation offers a cost effective way
of recovering variants that have lower call rate or are missing completely in the study sample
through the use of imputation methods [20]. The imputation methods use known information
like patterns of LD between the missing SNPs and their typed flunking SNPs in making inference
or estimating the untyped or missing genetic variants [75]. Imputation therefore increases the
number of genetic variants that can be tested for association hence improving the power of
association studies.
Genotypes imputation can either be carried out across the whole genome or in a particular
region of the genome [20]. When carried out across the whole genome, imputation can facilitate
the identification of novel susceptibility loci in association studies by making more variants
available for testing for the association. Additionally, GWAS data from different genotyping
platforms can be merged in a meta-analysis hence increasing the sample sizes, which consequently
improves the power of association studies [20, 98]. When imputation is carried within a specific
region of the genome, the goal is to fine-map a known susceptibility loci. Thus, the imputation
can find all the variants that are in LD with a given loci therefore making it possible to find the
causal variant.
Comparing the performances of different imputation tools can either be based on a specific
reference panel or based on different sets of reference panels. Usually, when evaluating the
performance of different genotypes imputation tools using a specific reference panel, the objective
is explicitly compare different imputation tools and to find the best tool that gives the highest
imputation accuracy for a given population. However, under this settings the choice of a given
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specific reference panel must be known in advance, for examples can be based on some previous
findings. On the other hand, when using more than one reference panel, then objective is to
compare different reference panels and to find the best reference panel that maximizes the
imputation quality for a given population. Moreover, different imputation tools can be used for
each of reference panel under evaluation and thus can help in the identification of the best tool,
from a given set of tools that gives the highest imputation accuracy.
Several studies have evaluated the performance of different genotypes imputation methods [58,
59, 60, 98, 99]. However, most of these studies have been focusing on the European populations.
In one of the studies for example, Nothnagel et al. compared the performances of four imputation
tools (BEAGLE, IMPUTE, MACH, and PLINK) using German population as the target sample
[100]. This study recommended using either MaCH or BEAGLE for practical use when imputing
GWAS data from German descent [100]. Nonetheless, no such studies has been carried out in
African populations. A notable exception, however, is a study by Howie et al. [58], that used
MalariaGEN datasets from Africa to compare the performance of two imputation tools: IMPUTE2
and BEAGLE. Using two reference panels, Gambian reference panel (GMB), which was obtained
by randomly extracting 100 individuals from the MalariaGEN and Gambian+Ghanians +HM3.afr
(GMB+GHN+HM3.afr) reference panel that had 100 Ghanian from MalariaGEN, 100 Gambians
from MalariaGEN and HM3.afr (phase 3 HapMap sample from Africa) that had 822 haplotypes
from ASW, LWK, MKK, and YRI. This study showed that IMPUTE2 [58] is more recommended
for studies of African descent [58]. However, despite the fact this conclusion has been applied in
most studies, as has been witnessed from the fact that majority of studies from African origin
that require imputation aspect, have actually used IMPUTE2 [58] as illustrated in Table 1.3, this
research only evaluated the performance of two tools. More tools have been developed since
then, and even the tools used in this analysis have undergone several modifications [60]. The
question then is, does the new tools, or the previous tools which have been modified or improved
to their present versions customized enough to handle a diverse populations, like the African
population? Additionally, the reference panels used by this study [58] were very small in size
and contained very few haplotypes as compared to the present reference panels. Notably, the fact
that the reference panel (GMB+GHN+HM3.afr) performed better than the population specific
reference panel (GMB) showed that a reference panel, like 1000 genomes project, that contains
more samples from across different populations should be prioritized over a population specific
reference panel [58].
In other studies, Howie et al. evaluated the effect of pre-phasing on genotype imputation
using three imputation tools, MaCH, IMPUTE2 [58] and minimac [59]. By using GWAS dataset of
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2,490 individuals from Wellcome Trust Case Control Consortium 2 (WTCCC2) for the 1958 British
Birth Cohort, Howie et al. [59] showed that pre-phasing of genotypes data improves imputation
performances. On accuracy, IMPUTE2 [58] and minimac [59] recorded better and similar results
across populations. However, low imputation accuracy were observed from the African American
[59]. Particularly, using genotypes data from Women’s Health Initiative (WHI) study that had
8,421 African Americans with 829,370 SNPs that remained after quality control, Howei et al.
[59] recorded an average R2 of 0.690 using 60 CEU (Utah residents with Northern and Western
European ancestry from the CEPH collection) + 59 YRI (Yoruba in Ibadan, Nigeria) of the 1000
Genomes project reference panel. This, however, improved slightly to 0.693 when pre-phasing
was done with MaCH and later imputed with minimac [59]. Similar results were obtained when
using 1000 genomes reference panel that had 283 EUR (European)+172 Africans. Additionally,
highest average R2 result of 0.73 was obtained from 1000 genomes project reference panel that had
381 EUR+174 Africans [59]. This again clearly shows that better imputation accuracy results can
be obtained when a larger and a more diverse reference panel is used in performing imputation.
Again, from the fact lower imputation accuracy were recorded from African Americans also
highlighted how population diversity affects the performance of imputation tools.
Similarly, in other studies, to address the question of the choice of a reference panel, Liu et
al. [98] used deep Whole Genome Sequencing (WGS) data of 90 European population (EUR) to
assess the performances of three imputations tools; BEAGLE, IMPUTE2 and minimac 2 using two
reference panels: Single population and Multi-population reference panels (referred to ALL in the
study) that had 1092 individuals from 14 populations. Liu and his colleagues demonstrated that
IMPUTE2 and minimac had higher imputation accuracy than BEAGLE, and that using a multi-
ethnic reference panel like 1000 Genomes Project is more beneficial than using a single population
reference reference panel, even when handling a specific population data like the European
dataset [98]. Additionally, in recent studies Vergara et al. [99] compared the performance
of three reference panel: Consortium on Asthma among African Ancestry Populations in the
Americas (CAAPA), Haplotype Reference Consortium (HRC) and 1,000 Genomes project (1000G),
using 3,747 African American populations recruited from two cohorts: HCV and COPDGene
cohorts. Again, 1000G reference panel, which is a multi-ethnic reference panel, recorded the best
performance both in coverage and in accuracy [99].
Here in this study, we evaluate and compare the potential of popular genotypes imputation
method in imputing GWAS data from African, European and admixed populations.
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3.3 Materials and Methods
3.3.1 Study Data and Reference Panels
We simulated three datasets for a five way admixed individuals using fractalSIM [101]. Informa-
tions about each of the datasets is summarized in Table 3.1 and simulation details can be found in
the next section. We further simulated homogeneous datasets that mimics African and European
ancestries. The information of simulation parameters for the homogeneous datasets had been
previously described in [101]. Each simulated population had three datasets as described in the
Table 3.1 below.
Table 3.1: Simulated Data of African, European and Admixed Population
Population No of Individuals Number of SNPs
AFRICAN 1,000 9,139,969
3,000 9,139,969
5,000 9,139,969
EUROPEAN 1,000 9,139,969
3,000 9,139,969
5,000 9,139,969
ADMIXED 1,000 623,330
3,000 623,330
5,000 623,330
3.3.2 Simulation approaches for the admixture datasets
For admixture simulations, we simulated case-control admixture datasets with five way admixture
process at single point using HapMap3 datasets, under null and causal disease model. We
extracted each of the parental population from HapMap3 using PLINK. The parental populations
comprised of samples from EUR (European Ancestry), MAFR (Mixed African Ancestry), SAS
(South Asian Ancestry), WAFR (West African Ancestry) and EAS (East Asian Ancestry), with
each contributing genetic population of 0.15, 0.35, 0.10, 0.30 and 0.10 respectively. A description
for each of the parental population is given in Table 3.2. Simulation approaches for homogeneous
African population and European populations can be obtained from [101].
The simulation parameters were chosen in such a way that the simulated dataset would mimic
the real dataset as much as possible. Indeed Mugo et al. [101] evaluated the resultant dataset
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and demonstrated that the simulated dataset were similar to the parental real dataset in terms
of minor allele frequency distribution and LD structure [101]. Consequently, the imputation
performance on the simulated dataset would reflect that of the real population.
Table 3.2: Ancestral populations for the admixture simulations. ASW are African ancestry in SW USA,
GBR are the British from England and Scotland, IBS represents Iberian populations in Spain,
FIN are the Finnish in Finland, LWK are the Luhya in Webuye, Kenya, ESN are the Esan in
Nigeria, ACB are the African Caribbean in Barbados, YRI represents Yoruba in Ibadan, Nigeria,
GWD are the Gambian in Western Division âA˘S¸ Mandinka, MSL are the Mende in Sierra Leone,
PJL are the Punjabi in Lahore, Pakistan, BEB are the Bengali in Bangladesh, ITU are the Indian
Telugu in the U.K, STU are the Sri Lankan Tamil in the UK, CHB are the Han Chinese in Beijing,
China, CDX are the Chinese Dai in Xishuangbanna, China, CHX are the Han Chinese South,
China, KHV represents Kinh in Ho Chi Minh City, Vietnam and JPT represent Japanese in
Tokyo, Japan
Ancestry DESCRIPTION HapMAP3 Samples Proportion
EUR European Ancestry CEU, GBR, IBS, FIN 0.15
MAFR Mixed African Ancestry LWK, ACB and ASW 0.35
WAFR West African Ancestry YRI, ESN, GWD, MSL 0.30
SAS South Asian Ancestry PJL, BEB, ITU, STU 0.10
EAS East Asian Ancestry CHB, CDX, CHS, KHV, JPT 0.10
For the null disease model admixture simulations, we simulated a null disease model for the
parental populations in chromosomes 1, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16, 18, 19, 21 and 22 in all
the pre-admixture simulation. For the disease causal model, we simulated a causal model in
chromosome 2, 6, 11, 15 and 20. Table 3.3 summarizes the SNPs and their relative risk of the
disease in each of the parental population.
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Table 3.3: Relative Risk for various disease SNPs. HET represents the heterozygous risk effect and HOMO represents
the homozygous risk. BP represent the Base Pair Position while SNP is the SNP ID. SAME implies the
risk effect and position is the same in all the ancestral populations
ANCESTRY CHROMOSOME SNP BP HET/HOMO RISK
SAME 2 rs17042838 113843337 1.001, 1.002
rs13410964 113843283 1.001, 1.002
SAME 6 rs2232238 29942857 1.001, 1.003
MAFR & WAFR 11 rs7106136 64748278 0.981, 0.980
rs10897540 64757496 0.980, 0.983
SAS rs7106136 64748278 0 .995, 0.996
rs10897540 64757496 0.997, 0.996
EAS rs7106136 64748278 0.991, 0.990
rs10897540 64757496 0.990, 0.993
EUR rs7106136 64748278 1.010, 1.015
rs10897540 64757496 1.005, 1.001
MAFR, WAFR & EUR 15 rs365314 62606413 0.9998, 0.9995
SAS & EAS rs365314 62606413 1.0002, 1.0001
MAFR, WAFR SAS, & EAS 20 rs6107104 25922993 1.00001, 1.00003
EUR 20 rs6115375 25871801 1.00001, 1.00003
3.3.3 Phasing and Imputation Using Different Tools
We extracted chromosome 1 to 22 from each of the datasets and phased each chromosome with
EAGLEv2.3. For each chromosome, we obtained a phased vcf output format file. Imputation
was carried out using five popular bioinformatics tools: IMPUTE2, IMPUTE4, MINIMAC3,
MINIMAC4 and BEAGLE4. For each imputation run, we used 1000 Genome Project reference
panel (1KG) as the reference panel. We performed imputation by splitting each chromosome into
5Mb overlapping chunks and thereafter specified the lower and upper bounds for each chunk
in each imputation tool for each imputation run. IMPUTE2 and IMPUTE4 allow this option by
specifying the int command preceded by indicating the lower and upper bound of each chunk.
Similarly BEAGLE4 and BEAGLE 5 has an option for specifying the chromosome and the region
for performing the imputation, in which case can be a chunk of interest. Mininac3 and minimac 4
on the other hand have an option of specifying a given region of the chromosome using –start
and –end flags. Each imputation chunk was submitted in parallel clusters.
We assessed the imputation accuracy using the internal quality metric obtained from each
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imputation program and the imputation concordance. First, we modeled the distribution of
imputation accuracy for each tool verses the minor allele frequencies. For the imputation accuracy
calculation, we only considered the imputed variants that had minor allele frequencies greater
than 0.05. Further we categorized the imputation accuracy into three classes: The first class
represented imputed variants with ma f > 0.05 and the imputation accuracy less than 0.4. We
regarded this class of imputed variants as poorly imputed. The second class were variants with
ma f > 0.05 and the imputation accuracy >= 0.4 but less than 0.7. We adopted the name
moderately imputed for this class. The third class were imputed variants that had ma f > 0.05 and
the imputation accuracy >= 0.7 and the class was considered as well imputed variants. Finally, we
summarized the results in form of tables and figures.
3.4 Results
We compared 5 imputation approaches in imputing simulated datasets that mimic African
populations, European populations and an admixed populations. We used 1,000 genome project
reference panel for imputing the missing variants. Details of this reference panel can be found
from their publication [102]. We used several criteria to evaluate the imputation performance.
First, we modeled the relationship between minor allele frequencies and the imputation accuracy
(using the internal imputation quality metric for each tool). Figure 3.1 (a) shows the relationship
between the imputation accuracy and the minor allele frequencies in Africa populations for the
1,000 samples dataset, while Figure 3.1 (b) and Figure 3.1 (c) for European and Admixed datasets
respectively. As expected, our result shows that imputation accuracy increases with increase in
minor alleles frequencies for all the populations. This is consistent with the previous studies
that modeled the relationship between minor allele frequencies and the imputation accuracy [58].
Interestingly, the effects were more pronounced in the African populations, across the simulated
datasets with different sample sizes than all the other populations as shown in Figure 3.1 below.
Similar trends were displayed by 3,000 samples and 5,000 samples datasets as illustrated in Figure
6.1 and Figure 6.2 in the Appendix section.
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(a) (b) (c)
Figure 3.1: Relationship between minor allele frequency and the imputation accuracy at different minor allele frequency bins for 1,000 samples from African population
(a), European population (b) and admixed population (c).
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We then evaluated the imputation accuracy per simulated population dataset to determine
the best imputation approach for each population. We applied two criteria in evaluating the
imputation accuracy. First, we calculated the percentage number of variants that were considered
as well imputed, moderately imputed and poorly imputed for each imputation method in
each simulated population dataset as described in the method section. We then compared the
imputation accuracy of the tools using different minor allele frequency bins: ma f < 0.01 (rare
variants), 0.01 ≤ ma f ≤ 0.05 (less common variants) and ma f > 0.05 (common variants).
Table 3.4 represents the percentages for the imputed variants with ma f > 0.05 at various
thresholds for the three populations. In Africa populations, for the 1,000 samples dataset, IMPUTE
2 recorded the highest percentage (74.697%) of well imputed variants, followed by IMPUTE4
(66.78%), with BEAGLE4.1 recording the least percentage (35.43%) for the well imputed variants
(Table 3.4). Similar trends were recorded for the 5,000 samples and 3,000 samples data with each
case BEAGLE4.1 performing worst (Table 3.4). However, for the moderately and poorly imputed
variants, BEAGLE4.1 recorded the highest percentages across all the African datasets, with
exception in the 5,000 samples where it recorded 22.88%, which was slightly lower in percentage
than minimac 4 (23.59%) (Table 3.4). The accuracy obtained from the admixed datasets recorded
similar trend to that of African datasets. However, a lower percentage of well imputed variants
were recorded across all the admixed samples, with IMPUTE2 recording the highest percentage
of well imputed across all the admixed datasets. Additionally, with exception of IMPUTE2, more
than half of the imputed variants from the admixed samples were falling within moderately and
poorly imputed categories for all the tools. In BEAGLE4.1 for example, more than 74% of the
variants were poorly imputed (Table 3.4).
For the European datasets, more than 85% of the imputed variants were falling within the
threshold of well imputed for all the tools, across all the datasets. Minimac3 recorded the highest
percentage (94.53%) for the well imputed variants, followed by IMPUTE4 (94.07%) across the
1,000 samples European dataset (Table 3.4). However, for the 3,000 samples and 5000 samples
datasets, IMPUTE4 recorded the highest percentage of well imputed variants (97.07% for the 3,000
samples and 98.68 % for the 5,000 samples). Overall, BEAGLE 4.1 recorded the lowest percentage
for the well imputed variants across all samples. Both the tools recorded less than 5% of the
variants as moderately imputed and less than 11% of the variants as poorly imputed across all
the European samples (Table 3.4).
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Table 3.4: Percentage Number of Imputed variants at different imputation thresholds. Imputed variants that were having > 0.7 imputation accuracy
were classified as well imputed (Well-Imp), while those with imputation accuracy between 0.4 and 0.7 were considered as moderately
imputed (Mod-Imp) otherwise poorly imputed (Poorly-Imp)
Well-Imp Mod Imp Poorly Imp Well-Imp Mod Imp Poorly Imp Well-Imp Mod Imp Poorly Imp
Tools Africa 1000 European 1000 Admix 1000
IMPUTE2 74.7 17.69 7.61 86.6 2.16 3.78 55.38 36.31 8.47
IMPUTE4 66.78 18.69 14.53 94.07 3.16 10.23 44.4 36.46 19.13
MINIMAC3 64.14 17.76 18.1 94.53 1.75 3.72 14.9 27.26 57.84
MINIMAC4 61.98 23.67 14.35 93.98 2.66 3.35 19.99 38.98 41.02
BEAGLE4 35.43 24.75 39.82 85.21 4.79 9.99 7.44 16.9 76.68
Africa 1000 European 1000 Admix 1000
IMPUTE4 67.13 18.66 14.21 97.07 0.96 1.97 44.11 36.5 19.39
IMPUTE2 74.64 17.75 7.61 78.83 16.45 4.72 55.39 36.08 8.47
MINIMAC3 64.19 17.72 18.09 94.62 1.66 3.72 5.77 12.43 81.79
MINIMAC4 62.21 23.66 14.13 94.19 2.42 3.39 19.96 38.95 41.08
BEAGLE4 34.5 24.61 40.89 85.75 4.83 9.42 7.21 16.11 76.68
Africa 1000 European 1000 Admix 1000
IMPUTE4 66.46 17.68 7.66 98.67 22.46 33.87 44.32 36.38 19.29
IMPUTE2 74.66 18.8 14.75 78.31 13.13 8.55 54.93 36.31 8.76
MINIMAC3 64.28 17.7 18.02 94.58 1.71 3.7 14.89 27.11 57.99
Continued on next page
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Table 3.4 – continued from previous page
Well-Imp Mod Imp Poorly Imp Well-Imp Mod Imp Poorly Imp Well-Imp Mod Imp Poorly Imp
MINIMAC4 62.24 23.59 14.17 94.12 2.52 3.37 19.92 38.83 41.23
BEAGLE4 33.63 22.88 43.49 83.77 5.37 10.86 7.98 17.99 74.03
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Table 3.5 shows the comparison of imputation accuracy at different bins for different simulated
datasets. For the simulated African datasets, across all the sample sizes, IMPUTE2 recorded the
highest imputation accuracy for the common variants (80.21 for the 1,000 samples data, 80.23%
for the 3000 samples data and 80.20 % for the 5,000 samples data) and less common variants
(72.11% for the 1000 samples, 72.31 % for the 3,000 samples and 72.24 %) (i.e common variants are
variants with ma f > 0.05 and the less common variants are the variants with 0.01 ≤ ma f ≤ 0.05).
However, for rare variants (varaints with ma f < 0.01) for the same simulated datasets, IMPUTE4
recorded the highest imputation accuracy followed by minimac 4, then minimac 3. However,
BEAGLE4 recorded the lowest imputation accuracy at all minor allele frequency levels (Table
3.5).
For the simulated European datasets, minimac 3 recorded the highest imputation accuracy
followed by minimac 4, IMPUTE4, IMPUTE2 and BEAGLE4 respectively for the common variants.
However, for the less common variants, IMPUTE4 recorded the highest imputation accuracy
followed by BEAGLE4 recording the least across all samples as shown in Table 3.5.
For the admixed individuals, IMPUTE2 recorded the highest imputation accuracy across all
the simulated datasets for both the common variants and the less common variants. IMPUTE4
recorded the highest imputation accuracy across all the simulated datasets for the rare variants
regardless of the population. Imputation accuracy for the simulated admixed datasets recorded
similar trend to that of the African samples across all the tools with the only difference being on
the percentage accuracies (Table 3.5).
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Table 3.5: Percentage Imputation Accuracy at different minor alleles frequency (MAF) bins.
Africa 1000 European 1000 Admix 1000
MAF>0.05 0.01<=MAF<=0.05MAF<0.01 MAF>0.05 0.01<=MAF<=0.05MAF<0.01 MAF>0.05 0.01<=MAF<=0.05MAF<0.01
IMPUTE2 80.21 72.11 7.020 92.41 86.85 12.33 69.46 51.02 7.300
IMPUTE4 75.64 59.84 43.42 94.10 90.15 76.13 62.79 37.42 29.28
MINIMAC3 73.94 57.52 12.11 94.4 88.18 17.08 37.94 11.42 0.970
MINIMAC4 73.58 59.50 12.86 94.31 88.84 16.98 46.33 24.47 3.33
BEAGLE4 57.14 40.92 5.23 85.77 63.09 10.08 20.51 8.310 1.050
Africa 3000 European 3000 Admix 3000
MAF>0.05 0.01<=MAF<=0.05MAF<0.01 MAF>0.05 0.01<=MAF<=0.05MAF<0.01 MAF>0.05 0.01<=MAF<=0.05MAF<0.01
IMPUTE2 80.23 72.13 7.270 81.35 75.48 14.46 69.52 51.12 8.26
IMPUTE4 75.94 60.20 42.07 94.02 89.79 75.29 62.61 37.47 26.09
MINIMAC3 74.01 57.76 13.31 94.54 87.95 19.53 22.80 11.96 0.990
MINIMAC4 73.77 59.76 13.38 94.45 88.66 19.41 46.31 24.57 3.67
BEAGLE4 56.64 40.50 6.170 86.66 63.39 12.04 20.16 8.130 1.080
Africa 5000 European 5000 Admix 5000
MAF>0.05 0.01<=MAF<=0.05MAF<0.01 MAF>0.05 0.01<=MAF<=0.05MAF<0.01 MAF>0.05 0.01<=MAF<=0.05MAF<0.01
IMPUTE2 80.2 72.24 7.270 82.21 74.27 11.21 69.28 51.11 8.660
IMPUTE4 75.38 59.64 41.30 93.68 88.86 75.24 62.70 37.83 24.68
MINIMAC3 74.06 58.08 13.42 94.55 88.04 20.23 37.85 11.51 1.010
MINIMAC4 73.75 59.97 13.49 94.45 88.72 20.10 46.24 24.61 3.720
Continued on next page
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Table 3.5 – continued from previous page
MAF>0.05 0.01<=MAF<=0.05MAF<0.01 MAF>0.05 0.01<=MAF<=0.05MAF<0.01 MAF>0.05 0.01<=MAF<=0.05MAF<0.01
BEAGLE4 55.45 40.19 5.960 84.98 58.01 12.02 21.23 8.480 1.260
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Finally, we compared the imputation concordance the common variants. We restricted the
comparison to common variants since it has been previously shown that direct comparison
of concordance rate for low frequency or rare variants generally leads to incorrect assessment
of imputation accuracy [94]. Table 3.6 shows the comparison for imputation concordance for
different datasets. Just like in imputation accuracy, IMPUTE2 recorded the highest imputation
concordance with at least 99.2% concordance across all the simulated African datasets. IMPUTE4
equally recorded higher concordance with at least 97.8% across all the African datasets whereas
minimac3, minimac4 and BEAGLE 4 recorded slightly lower imputation concordance percentage
with BEAGLE 4 recording the lowest. Similar trend was observed for the admixed datasets, with
IMPUTE2 recording the best concordance percentage and BEAGLE4 recording the least. However,
for simulated European datasets, IMPUTE4 recorded the highest concordance percentage that all
the other tools. Interestingly, we obtained higher concordance percentages across all the tool with
each tool attaining at least 99.90% concordance as shown in Table 3.6.
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Table 3.6: Percentage imputation concordance for variants with maf>0.05.
Africa 1,000 European 1,000 Admix 1,000
IMPUTE2 99.21 99.90 90.92
IMPUTE4 97.97 99.99 87.09
MINIMAC4 89.02 99.93 88.86
MINIMAC 3 89.64 99.97 88.93
BEAGLE4 87.14 99.96 87.57
Africa 3,000 European 3,000 Admix 3,000
IMPUTE2 99.27 99.96 91.12
IMPUTE4 97.88 99.99 87.51
MINIMAC4 89.30 99.93 87.87
MINIMAC 3 90.71 99.97 89.19
BEAGLE4 88.53 99.93 87.57
Africa 5,000 European 5,000 Admix 5,000
IMPUTE2 99.21 99.96 91.31
IMPUTE4 97.97 99.99 87.50
MINIMAC4 89.02 99.94 87.79
MINIMAC 3 89.64 99.97 89.14
BEAGLE4 87.14 99.93 87.57
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3.5 Discussion and Recommendation
Imputation has been recognized as one of the gold standard methods in Genome Wide Association
Studies (GWAS) owing to its potential of increasing the number of markers that can be tested
for association, hence improving the power of association studies [60] through fine-mapping,
meta-analysis and functional GWAS. Several tools for performing genotypes imputation have
been proposed and as such, their evaluations are very important as it can inform studies of
the best tool that suits a given population. By using simulated genotypes that mimics African,
European and admixed populations, we performed imputation with five popular, current and
widely used imputation methods: IMPUTE4, minimac 4, BEAGLE4, minimac 3 and IMPUTE2
using 1000 Genomes Project reference panel. All the imputation programs requires the genotypes
data to be pre-phased with exception of IMPUTE2 and BEAGLE 4 that perform both phasing and
imputation. However, for better imputation experience, the developers recommends pre-phasing
the study data. IMPUTE4 is the latest version of IMPUTE tools and represents a modification
of IMPUTE2 to accept only a pre-phased study data. Minimac4 on the other hand is the latest
version of minimac tools, and represents recent software advancements that have been developed
to efficiently handle large reference panel at a lower computation cost and high accuracy [54]. We
used 1000 genome project reference panel as the reference panel for imputing the missing variants.
Details for the reference panel can be found from the developers website [102]. Our results,
however, mainly focuses on the simulated dataset of African populations, which has had little
attention as far as the evaluation of imputation performances for various methods in different
populations are concerned. Additionally, we compared the imputation performances for the
simulated African populations with that of the European populations and a multi-way admixed
populations (as summarized in Table 3.3), which actually is the largest admixture individuals
ever evaluated. Schurz et al. [103], for example, recently evaluated imputation performace on
the South African colored (SAC) population, which is considered as a 5 way multi-admixed
individuals, which as at that time was considered the largest admixed individuals ever evaluated.
Our study therefore raises very serious considerations, since international migration expands at
an exponential rate, we will soon have populations that are more than 5 way admixed individuals
and as such, current tools should be advancing for the challenge that comes with admixed
populations.
To put the results into context, we also modeled the relationship between minor allele
frequencies and the imputation performance for each tool. Previous studies have demonstrated
that the imputation accuracy increases with the increase in the frequency of the minor alleles.
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As expected, and as shown in Figure 3.1, and Figure 6.1 and Figure 6.2 in the Appendix section,
our results suggested similar trends for all the imputation tools across all simulated African
and European populations. However, the simulated admixture population that recorded mixed
results where the imputation accuracy increases and declines at some point with increase in
minor alleles frequency. We nevertheless address a number of questions including: what is the
best imputation approach for the African populations? How do current imputation approaches in
Africa population compare with European populations and the admixed populations? Does the
recent version of the imputation tools customized enough to handle African populations? Does
the size of the study sample affects the imputation performance?
Based on the overall imputation performance, our results suggest that IMPUTE2 and IMPUTE4
should be the preferred choice when imputing data from homogeneous African decent, especially
from West and Central Africa, and can make better imputation prediction than minimac 3,
minimac 4 and BEAGLE4.1. However, BEAGLE 4 consistently gave lower imputation performance
across all the three datasets of the simulated African origin. For the European populations descent,
most of the softwares gave comparatively higher imputation quality. Indeed, all the softwares
recorded a mean of more than 85% imputation quality for the common variants and a mean
of over 60% for the less common variants. Based on the common variants alone, minimac 3
recorded the highest imputation quality, followed by minimac 4 and IMPUTE4. However, for
the rare and less common variants IMPUTE4 recorded the highest imputation accuracy. In fact,
IMPUTE4 recorded a mean of over 75 % for the rare variants across all the European samples,
which was higher than what was attained by best tool (IMPUTE2) in the simulated African
datasets based on common variants. For the admixed individuals, we obtained lower imputation
qualities across all the samples. Nevertheless, IMPUTE2 gave the highest imputation accuracy
and BEAGLE4.2 recorded the least imputation quality. Our results highlights that although
Africa populations could be diverse, admixed individuals could be more diverse than the African
populations and hence can present serious challenges for the imputation programs as evidenced
by the results. Moreover, majority of African populations are highly admixed and similar results
may be obtained in such populations.
Our results also suggests that imputation performance does not depend on the size of the study
data but rather on the size of the reference panel, supporting previous finding [91]. Particularly,
our study recorded very low or no effect of the imputation quality as a function of the size of
the study sample for all the populations, across all the simulated datasets. Previously, Huang
et al. [104] for example observed that when the sample size is small (about 10 individuals) and
no reference panel is used, the boost in accuracy is generally very high as more individuals are
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added into the study data. However, this reaches a plateau at some point, and the accuracy does
not improve with increase in the number of individuals. In contrast, when a reference panel is
used in performing imputation, then the imputation quality generally increases with increase in
the size of the reference panel and does not generally depend with the size of the study sample
[104]. Similarly, Zheng et al. [105] showed that using the largest and a diverse reference panel like
the 1000 genome project reference panel, that we used in this study, results to better imputation
quality. This is because, larger and a diverse reference panel can contain more information on
the parental diversity than a population specific reference panel, hence improving the chances of
imputing the rare variants [58].
Further, we observed that even though the imputation tools have been advancing to the newer
versions, or newer tools being developed altogether, our results suggest that these advancements
are so far not customized enough to capture the low linkage of disequilibrium and higher diversity
within the African populations and the admixed populations. Surprisingly, all the newer version
of the imputation programs recorded lower imputation accuracy than their older versions for
both the African and Admixed populations. It this therefore very clear that the newer version
or the new imputation programs are being developed to reduce the running time in processing
large reference panels, and not to account for the genetic diversity and patterns of LD like those
found in African and admixed populations. Nevertheless, for the European populations, there
was a substantial improvement in imputation quality. Although not assessed by the current study,
the computation speed for all the newer versions improved considerably and the experience were
far much better as compared with the older versions.
Previous studies that compared the performance of genotypes imputation in different popula-
tions have shown that European population have higher imputation accuracy than the African
and the admixed populations. Huang et al for example evaluated imputation accuracy on 29
populations [104]. Based on their results, the highest accuracy was observed from the European
populations, then East Asian population, followed by East Asia, Central Asia, South Asia, Amer-
ica, Oceania and Middle East, and Africa recorded the least. However, our study extends this
further and applies the recent and a more diverse reference panel, 1000G reference panel, and
the most recent version of the imputation programs, as opposed to Huang et al. [104] that only
evaluated the performance based on only one imputation program (MACH), which has been
overtaken by the newer version of the imputation programs. In other studies, Hancock et al.
also evaluated imputation performance in African American individuals using four imputation
programs: IMPUTE2, MaCH, BEAGLE, MaCH-Admixed. Interestingly, IMPUTE2 recorded the
overall highest imputation quality of 0.68 when using the reference panel that comprises of
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YRI+CEU+ASW, which dropped to 0.55 when the whole 1000 Genomes reference panel was
used, similar to our findings for the admixed populations for the common variants. Remarkably,
this findings illustrated that the comparison of imputation metric can be assessed directly by
the internal metric from the imputation programs. Specifically, the evaluation based on internal
quality metric and that of masked analysis generated the same conclusion as far as the best
performing software is concerned [106]. Elsewhere, Liu et al. compared the performance of
IMPUTE2, minimac and BEAGLE 3 in European populations [98]. IMPUTE2 and minimac
performed better than BEAGLE, and that the speed of both the programs, although not evaluated
here, were superior to that of BEAGLE. Similarly Nothnagel evaluated the performances of
imputation tools using German Descent populations[100] and recommended either BEAGLE or
MACH for performing imputation the German descents.
The inability of the imputation tools to capture this diversity highlights that indeed imputation
tools have still a long way to go and should be prepared for such challenges. Our study highlights
the need of newer and robust imputation tools that can handle the diversity and low LD patterns
of the admixed and African populations.
In conclusion our study is the first to evaluate potential of genotyoes imputation tools in
African populations using the most current software tools. African and Admixed population
recorded very low quality imputation for both low frequency SNPs (SNPs with MAF between
0.01 and 0.05) and rare SNPs (with MAF<0.01). Irregardless of the software used, or the best
software from the results, our study highlights that future tools should exploit models that can
capture the diversity and patterns of LD found in African and admixed populations. Moving
forward, IMPUTE2 should still be the preferred method when imputing data from African or
admixed populations regardless of its computation cost.
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Chapter 4
Raw Genotypes Verses Summary Statistics
Imputation on Malaria GWAS from
MalariaGen
4.1 Introduction
Hidden Markov model based imputation methods have been applied as the gold standard
for performing genotypes imputations [107]. However, these methods can only be applied to
individual level genotypes [84], which in most cases may not be readily available due to the logical
constraints or confidentiality [107] and the process for data sharing can be very time consuming
given data sharing agreements that have to be met [108]. Nevertheless, it has been shown that
comparative power in association studies can be achieved when the imputation is implemented
at summary statistics level, which in most cases are readily available from the published findings
[84]. Indeed studies have demonstrated that imputation from summary statistics has a potential
of recovering almost the same signal as that of individual level genotypes imputation with
minimal or no increase in false positive association rate [84]. Moreover, summary statistics based
imputation is known to be very fast and computationally more efficient than the individual level
genotypes imputation methods [84, 107]. Additionally, it has been shown to improve the power
of enrichment in most loci [84] thus making it very essential for enrichment analysis.
There exists many summary statistics based imputation tools. Some of the most commonly
used summary statistics based imputation methods include ImpG [84], DIST [107], DISTMIX
[109] (which is a modification of DIST to handle both homogeneous and admixed population),
DISSCO [108] and many more. To date, although the comparison of different summary statistics
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based imputation is still lacking, ImpG [84] (which applies Multivariate Gaussian method to
estimate associations at various missing SNPs) is considered the most popular method. In fact, in
one of the studies that evaluated the performance of this tool demonstrated that it can recover as
much signal as that obtained via raw genotypes based imputation [84]. Particularly, this study
showed that summary statistics based imputation with this method (ImpG) can recover up-to
approximately 87% of the effective sample size, which is almost the same as individual level
genotypes imputation, which can recover up-to 89% of the effective sample size [84].
While several studies have compared summary statistics based imputation [84, 107, 109],
evaluation of the performance of any summary statistics based imputation in African populations
is still lacking. In this chapter, we compare the performance of two imputation approaches:
Imputation via summary statistics using IMPG [84] and imputation on the raw genotypes data
using IMPUTE2 [58] , which we have identified as the best tool for imputing GWAS data from
African populations. We then perform a meta-analysis of the imputed datasets. Finally, we
perform a pathway analysis using the meta-analysis results.
4.2 Comparison of GWAS from Raw Genotypes Data Imputed
with IMPUTE2 [58] and Summary statistics from ImpG
4.2.1 Study Data, Imputation and Quality Control
We obtained both raw genotypes and summary statistics data of children diagnosed with severe
malaria for the Kenyan population from MalariaGen website, which is available for public access.
The data was initially applied in GWAS of severe malaria [30]. All the quality control steps, DNA
extraction and sequencing are well described in the publication paper ([30]).
The study datasets contained case/control subjects that had severe malaria from the African
populations: Kenya, Gambia and Malawi. We did quality control with PLINK 2.0 [110] on
3,142 individuals (1,505 cases and 1,474 controls and 163 missing phenotypes) from the Kenyan
population, 4,179 from The Gambia and 4,473 from Malawi. We excluded the imputed SNPs
that had less than 0.7 imputation in f o and then applied missingness test (geno>0.05), minor
allele frequency test (maf<1%) and Hardy Weignberg Equilibrium (–hwe include-nonctrl <0.0001).
Additionally, we applied a less stringent HWE on both cases and controls (hwe<0.0000001) and
conducted a heterozygosity check removing individuals that deviated more than 3 times the mean
heterozygosity rate. Further, we performed relatedness check (pˆi > 0.1875 (median of 2nd degree
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relative and 3rd degree relatives), removing individuals with the lowest call rate in each of the
closely related individuals pairs. We finally retained curated datatsets with a total of 14,663,086
SNPs (for the 1,505 are cases and 1,474 are controls), 7,558,176 SNPs (for the 2429 cases, 2,491
controls) and 8,193,112 SNPs (for the 1,193 cases and 1,321 controls) for Kenya, Gambia and
Malawi populations respectively.
To evaluate the possibility of population substructure and self reported ethnicity in the
datasets, we characterized the presence of population substructure in the data which can bias the
GWAS findings by performing Principal Component Analysis (PCA). We applied PLINK 2.0 in
calculating the first top ten principal components (PCs) for each of the curated datasets. We then
plotted all the individuals on the first two PCs as shown in Figure 4.1 for Kenya (A), for Malawi
(B) and (C) for The Gambia.
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Figure 4.1: Principal Component Analysis plots for Kenya (A), Malawi (B) and Gambia (C) using the first two top Principal Components (PCs).
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As expected, we observed substantial population substructure across all the datasets. Some
individuals across all the populations could be assigned to a distinct ethnic group whereas
others seem to have complex ancestries, and could not be assigned to any specific ethnic group.
Importantly cases and controls were not separated using the plot of the forst two PCs as shown in
the Figure 4.1. Nevertheless, we included the first ten PCs as covariates in the association analysis
on the curated datasets to account for the self reported ethnicity and population substructure.
Additionally, we applied a mixed model approach implemented in EMMAX in calculating the
kinship matrix, which we thereafter included in the logistic regression. All the analysis were
based on the additive model of association.
For the summary statistics data, we retained only SNPs that had r2pred > 0.6, which is an
internal accuracy measure by ImpG, for the downstream analysis. There were 7,835,854 for the
Kenyan sample, 6,986,174 SNPs for the Gambian sample and 7,958,269 SNPs from Malawi.
4.2.2 Results
Association Result for Raw Genotypes Based Imputation
Figure 4.2 (a), 4.3 (a), and Figure 4.4 (a) shows the Q-Q plot for Kenya, Gambia and Malawi
respectively. The genomic control (λGC) for Kenya was 1.054428, 1.050381 for The Gambia and
1.052303 for Malawi. All these genomic control values are acceptable and suggest very little
deviation from the null expectation. On the other hand, Figure 4.2 (b), 4.3 (b), and Figure 4.4 (b)
shows the respective Manhattan plots for Kenya, The Gambia and Malawi. The genome wide
significance threshold was set at 5× 10−8 and is represented by the red line in each Manhattan
plot. No SNP surpassed this threshold for Malawi and Gambia associations. However, there were
some SNPs on chromosome 11 from the Kenya dataset that surpassed the threshold value.
For the summary statistics, the genomic control values were 0.9957279, 0.988425, 0.9983602 for
Kenya, Gambia and Malawi respectively. All these values suggest a little deflation of the P-values,
and little departure from the null expectation.
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(a)
(b)
Figure 4.2: QQ-Plot and Manhattan plot for GWAS of raw genotypes from Kenya. The Genomic control value after adjusting for the covariates was 1.054428 and
suggest very little departure from the null expectation. Some SNPs, on chromosome 11, surpassed the genome wide threshold.
72
(a)
(b)
Figure 4.3: QQ-Plot and Manhattan plot for GWAS of raw genotypes from The Gambia. The Genomic control value after adjusting for the covariates was 1.044292
and suggest very little departure from the null expectation. No SNP attained the genome wide threshold.
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(a)
(b)
Figure 4.4: QQ-Plot and Manhattan plot for GWAS of raw genotypes from Malawi. The Genomic control value after adjusting for the covariates was 1.045736 and
suggest very little departure from the null expectation. No SNP attained the genome wide threshold.
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Association Result for Raw ImpG Imputed Summary statistics
Figure 4.5 (a), 4.6 (a), and Figure 4.7 (a) shows the Q-Q plot for Kenya, The Gambia and Malawi
respectively. The genomic control (λGC) were 0.9957279, 0.988425, 0.9983602 for Kenya, Gambia
and Malawi respectively. All these values suggest a little deflation of the P-values, and little
departure from the null expectation. Similarly, Figure 4.5 (b), 4.6 (b), and Figure 4.7 (b) shows
the respective Manhattan plots for Kenya, The Gambia and Malawi. Just like the raw genotypes
imputed by IMPUTE2 association, we set the genome wide significance threshold at 5× 10−8
and is represented by the red line in each Manhattan plot. However, no SNP surpassed the
significance threshold for all the datasets.
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(a)
(b)
Figure 4.5: QQ-Plot and Manhattan plot for ImpG imputed summary statistics from Kenya. The Genomic control value after excluding the strand ambiguous SNPs
and SNPs with r2 pred < 0.6 was 0.9957279. No SNP attained the genome wide threshold.
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(a)
(b)
Figure 4.6: QQ-Plot and Manhattan plot for ImpG imputed summary statistics from Kenya. The Genomic control value after excluding the strand ambiguous SNPs
and SNPs with r2 pred < 0.6 was 0.988425. No SNP attained the genome wide threshold.
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(a)
(b)
Figure 4.7: QQ-Plot and Manhattan plot for ImpG imputed summary statistics from Kenya. The Genomic control value after excluding the strand ambiguous SNPs
and SNPs with r2 pred < 0.6 was 0.9983602. No SNP attained the genome wide threshold.
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Comparison of GWAS from imputed raw genotypes and imputed summary statistics
To break down the results further, we lowered the genome wide threshold at various P-values
and compared the number of SNPs at each P-value thresholds for association results from the raw
genotypes data and the association result for the ImpG summary statistics. Table 4.1 shows the
number of SNPs at various P-value thresholds. At the stringent genome wide threshold of P-value
<= 5× 10−8, there were 9 significant SNPs from the Kenyan GWAS from the raw genotypes.
However, there were no significant SNPs for both GWAS of raw genotypes from Malawi and
The Gambia at this stringent GWAS threshold. Similarly there were no significant SNPs for all
the population from the ImpG summary statistics at this threshold as shown in Table 4.1. At
P-value of < 5× 10−7, we obtained 12 SNPs from Kenyan GWAS of raw genotypes imputed by
IMPUTE2 and 3 SNPs from Malawi GWAS from ImpG. Finally, at P-value < 5× 10−6, there were
no significant SNPs for the raw genotypes data from Malawi GWAS whereas Kenya and Gambia
had 76 and 39 respectively. On the other hand, for ImpG imputed summary statistics, Malawi
had the highest number of SNPs that attained P-value of < 5× 10−6, followed by Kenya with 3
SNPs and The Gambia with 2 SNPs.
Table 4.1: Signifiant SNPs at various thresholds from the GWAS of raw genotypes from Kenya, Malawi and Gambia
imputed with IMPUTE2 [58] , and the GWAS of imputed summary statistics using ImpG from the same
populations respectively.
P-value Population Number of SNPs (IMPUTE2 [58] ) Number of SNPs(ImpG)
P-value <= 5.0× 10−8 Malawi 0 0
Kenya 9 0
Gambia 0 0
P-value <= 5.0× 10−7 Malawi 0 3
Kenya 12 0
Gambia 0 0
P-value <= 5.0× 10−6 Malawi 0 8
Kenya 76 3
Gambia 39 2
Finally, Table 4.2 list the SNPs that were identified to be associated with severe malaria with
P-Value < 5.0× 10−8. All the 9 SNPs were located on chromosome 11 and were identified from
the association studies of the Kenyan raw genotypes data after imputation with IMPUTE2. Of
these, 3 SNPs were located on the HBG2 gene. The remaining SNPs were not mapped to any
gene from the dbSNP database. The other SNPs that were identified at various P-value thresholds
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are listed in the Appendix 6.
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Table 4.2: Table showing the SNPs that were identified to be associated with severe malaria with P-value 5.0× 10−8. * represents the variants that were found in the
dbSNP but was not mapped to any gene and # represent SNPs that were not found in the dbSNP but existed the association file.
CHR SNP BP Gene A1 A2 MAF BETA SE P
11 rs143022364 4617306 * A G 0.072437 -0.141144 0.025209 2.15648e−08
11 rs12295158 5252794 * G A 0.0955631 -0.130534 0.0224625 6.20201e−09
11 rs112075505 5276402 HBG2 T TTTAAAG 0.072314 -0.160681 0.0255521 3.20877e−10
11 rs112035597 5277116 HBG2 A G 0.072314 -0.160681 0.0255521 3.20877e−10
11 rs113981422 5277117 HBG2 A C 0.072314 -0.160681 0.0255521 3.20877e−10
11 rs12292063 5302406 * A G 0.0744936 -0.155516 0.025345 8.46414e−10
11 kgp12988299 5304648 # G A 0.0609265 -0.207343 0.0274388 4.13903e−14
11 rs111978456 5311492 * GC G 0.0683305 -0.185135 0.0262375 1.7121e−12
11 rs145843585 5321510 * C CAGG 0.0593421 -0.216745 0.0279629 9.10445e−15
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4.2.3 GWAS-based Imputation: Discussion
Our study focused on the comparison of two imputation approaches: imputation via summary
statistics and imputation via raw genotypes data from Kenya, Malawi and Gambian populations.
We have shown that imputation via raw genotypes has more power in identifying SNPs that are
associated with a phenotype. For example, we obtained a total of 11 significant associations from
the GWAS of dataset that was imputed with IMPUTE as opposed to no significant association
from the summary statistics that was imputed with ImpG. Moreover, our results further suggests
that despite the fact that imputation via summary statistics is possible, the P-values generated
from such studies are in most cases deflated and could not be corrected even upon application
of further QC. As such, it almost impossible to assess the bias from GWAS findings due to
population stratification or hidden relatedness from such associations. Previously, in the initial
application of ImpG [84], Pasaniuc et al. obtained a λGC = 0.94 and they further observed that
this could be improved up-to λGC = 1.00 upon inclusion of the pairwise correlation among the
SNPs from the GWAS data. However, this information may not be available from most summary
statistics and thus we did not consider that possibility in our analysis.
In other studies, Lee et al. evaluated the performance of DISTMIX [109], which is also
a summary statistics based imputation program, and IMPUTE2 [58] in imputing data from
Psychiatric Genetic Consortium Schizophrenia Phase 2 [109]. Their results show that GWAS
conducted from data imputed by IMPUTE2 [58] has more potential in identifying more SNPs
associated with any given phenotype. Nonetheless, the authors showed that some associations
were identified by DISTMIX that were never identified by IMPUTE2 based association just like in
our findings. Additionally, although they showed that DISTMIX can reduce the false positive
errors that can bias the GWAS findings, this study did not calculate the genomic control value
which has a potential of quantifying whether the GWAS results are inflated or deflated.
Out of the 9 significant SNPs, all from chromosomes 11, three were located on the protein
coding gene, HBG2. The HBG2 gene is known to be expressed in the fetal liver, spleen and bone
marrow [111]. Previously, this gene, has been tested with association with Malaria [10] from the
Gambian samples. However, there was only one SNP (from Jallow et al. studies) within 50 kb
region of HBG2 and HBG1 hence was insufficient to warrant any association [10]. HBG2 gene on
the other hand has been previously shown to be associated with sickle cell disease in Tanzania
[112]. Interestingly, all the three SNPS had a P-Value 3.20877−10 with BETA equal to -0.160681.
However, the five other significant SNPs had only been validated via frequency and clustering
and were not mapped to their respective genes and one SNP could not be identified from the
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dbSNP database.
In the next Section 4.3, we apply a meta-analysis of these studies and try if we can replicate
and improve the association signal of these findings in a meta-analysis sample.
4.3 Meta-Analysis
4.3.1 Methodology
We then sought to compare the meta-analysis using the summary statistics from ImpG and the
meta-analysis using summary statistics from the raw genotypes imputed by IMPUTE2 [58]. Only
SNPs that were common in all the datasets (Kenya, Gambia and Malawi) were retained for meta-
analysis. We used METASOFT [113] tool, which has the potential of carrying out meta-analysis
using both fixed, random effect, binary effect and the Han and Eskin random-effects model
[113, 114]. We used an in-house python script to obtain the set of SNPs that were common among
the datasets in each case. To control any possible confounding from population stratification, we
first run all the SNPs without −lambdamean and −lambdahetero parameters in the METASOFT. We
then obtained the values as −lambdamean = 0.974629 and −lambdahetero = 0.599252 from the log
files of the meta-analysis run for the raw genotypes GWAS data imputed by IMPUTE2 [58] and
−lambdamean = 4.859256 and −lambdahetero = 1.005534 for the ImpG summary statistics. We then
repeated the meta-analysis by supplying these values to the METASOFT as recommended [114].
Variants with meta-analysis p-values less than < 5× 10−8 were considered significant.
4.3.2 Results and Discussion
We obtained a total of 7,805,875 common SNPs across the three studies for IMPUTE2 based
meta-analysis and a total of 840,249 from the ImpG based meta-analysis. Table 4.3 summarizes
the number of SNPs at various P-value thresholds.
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Table 4.3: Number of SNPs at different P-value threshold for different models from the meta-analysis of GWAS that was generated by datasets that
were imputed with IMPUTE2 and meta-analysis of summary statistics that was imputed by ImpG.
P-Value Fixed Effect Random Effect Binary Effect
IMPUTE2 ImpG IMPUTE2 ImpG IMPUTE2 ImpG
5× 10−8 1 10 1 7 2 5
5× 10−7 2 49 2 42 3 14
5× 10−6 19 150 6 119 17 73
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We identified a total of 27 SNPs above the P-value threshold of < 5.0× 10−6 for the IMPUTE2
based meta-analysis. Table 6.1 in Appendix lists all these SNPs, their base pair position (BP), the
genes where there are located on and their P-values under various models. Of these SNPs, only
two SNPs had a P-value of < 5.0× 10−7 across all the models (random effect, fixed effect and
binary effect). Of the two SNPs, one SNP was identified to be significantly associated with severe
malaria at P-value < 5.0× 10−8 across all the models. This SNP was identified as rs12295158
located in the HBB gene, which causes sickle cell disease for the homozygotes and has a protective
effect for the heterozygotes [30]. Table 4.4 further list the SNPs that had a P-value of <= 5.0−7
across all the meta-analysis model for IMPUTE2 based meta-analysis.
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Table 4.4: Top SNPs that had a P-Value of less that 5.0−8 across all the models of meta-analysis of the GWAS from datasets imputed by IMPUTE2.
P-FE and B-FE are the P-value and beta under fixed model; P-RE and B-RE are the P-value and beta under random effect; P-BE is the
P-value under binary effect.
SNP BP GENE P- FE BETA-FE P-RE BETA-RE P-BE
rs3837432 205757 B3GNTL1,SCGB1C1 7.62690× 10−12 -0.0373725 7.62690× 10−8 -0.0373725 5.04733× 10−7
rs12295158 5252794 HBB 2.87576× 10−12 -0.125517 2.87576× 10−12 -0.125517 9.63597× 10−12
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On the other hand, for ImpG based meta-analysis, 7 SNPs attained a P-value threshold of
< 5.0× 10−7 across all the meta-analysis models (random effect, fixed effect and binary effect).
Table 4.5 lists all these SNPs, their base pair position, genes they are located on among others. Of
these, only two SNPs had P-value of < 5.0× 10−8 across all the meta-analysis models. These SNPs
were rs183731078, which is located in RFX3 gene, and rs8096513, which is located in DLGAP1 gene.
RFX3 is a protein coding gene that encodes transcription factors, and is a member of the gene
family of the regulatory factors X [115]. DLGAP1 on the other hand is also a protein coding gene
and has been shown to be associated with diseases like schizophrenia and Obsessive-Compulsive
Disorder among others [116]. Several other SNPs showed strong but not conclusive associations
using different models. A total of 159 SNPs attained a P-value of < 5.0× 10−6. Table 6.2 in the
Appendix list all these other SNPs.
Table 4.5: SNPs that had a P-Value of 5× 10−7
SNP BP GENE P- FE BETA-FE P-RE BETA-RE P-BE P-Kenya P-Malawi P-Gambia
rs60577152 5079600 ITPR1 1.78471× 10−8 0.948862 1.78471× 10−8 0.948862 1.21524× 10−7 0.000166278 0.00652561 0.00100309
rs74857376 1731779 GMDS 2.67359× 10−8 0.929216 2.67359× 10−8 0.929216 1.93380× 10−7 0.00132840 0.00199223 0.000851119
rs114760297 6534810 LY86-AS1 3.24272× 10−8 0.980051 3.24272× 10−8 0.980051 2.23611× 10−7 0.000407766 0.00628715 0.000915931
rs183731078 3780522 RFX3 8.39562× 10−9 0.899794 8.39562× 10−9 0.899794 4.46842× 10−8 0.000157072 0.0115578 0.000163379
rs111685758 114426898 RBM19 1.46762× 10−8 0.890990 1.46762× 10−8 0.890990 1.07231× 10−7 0.00109744 0.00130871 0.000827569
rs112736328 128188145 LOC440117 1.27092× 10−8 1.00007 1.27092× 10−8 1.00007 9.10594× 10−8 0.00480794 0.000325555 0.000595629
rs8096513 4455491 DLGAP1 1.42909× 10−9 1.03503 1.42909× 10−9 1.03503 1.00692× 10−8 0.00455867 1.35397× 10−5 0.00106408
4.3.3 Identification of significant SNPs using m-value cut-off
To ensure that the SNPs identified were indeed significantly associated with severe malaria. We
calculated meta-analysis P-value and restricted the calculation to only SNPs that were identified to
have an effect by applying an m-value approach implemented in METASOFT, and then computing
the combined P-value. We retained only SNPs that had an m-value of > 0.9 in at least two studies
and a combined meta-analysis P-value of < 5.0× 10−8. Figure 4.8, 4.9 and 4.10 shows the forest
plots of these SNPs together with their respective P-M plots. For this, rs12295158 on the HBB gene
that was obtained from the meta-analyis of datasets that was imputed with IMPUTE2 met this
criteria and obtained a meta-analysis P-value of 1.06−14 . On the other hand, for ImpG summary
statistics meta-analysis, we again retained all the two SNPs, rs183731078 which belongs to RFX3
gene and rs8096513, which is located in DLGAP1 gene, with combined meta-analysis P-Value of
7.69× 10−9, 1.30× 10−9 respectively. Figure 4.8, 4.9 and 4.10 illustrates the forest plots of these
SNPs.
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Figure 4.8: Forest plot of the rs12295158 of the HBB gene from the meta-analysis of the case-control datasets of severe malaria from Kenya, Malawi and Gambia. The
data was first phased and imputed with IMPUTE2 and finally a meta-analysis was performed on the summary statistics of the imputed datasets. The
combined P-value for the meta-analysis was 1.06× 10−14 with logs of odds ratio of ≈ −0.13 implying a protective effect
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Figure 4.9: Forest plot of rs8096513 of the DLGAP1 gene from the meta-analysis of the case-control dataset of severe malaria from Kenya, Malawi and Gambia from
the summary statistics that was imputed by ImpG. The combined meta-analysis P-value was 1.30× 10−9 with logs of odds ratio ≈ 1.0, which implies the
effect is neither protective nor increases the risk.
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Figure 4.10: Forest plot of rs183731078 of the RFX3 gene from the meta-analysis of the case-control dataset of severe malaria from Kenya, Malawi and Gambia from
the summary statistics that was imputed by ImpG. The combined P-value for the meta-analysis was 7.69× 10−9 with logs of odds ratio of ≈ 0.9 implying
a protective effect.
90
4.3.4 Pathway analysis and identification
To put the results into biological context, we then sought to understand the biological significance
of genes identified from ImpG meta-analysis and IMPUTE2 based meta-analysis, and their
relationship with the phenotype of interest (severe malaria). For this analysis, we used the genes
obtained from the meta-analysis as the query genes and applied Genemania in predicting the
genes they are related to in terms of co-expression, physical interaction, genetic interaction and
shared pathways. Genemania is one the most popular and powerful web based application
tool that has been applied in predicting pathway gene set of the genes identified from a given
study [117]. Genemania, by default, predict twenty other additional genes that are functionally
similar to the query list of genes. However, for this analysis, we adjusted the number of genes
until we obtained the prediction network with the best FDR (False Discovery Rate) values. We
performed three types of prediction: First, we used genes identified from IMPUTE2 as query
list of genes; then genes identified via ImpG as the query list of genes, and finally we used both
genes identified from ImpG and IMPUTE2 meta-analysis as the query list of genes.
For IMPUTE2 meta-analysis, we obtained a network of 23 related genes with 5,304 interactions.
Figure 4.11 shows the resulting network that was generated by the best FDR values and genes
together with their scores. HBD was identified as gene that had the strongest association with a
score of 0.005. The top biological functions which were associated with this network were blood
microparticle at a P-value of 8.813× 10−9, cytoplasmic membrane-bounded vesicle lumen, vesicle
lumen, and bicarbonate transport both at a P-value of 1.977× 10−4 and gas transport at P-value
of 7.561× 10−4.
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Figure 4.11: The resulting network from the interaction of the query genes and other genes using biological databases
in Genemania
For ImpG meta-analysis, we obtained a network of 25 related genes with 483 interactions.
Figure 4.12 shows the resulting network that was generated by the best FDR values and genes
together with their scores. DYNLL2 was identified as gene that had the strongest association
with a score of 0.002. The top biological functions which were associated with this network were
transmembrane transporter complex, learning or memory, glutamate receptor signaling pathway,
scaffold protein binding, ion channel complex and ionotropic glutamate receptor complex both at
a P-value of 7.88× 10−5 .
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Figure 4.12: The resulting network from the interaction of the query genes and other genes using biological databases
in Genemania
Finally, using both the genes identified from ImpG and IMPUTE2 meta-analysis as the query
genes. We obtained a network of 60 genes with 10,391 interactions. Figure 4.13 shows the
resulting network that was generated by the best FDR values and genes together with their
scores. Again, HBD was identified as gene that had the strongest association with a score of
0.005. The top biological functions which were associated with this network were cytoplasmic
membrane-bounded vesicle lumen at a P-value of 1.15× 10−7, blood microparticle at a P-value
of 1.15× 10−7 and blood microparticle at a P-value of 0.0000509.
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Figure 4.13: The resulting network from the interaction of the query genes and other genes using biological databases
in Genemania
4.3.5 Pathway Enrichment Analysis
Finally to gain the mechanistic insights of the genes that were identified to be functionally related
to the genes identified from the meta-analysis, we performed an enrichment analysis of both the
networks (from ImpG interaction network, from IMPUTE2 meta-analysis network and both) to
ascertain pathway relevance to the disease for each network. To achieve this, we used enrichR to
perform pathway enrichment analysis for both the network generated by IMPUTE2 meta-analysis
genes, ImpG meta-analysis genes and finally enrichment of network generated by both IMPUTE2
and ImpG meta-analysis genes. Further, we also explored disease/drugs that are associated with
each of the network using enrichR.
For IMPUTE2 based meta-analysis network enrichment, African trypanosomiasis was the
most enriched pathway with a combined score of 768.55 and a P-value of 1.148× 10−5, followed
by malaria with a combined score of 536.77 and a P-value of 2.697× 10−5 using KEGG 2019
Human reference database. Other enriched pathways are listed in Table 6.3 in the Appendix.
Moreover, according to OMIM disease database, this network was associated with anemia with a
P-value of 7.948× 10−7, malaria with a P-value of 0.01667. Other diseases associated with this
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network is listed in Table 4.6.
Table 4.6: Diseases that were identified from OMIM disease database to be associated with the pathway
network from IMPUTE2 based meta-analysis.
Name P-value Adjusted P-value Odds
Ratio
Combined
score
anemia 7.948× 10−7 0.00007154 54.64 767.49
Malaria 0.01667 0.7504 59.52 243.68
charcot-marie-tooth disease 0.03192 0.9576 30.86 106.31
blood 0.04234 0.9527 23.15 73.19
On the other hand, For ImpG based meta-analysis, according to KEGG 2019 human database
reference network, Glutamatergic synapse was identified as the top enriched pathway with a
P-value of 1.311× 10−10 and a combined score of 1035.00, followed by Cocaine addiction at
P-value of 3.878−5 with a combined score of 460.66. Other additional top pathways are listed in
Table 6.4 in the Appendix section. The top diseases that were identified to be associated with
this network were microphthalmia at a P-value of 0.02535, autism at a P-value of 0.02535. Other
diseases associated with this network is listed in Table 4.7
Table 4.7: Diseases that were identified from OMIM disease database to be associated with the pathway
network from ImpG based meta-analysis.
Name P-value Adjusted P-value Odds
Ratio
Combined
score
microphthalmia 0.02535 1.000 38.99 143.27
autism 0.02535 1.000 38.99 143.27
diabetes mellitus,type 2 0.04234 1.000 23.15 73.19
epilepsy 0.07547 1.000 12.77 33.00
diabetes mellitus 0.07547 1.000 12.77 33.00
ataxia 0.07797 1.000 12.35 31.50
diabetes 0.09652 1.000 9.88 23.09
Finally, for the enrichment of the network generated by both the genes from IMPUTE2 and
ImpG meta-analysis, malaria was identified as the most enriched pathway with a combined score
of 284.57 and a P-value of 0.00001703. African trypanosomiasis was the second most enriched
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pathway with a score of 217.44 and a p-value of 0.00002144. Table 6.5 lists all other additional
pathways that were enriched. The top diseases that were identified to be associated with this
network were malaria at a P-value of 0.000867, anemia at a P-value of 0.00004077. Other diseases
associated with this network is listed in Table 4.8.
Table 4.8: Diseases that were identified from OMIM disease database to be associated with the pathway
network from ImpG based meta-analysis.
Name P-value Adjusted P-value Odds
Ratio
Combined
score
malaria 0.0008672 0.03902 45.35 319.74
anemia 0.00004077 0.003669 20.82 210.41
blood 0.005742 0.1723 17.64 91.00
dementia 0.03716 0.8361 26.46 87.10
autism 0.05821 1.000 16.71 47.51
parkinson disease 0.06709 1.000 14.43 38.99
charcot marie tooth disease 0.08171 1.000 11.76 29.45
Our study suggests that while it is possible to perform imputation, both at summary statistics
level or at raw genotypes level, much can be gained in a given study if imputation is performed
in two steps especially for meta-analysis: First at raw genotypes level using the best performing
genotypes imputation algorithm, and then at the summary statistics level after performing
associations. Our studies show that this increases the chance of identifying association that
would have been missed. Interestingly, based on the adjusted P-values, only one disease (anemia
with an adjusted P-value of 0.00007154), was identified to be significantly associated with the
network generated from IMPUTE2 meta-analysis enrichment and for ImpG based meta-analysis,
no disease attained the significance level of 0.05 using the adjusted P-value. However, for the
combined network, two diseases were identified to be significantly associated with the network:
anemia with adjusted P-value of 0.003669 and malaria with adjusted P-value of 0.03902.
Previously, it has been shown that there is almost 99% correlation between the effect size
and P-value of association of the masked SNP and the imputed SNPs with ImpG [84, 109]. This
implies that the association values from the imputed summary statistics are as good as the
association values that can be obtained when the SNPs are directly genotyped. Thus going by
this claim, and as proven from the enrichment analysis, we can confidently report that both
imputation via summary statistics and raw genotypes can improve the chance of identifying the
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associations that were not typed in the original study. However, it is universally accepted that
imputing the raw genotypes via the Hidden Markov Model (HMM) tools is the gold standard
[84] for performing imputation. Thus the previous studies have instead recommended the use of
summary statistics based imputation to avoid the restrictions that are encountered on accessing
the individual level genotypes data [84, 118]. Similarly, we cannot confirm which approach is
superior than the other especially when both the summary statistics and raw genotypes data can
be accessed. Instead, we recommend implementing both of the approaches if possible in any
given study: impute the raw genotypes and then impute the summary statistics after performing
the associations.
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Chapter 5
Evaluation of Polygenic Risk Scores
Methods
5.1 Overview
The objective of epidemiology is to identify and characterize the genetic risk factors that are
associated with complex diseases or trait [72]. Knowledge of the risk can then be applied by
clinicians in prevention, diagnosis, prognosis and treatment of a particular disease. Genome
Wide Association Studies (GWAS) have been successful in the identification of single nucleotide
polymorphism (SNPs) and genes that are associated with a wide range of complex diseases [36].
Nevertheless, majority of the variants that have been identified through GWAS to be significantly
associated with complex diseases/traits, and have been replicated across studies, explains just a
small proportion of variability in the trait of interest, hence limiting their predictive power [17].
Moreover, results from GWAS findings have suggested that much of the genetic basis for most of
the complex traits is a combination of small effects of hundreds or thousands of genetic variants
[17]. This realization indicates that Single SNP-based analyses alone do not address the overall
genomic or polygenic architecture for most of the complex diseases [72]. Thus for complex traits,
if the polygenicity is not accounted for, then individuals genome wide prediction or the genetic
profile is compromised [17].
Polygenic Risk Score (PRS), or Polygenic Score, is the sum of risk alleles corresponding to a
given trait or disease for each individual in the study weighted by the estimates of the effects
size from GWAS published result or met-analysis [17]. PRS therefore summarizes the genome
wide data into a single variable which measures an individual liability or tendencies to a trait or
phenotype of interest [36]. Although there are other methods (like GCTA [73] and LDSCORE
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[119])that have been proposed and can summarize the risk of common SNPs that do not achieve
stringent GWAS threshold, it is only PRS that summarizes these effects at the individual level
[120].
In this chapter, we present a brief overview of Polygenic Risk Score, a review of PRS methods
and a brief literature review. We then simulate GWAS datasets and compare the performances of
several PRS methods and compare the performances of different PRS methods using a simulated
data that mimics African population. We finally apply the best PRS method from the simulation
study in GWAS dataset of malaria.
5.2 Polygenic Risk Scores (PRS) Applications and Challenges
PRS for each individual in a given study is calculated by computing the sum of the risk alleles
corresponding to a phenotype of interest, and the scores are weighted by the effects estimates
from GWAS summary statistics. PRS has a number of applications: It may be used to detect
shared genetic etiology among traits [17]. This is achieved by training the score on one trait and
testing the score against another trait and if there are associations, then there is shared genetic
basis. When there is shared genetic etiology, then this shows that there exist a common molecular
etiology between the traits and this may be applied in developing new treatments or can be
applied in identifying individuals at risk. Moreover, this knowledge of shared etiology can also
be used to pinpoint problems with the current diagnosis or nosology
PRS may also be used in risk prediction and for stratifying individuals into different risk
groups. For example, PRS was applied in schizophrenia and demonstrated that individuals
whose PRS values were falling within the upper 10 percentiles were shown to be having 10 times
chance of developing schizophrenia than the individuals whose PRS were falling with the lower
10 percentile. Similarly, in a recent study of breast cancer, individuals whose PRS were falling
within the top percentile had the highest overall lifetime risk of 32.6% of breast cancer [38]. PRS
may therefore be applied as a guide in providing intervention or treatment options according to
the risk groups.
5.2.1 Challenges in the Calculation of PRS
Besides very many applications, there exists a number of challenges in the calculation of PRS. First,
the total number of SNPs that should be included in the calculation of PRS is not known [121].
Usually, a p-value threshold has been applied in the selection of SNPs for inclusion. However,
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the optimal P-value for inclusion is generally unknown. Consequently, as in most studies, PRS
is calculated at a range of P-values and the p-value that gives the best prediction accuracy (or
the p-value that gives the highest correlation or association with the phenotype in the validation
dataset) is adapted [17, 122]. Nevertheless, this kind of approach is less useful if the phenotype is
not available in the target dataset. Mak et el. suggested a down-weighting of the weights with
the SNPs’ local discovery rate, in which an individual shrinkage factor is estimated using a data
driven approach [121]. This has been shown to give comparative predictive performance with the
best predictive P-value. However, this kind of approach is not implemented in most tools.
Another issue in the calculation of PRS is linkage of Disequilibrium (LD). Some PRS methods
do not take into account that some SNPs are in LD with each other. This lead to biased estimates
of the scores. It is however recommended to prune the SNPs before inclusion in the PRS, as
was done with Purcell et al. [123]. However, this kind of approach has a potential of discarding
the most predictive SNPs and as a result reducing the prediction power. Wray et al. [124] has
since then suggested clumping, which removes SNPs that are in LD based on their p-value of
associations. Other methods have recommended inclusion of LD matrix from the reference panel
to control LD.
5.3 Review of PRS
5.3.1 Overview
Polygenic risk scores analysis requires two inputs; (1) the GWAS base dataset which is essentially
the GWAS summary statistics data of an association between genotypes and a given phenotype
and (2) the target dataset, which is just the GWAS data of the target/study sample [17].
Let G denote the genotype matrix for the GWAS dataset. Let the number of markers be M
and let the number of individuals in the target population be N. Then the general form for a
standard polygenic risk score of an individual i is defined follows;
PRSPT ,i =
M
∑
m=1
Gim βˆm (5.1)
Where Gim is the genotype dosage for individual i at marker/SNP m and βm is the estimate
of the effect size of the mth variant from the discovery/base GWAS summary statistics. Usually,
standard PRS methods begins by removing SNPs in LD using a LD prunning procedure and then
applies a P-value threshold in selection of SNPs to be included for the calculation of PRS. This
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kind of approach, however, can remove more predictive SNPs during the pruning process hence
reducing the predictive values. Nonetheless, this was the first approach used in the first study
that implemented PRS.
To improve prediction accuracy, several methods have been proposed including, LD clumping
as opposed to pruning, Bayesian methods, Penalized regression methods, and including functional
annotations. We present a review of these methods in the next section.
5.3.2 Classification of PRS Methods
Methodologies for the construction of the polygenic risk scores differ primarily across two
dimensions: 1) how weights used in PRS calculations are generated, and 2) how to determine
which SNPs to include in the PRS calculation. Particularly, one of the fundamental problems
at the early stage of the development of PRS methods was the fact that there is no inherent
information of LD from summary statistics. Thus if SNPs in a given loci are in high LD with
one another, and all are included in the score, then definitely the score will be inflated [122].
Consequently, several methods have been suggested to control LD including LD pruning, LD
clamping, using Bayesian methods, penalized regression, and including functional annotation.
As a consequence, PRS methods may be classified based on how they model the LD. Thus, we
can classify PRS methods into two general classes: Bayesian PRS and non Bayesian PRS methods.
Non Bayesian PRS Methods
PRSice
PRSice is the first dedicated PRS software. It was developed in 2014 by Euesden et al. [17]
and represent one of the simplest current PRS methods. PRSice uses a similar model as that of
Equation 5.1, except that it applies a LD clumping and a P-value threshold in the calculation
of PRS. In this kind of settings, pairs of SNPs in LD are clumped based on their P-values [17].
For example, for two linked SNPs, one pair of the linked SNPs with less significant value is
excluded from the calculation of PRS.
PRSice has the capability of calculating the PRS at various P-value thresholds thus obtaining the
best predictive threshold. However, over-fitting is common in case of high resolution PRS and
that the P-value from the PRS could be inflated. Thus, the authors suggests that a permutation
test should be performed to minimize the over-fitting [17].
PRS uses observed genotypes or imputed posterior probabilities that have been converted
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to dosages. However, it relies on PLINK 1.07 for the conversion. Recently, Chen et al. [125]
implemented a new PRS software called PRSoS that accommodates both genotypes and imputed
posterior probabilities. Moreover, PRS on the Spark (PRSoS) does not discard strand ambiguous
SNPs as was in the case in PRSice [17]. Nonetheless, both PRSos and PRSice uses a similar
model for calculation of PRS. PRSoS uses the following model to calculate PRS from imputed
genotypes posterior probabilities.
PRSPT ,i =
M
∑
m=1
βˆm{2P(AA)m + P(AB)m} (5.2)
Where P(AA)m and P(AB)m in Equation 5.2 is the probability of homozygous genotype with
two copies of effect allele (AA) at the SNP m and the probability of heterozygous genotype with
one copy of the effect allele at SNP m [125].
POlygenic Ld-Adjusted RIsk Score (POLARIS)
POLARIS [126] was published in 2017 and applies a similar approach like that of PRSice in
the calculation of PRS. However as opposed to PRSice which accounts for LD via clumping,
POLARIS [126] accounts for LD between SNPs via spectral decomposition of the SNP correlation
matrix. Vector of the target genotypes are replaced by a vector of adjusted dosages. The PRS of
POLARIS is given by the following:
PRSi =
M
∑
j=1
β j
(
M
∑
k=1
1
λk
xkxTk g
)
=
M
∑
i=1
β j
(
M
∑
k=1
1√
λk
xk(j)
M
∑
j=1
xk(j)gj
)
(5.3)
Where xk are the eigen vector of an M × M matrix of SNPs and λk is the eigen value corre-
sponding to the eigen vectors. To avoid instability, a ridge parameter λ0 = 1N is introduced to
Equation 5.3 to obtain the following.
PRSi =
M
∑
j=1
β j
(
M
∑
k=1
√
1+ λ0
λk + λ0
xk(j)
M
∑
j=1
xk(j)gj
)
=
M
∑
j=1
β j gˆj (5.4)
P+T funct LASSO
P+T funct LASSO was introduced by shi et al. [127] in 2016. This method was motivated by the
fact selection of SNPs using a particular threshold for the inclusion of PRS calculation may affect
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the density of the effect size estimate and thus may result into upward bias estimate, an effect
known as Winner’s curse. To correct for this effect, Shi et al proposed two shrinkage methods:
shrinkage via Maximum Likelihood Estimation (MLE) and shrinkage via lasso regularization.
Additionally, Shi et al.[127] also introduced a 2D PRS, in which SNPs are partitioned into two
groups: S1, which includes SNPs with higher priors, and S2 includes the SNPs with lower priors.
The high prior SNPs and the low prior SNPs are obtained from an external annotation datasets.
A differential treatment is then applied to both the two groups (S1 and S2) in the calculation of
PRS. Thus, PRS under this settings PRS is given as follows:
PRS(pT1 , pT2)i = ∑
m∈S1
βˆm I(pm < pT1)gim + ∑
m∈S2
βˆm I(pm < pT2)gim (5.5)
Where SNPs in S1 are selected at less rigorous threshold than SNPs in S2. This approach has
been shown to perform better than the popular 1D PRS in Equation 5.1 and gim is the genotype
dosage for individual i at SNP m.
MLE shrinkage is implemented by assuming that the estimate of the effect sizes of SNP
m
∫ {1, . . . , M} follows a normal distribution βˆm ∼ N (βm, ˆsigmam). A shrinkage estimator
that maximizes the likelihood of P(βˆm|Pm < α) is then used as the new estimate of the effect
size, βˆmlem . However, this approach is highly intensive for large SNPs and at a grid of p-values
[127]. Thus, Shi et el. proposes a less intensive method that applies a lasso regularization.
Consider an objective function below,
f (β) = (y− Xβ)T(y− Xβ) + 2λ∑
j
β j (5.6)
Where X is the standardized genotypes and y are standardized phenotype. Then by assuming
that SNPs are independent, and let βˆm =
N
∑
i=1
(yj− y¯)xim (where N are the number of individuals),
then
βˆlassom = sign(βˆm)
∣∣|βˆm| − λ∣∣ I(βˆm > λ) (5.7)
= sign(βˆm)
∣∣|βˆm| − λ∣∣ I(Pm > α) (5.8)
Since Pm < α is equivalent to βˆm > λ. And PRS calculation follows by substituting βˆlassom in the
equation.
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lassosam
Introduced in 2017 by Mak et al. [121]. Lassosam uses a similar lasso regularization as that
used by P+T funct lasso [127]. Here however, the main motivation was to not to correct the
Winners’ curse as was in the case of P+T funct lasso [127] but rather to account for LD using
an external datasets. Thus, despite having similar objective function in Equation 5.6, here XTX
can be viewed as LD between the SNPs, which can be estimated from the reference panel. On
the other hand, XTy can be viewed as SNP-wise association, which can be obtained from the
summary statistics. Thus, making it no-longer an regularization problem on the penalty term
since the genotypes used in the estimation of LD are different from the genotypes used in the
estimation of summary statistics. Mak et al. [121] applies another regularization on Equation
5.6 to obtain an elastic net problem given by the following.
f (β) = yTy + (1− s)βTXTr Xrβ− 2βTr + 2λ(||β||11) (5.9)
Where r = XTy, to note that the genotypes used in the construction of XTr Xr and XTy are not
the same. A coordinate descent algorithm is applied on Equation 5.9 to obtain an estimate of
each βm.
β(t) =

sign(v(t)j )
∣∣∣v(t)j −λ∣∣∣
X˜Tj X˜j+s
if |v(t)j | − λ > 0
0, Otherwise
(5.10)
Where v(t)j = ri − X˜Ti
(
X˜β(t−1)i − X˜β(t−1)i
)
Bayesian PRS Methods
Just like in non Bayesian approaches, the main idea for the use of Bayesian methods was to
overcome lower prediction power as a result of not accounting for LD. Bayesian methods applies
a prior on the genetic architecture and LD from the reference panel. Among the popular tools
under Bayesian method include LDpred, LDpred-inf, AnnoPred, and many more.
LDpred and LDpred-inf
LDpred-inf and LDpred were the first PRS methods using Bayesian methods to be developed
in 2015 by vilhjalmsson et al. [122]. LDpred-inf and LDpred applies a Bayesian approach in
the calculation of PRS by assuming priors from the genetic architecture and LD information
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from the reference panel [122]. The prior has a point normal mixture distribution and has two
parameters: (a) Heritability explained by genotypes, which is estimated from GWAS summary
statistics, and (b) a fraction of causal markers with non zero effects. This prior allow also for the
non infinitesimal genetic architectures.
The posterior mean effect is calculated by conditioning on the genetic architecture and LD,
which is approximated from the reference panel or from an independent validation data. For
the unlinked markers, an assumption is made that distant markers are not linked and thus the
posterior mean effect sizes under a small region pf LD can be estimated as follows:
E[βlm|βˆlm, D] =
(
M
Nh2g
I + Dm
)−1
βˆlm (5.11)
Where h2g denotes heritability explained by SNPs, M is the number of SNPs in the region l, N is
the number of samples in the target sample, Dl is the LD matrix within the region l and D is
the LD matrix estimated from the reference panel [122]. This posterior effect estimate can be
calculated analytically.
When Dl = I, then Equation 5.11 generalizes to a posterior with infinitesimal priors. Thus this
generalization can be used to calculate the posteriors for the SNPs that are linked [122]. Equation
one is computed analytically by LDpred-inf [122] and PRS for each individual is obtained by
substituting βˆm in Equation 5.1 by posterior mean effect estimated from Equation 5.11.
LDpred is the modification of LDpred-inf [122]. Here, a non infinitesimal Gaussian mixed prior
is used to estimate the posterior mean of the causal effect sizes. However, the posterior mean
effect size under this settings cannot be derived analytically. Thus, LDpred applies MCMC
Gibbs sampling to numerically approximate these estimates. To ensure convergence, a shrink
probability (given by f = min(1,
hˆ2g
(h¯g
2
) i
) of being causal is applied at each iteration. Additionally,
Rao-Blackwellization is further applied to speed convergence [122].
Annopred [128]
Annopred was developed by Hu et al. [128] in 2017 and is the first Bayesian PRS method to
include functional annotations [128].
AnnoPred implements a three stage framework: First, GWAS signals are enriched using external
annotation data and are assigned in different categories based on the enrichment. Second, an
empirical prior on the SNPs effect size is then estimated based on annotation assignment and
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signal enrichment. Finally, the prior together with the marginal summary statistics and the LD
matrix are used to infer the posterior effect size for each SNP in a joint modeling framework
[128]. Posterior effect size if given by:
EA[β j|βˆ, Dˆ], (5.12)
where Dˆ in Equation 5.12 is the LD matrix estimated from the reference panel or in the target
datasets.
Annopred applies LD score regression to partition trait heritability by annotation. Suppose there
are K+1 partition labeled as S0 . . . , SK, such that the estimated SNP heritability per partition is
given as follows Var(βi) = ∑
j:i∈Sj
τˆj, where τj is the ith SNP on partition j of K.
AnnoPred implements two priors to ensure flexibility against different architectures. First prior
assumes spike and a slab distribution of the effect size given by β ∼ p0N(0, σˆ
2
i
p0
) + (1− p0)δo.
This prior assumes that each annotation category has the same number of causal SNPs although
the effect sizes are different across the annotation categories. Second prior on the other hand
assumes same effect sizes across annotation categories but different proportions of SNPs.
Let Ti denote SNPs with the similar annotation assignment with SNP i, and that MTi is the
total number of such collections. Also define total heritability is given as follows H20 = p0M0V.
Then heritability of SNPs within a given collection Ti is given as H2Ti = pTi MTiV, where pTi
is the proportion of causal SNPs in Ti, σ0 is a Dirac function, V is the variance of the causal
V = Var(βcausal), M0 is the total number of SNPs, and p0 is overall proportion of SNPs. The
prior is thus given by the following;
Bi ∼ pTi N(0, V) + (1− pT)δo (5.13)
Where V = H0p0No and PTi = p0
Mo H2Ti
MTi H
2
0
. And the posterior effect size for the two priors is given by,
f (βb|βˆb, Dˆb) ≡ N(E[βˆb|βb, Dˆb], var(βˆb|βb, Dˆb)∏
i∈b
f (βi) (5.14)
N(E[βˆb|βb, Dˆb], var(βˆb|βb, Dˆb)∏
i∈b
[
p0N(0,
σ2i
p0
) + (1− p0)δ0
]
N(E[βˆb|βb, Dˆb], var(βˆb|βb, Dˆb)∏
i∈b
[
pTi N(0,
H0
p0N0
) + (1− p0)δ0
] (5.15)
Deriving E[βb|βˆb, Dˆb] from the join distribution of β is difficult hence drawn from a Gibbs
sampling of f (β|βˆbDˆb), using the sampling mean as an approximation of E[βb|βˆb, Dˆb]. The
posteror effect sizes are then used as the new weight for the calculation of an individual score
using the standard PRS in Equation 5.1.
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LDpred -inf -funct and LDpred -funct.
Both LDpred -funct inf and LDpred-funct are modifiations of LDpred-inf to include the functional
information in the calculation of PRS, just like in the case of PRS with winner’s curse correction
via Maximum Likelihood estimation (mle) or lasso. However, the difference between these
methods is that, LD-pred funct inf and LDpred- funct applies a Bayesian approach in the
calculation of PRS while PRS with winner’s curse correction via mle or lasso applies the
frequentist approach. Thus, the functional information are incorporated in the priors under
these methods [129].
LDpred inf funct, uses a similar priors to LDpred inf by [122] except that here, the priors are
assumed to have the following distribution β ∼ N (0, c ∗ σ2m), where σm is the expected per SNP
heritability under the baseline LD model that incorporates the functional annotations and c is
the normalizing constant and is given by c = 1
h2g
M
∑
m=1
I(σm > 0). Thus, the posterior mean effect
size under this model is just the same as LDpred-inf except that it is additionally conditioned on
the per SNP heritability. Particularly, posterior mean under this model is obtained by solving
the following system equation.

N × D + 1
c

1
σ21
... 0
0 1
σ21


E
[
β|βˆi, σ21 , . . . σ2m+
]
= Nβˆ (5.16)
Where m+ in Equation 5.16 denotes the number of SNPs whose expected per SNP heritability is
greater than zero. Thus, under this model the PRS of an individual in the study is obtained by
substituting the βˆm in Equation 5.1 by the posterior effect size estimates from Equation 5.16.
LDpred-funct uses exactly the same model as that of LDpred-funct-inf in Equation 5.16 except
that the posterior mean effect sizes are further regularized via a cross validation. The posterior
mean effect size estimates are first partitioned into K bins and a PRS is calculated for each bin.
Specific weight of the bins are optimized via cross validation using the validation dataset. The
overall PRS under this method is given by the following:
PRSLDpred f unct =
K
∑
k=1
αkPRS(k) (5.17)
Where αk is the specific weight for each bin and is optimized via a cross validation [122] and K
is the number of bins.
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Table 5.1 summarizes some of the popular PRS methods, their models, publication year among
others.
108
Table 5.1: Summary of some of the popular PRS tools
SOFTWARE Model Accounting for LD YEAR COMMENT Effect Size Data
format
Target Format REF
SOFTWARE Model Accounting for LD YEAR COMMENT Effect Size Data
format
Target Format REF
PLINK Standard
PRS
LD Clumping 2009 First tool to be ap-
plied in the calcula-
tion of PRS
Summary statistics PLINK FORMAT [78]
PRSice Standard
PRS
LD Clumping 2014 First Standalone PRS
software
Summary statistics PLINK
(bed/bim/fam)
[17]
LDpred & LD-
pred inf
Bayesian
PRS
Calculate LD from
the reference Panel
2015 First Bayesian PRS
software
Summary Statistics PLINK
(bed/bim/fam)
[122]
Annopred Bayesian
PRS
Calculate LD from
the reference Panel
2017 Bayesian PRS Summary Statistics PLINK
(bed/bim/fam)
[128]
Lassosum Bayesian
PRS
Calculate LD from
the reference Panel
2017 Penalized Regression
PRS
Summary Statistics PLINK
(bed/bim/fam)
[121]
PRSoS Standard
PRS
Spectral Decomposi-
tion
2018 First PRS to imple-
ment Spectral Decom-
position
Summary statistics Oxford (.gen/ .sam-
ple),Variant Call For-
mat (vcf)
[125]
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POLARIS Standard
PRS
Applies Principal
Component Analysis
(PCA)
2018 First tool to apply
PCA to adjust for LD
Summary statistics PLINK
(bed/bim/fam)
[126]
LDpred -inf -
funct & LDpred-
funct
Bayesian
PRS
Calculate LD from
the reference Panel
2018 Bayesian PRS Summary statistics PLINK
(bed/bim/fam)
[129]
Multi-ethnic
PRS
Bayesian
PRS
Calculate LD from
the reference Panel
and Target data
2018 Bayesianregression
PRS
Summary statistics PLINK
(bed/bim/fam)
[130]
PRS-CS Bayesian
PRS
Calculate LD from
the reference Panel
2019 Bayesian regression
PRS
Summary statistics PLINK
(bed/bim/fam)
[131]
EBPRS Bayesian
PRS
No LD calculation
and No training data
2020 Bayesian PRS Summary statistics [132]
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5.4 Literature Review: Comparison of PRS Methods
Polygenic risk score methods have been evaluated by a number of studies. In one of the studies
Mek et al. [121] compared the performance of their method (lassom, which uses penalized
regression approach to estimate the weights used in the PRS) with LDpred [122] (which applies a
Bayesian approach in the estimation of the posterior mean of the effect sizes) using a simulated
data of seven diseases from Wellcome Truct Case Control Consortium (WTCCC) that had 358,179
SNPs and 12,744 cases and 2,859 controls after quality control . Their results suggest that lassom
[121] is faster and more accurate than LDpred. Importantly, this study also compared the effect
of using lassosam when P-value threshold is applied (by activating the p-thres flag in the tool).
Interestingly, lassosam without p-value thresholding and clumping still performed better than
LDpred. Thus this approach seems to offer a solution to reduction in prediction power that arises
from exclusion of some SNPs based on their P-value [121].
Hu et al. [128] compared the performance of AnnoPred with other four best prediction
methods: PRS method based on P-value threshold (PRSsig), PRS based on P-value theshold
and Prunning (PRSP+T) and LDpred and PRSall (PRS based on all SNPs). Using both real and
simulated data, Hu et al. [128] showed AnnoPred performs better than all the other PRS methods
in all settings using both real and simulated data. Interestingly, PRS method based on all markers
demonstrated the lowest performance nearly in all the settings thus highlighting the importance
for selecting a subset of SNPs in the calculation of PRS. However, although not assessed by
this study, lassosam has been shown to give better prediction accuracy by using all the SNPs
rather than a just a subset of the SNPs. Additionally, Hu et al. [128] demonstrated that methods
estimating the PRS weights based on Bayesian framework (LDpred and AnnoPred) had almost
similar performances and outperformed the non Bayesian methods in all settings as illustrated in
table 5.2. This study moreover highlighted that including functional annotations in the calculation
of PRS improves the performances of PRS method [128].
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Table 5.2: Correlation between PRS and different traits in the real data set [128]. PRS(all) represent PRS computed
with all the P-value, PRS(sig) for the SNPs that were identified to be associated with a given trait,
PRS(P+T) implies SNPs were first clumped that a P-value threshold was applied in selecting the SNPs.
Annopred outperformed all the approaches.
Disease/Trait PRS(sig) PRS(all) PRS(P+T) LDpred AnnoPred
Crohn’s Disease 0.27 0.229 0.32 0.325 0.343
Breast Cancer 0.084 0.055 0.12 0.122 0.137
Rheumatoid Arthritis 0.204 0.114 0.248 0.282 0.287
Type-II Diabetes 0.165 0.156 0.204 0.202 0.22
Celiac Disease 0.11 0.136 0.18 0.197 0.213
Recently, Marquez et al. [129] compared the performances of five PRS methods P+T, LDpred-
inf [122], P+T-funct-LASSO, LDpred-funct-inf [129], and LDpred-funct [129] methods using a
simulated dataset from the UK biobank interim release. On average, method tha incorporate
functional annotations showed better results than methods that do not include the functional
annotation. In particular, incorporating functional annotations led to over 17% improvement in
the method and further, regularization led to over 27% improvement compared the most accurate
method that does not include functional annotation [129]. In overall, LDpred-funct had the best
result and P+T produced the least result. These findings are consistent with the previous findings
by [128], that illustrated that the potential of functional enrichment in the calculation of PRS.
Interestingly, comparison and evaluation of the Polygenic Risk Scores methods have mainly
been done by their authors, who in most cases compare their new method with the existing
methods. Surprisingly, nearly all these new methods, from the reported results seems to be
superior than other existing methods. Moreover, tools like lassosam, which seem to perform very
well, has never been compared with the new methods like LDpred-funct [129] and Annopred
[128]. Here, we will compare the performance of Polygenic Risk methods which have been shown
to be superior in most of the studies. So far, previous studies have done the comparison using
European populations and no study has assessed the performance of different PRS methods using
a diverse population, like African. Thus, here we use a simulated both from Africa to compare
the performances of different PRS tools.
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5.5 Evaluation of PRS methods using Simulated Data
5.5.1 Study Data and Methodology
We used the simulated dataset of 5,000 samples that mimics African populations. How the dataset
was obtained is described in Section 3.3. Additionally, we obtained the summary statistics of the
case/control datasets datasets from Mugo et al. [101]. How the summary statistics was generated
is well described in the publication paper [101].
PRS calculations for all the tools are not similar. Some of the programs are stand alone
programs and do not rely on other programs to compute the score whereas others like PRScS can
only weight the SNPs and thereafter relies on PLINK in generating the individual risk scores.
Unless mentioned, we applied the default program settings in generating the scores.
PRSice can generate the risk scores at a range of P-values in a single run and has a potential
of determining the P-value that gives the best predictive risk scores. PRSice does this in a simple
way by allowing users to specify the lower interval using the flag − − lower and the upper
interval using the flag −− upper and an interval for each iteration using the flag −− interval. We
retained only the best predictive PRS, which was generated at P-value of 5.0× 10−5. Moreover, as
recommended by the developers, all the SNPs that were in LD were clumped prior to performing
the PRS. For fair and uniform comparison of the tools, we restricted the calculation of PRS for
each of the tools using only the best predictive P-value that was obtained from PRSice.
PRS calculation with LDpred involves three steps. First, the program synchronizes the study
genotypes with the summary statistics in which an HDF5 file is generated. This HDF5 file
contains the synchronized genotypes and reduces the processing time for the subsequent runs.
The program then re-weights the SNPs effects sizes using either a Gibbs sampling approach or
can also apply P-value by first clumping SNPs depending on what the user has activated. Our
study, however, mainly focused on the comparison of PRS methods that implement clumping
and P-value threshold hence we did not consider gibbs sampling algorithm of the tool. Finally,
the program generates risk scores of the individuals at various P-value thresholds. We restricted
the calculation of the scores using one standard P-value of 5.0e−5 that was predicted by PRSice as
the most predictive threshold value.
For PLINK, we followed a similar approach as that of PRSice. However, provide an option
for specifying a range file which guides the program on what P-value range to generate the
scores. This setting generates scores for an individual using all the P-values within the range.
To circumnavigate this, we developed an in-house python script that selects all the SNPs from
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the summary statistics that satisfy only the P-value of 5.0× 10−5 as estimated from PRSice. We
then applied this new summary statistics file in computing the scores. We applied a similar
approach for the PRSoS and PRScS. However, PRScS requires input from a reference panel which
can be downloaded from the programs website. Moreover, PRScS cannot generate PRS on it owns
but rather relies on PLINK in generating the scores. We thus applied PRScS in weighting the
summary statistics and thereafter applied PLINK in generating the scores.
To compare the performances of the tools, we evaluated the potential of each tool in predicting
the phenotype of each individual in the study. To do this, we implement a logistics regression
model in R and regress phenotypes of individuals against their risk scores. We compare how
much variance in the phenotypes is explained by the PRS generated from each tool. Finally,
we fit Receiver Operator Curve (ROC), which has a potential of assessing the specificity and
sensitivity of each tool in prediction. Such an assessment can help in determining how the model
is able to distinguish between cases and controls, given the PRS scores. Moreover, we use Area
Under Curve (AUC) to quantify how well the PRS scores can be used in predicting an individual
phenotypes.
5.5.2 Results and Discussion
Table 5.3 shows the predicted r2 for different tools when the scores are applied in predicting the
phenotypes for each individual in the study. PRSoS gave a slightly better prediction performance
followed by PRSice. However, the other tools gave very low prediction with PLINK giving
the lowest prediction. To measure the accuracy of the scores in predicting the phenotypes, we
calculated AUC (Area Under Curve) for different tools as represented in column three of Table 5.3.
The highest AUC was obtained from PRSoS, followed by PRSice. However, in overall, the AUC
values were very low and depicted only ≈ 50% to 52% that the PRS scores can distinguish cases
from controls. Again, LDpred(P+T) and PRScs gave the most uncertain predictive accuracies.
Table 5.3: Percentage variation of the phenotypes explained by the PRS across differnet PRS tools.
Tool percentage Rsq AUC
LDpred(P+T) 6.710072−4 0.5007
PRSoS 0.01736 0.511
PRScS 1.27118× 103 0.5002
PLINK 8.1990× 10−7 0.5018
PRSice 0.01398 0.5091
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The plots displayed by ROC in Figure 5.1 further shows how the model has very low predictive
accuracy in predicting the phenotype.
Figure 5.1: Plot of sensitivity and specificity of different PRS tools. LDpred(p+t) represents the result from the
LDpred that implements clumping and P-value threshold when calculating the scores.
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To put our result into global context, Marquez et al. [129] previously compared the perfor-
mance of five (i.e P+T, P+T funct lasso, LDpred-funct-inf and LDpred-pred-funct) PRS methods
using both simulated and real datasets. Their results shows that the methods that incorporates
functional annotation into the PRS calculation performs better than the standard PRS methods.
In other similar studies, Hu et al also demonstrated that method that incorporates functional
annotations in the calculation of PRS outperforms the general P+T methods [128]. However, these
studies only evaluated basic P+T methods and the result may not reflect the overall performance
of all the P+T methods. By the fact that these studies obtained higher prediction power than our
current study, one reason could be due to the fact that their study settings and our study settings
are completely different. European populations are well characterized with high level of LD
than African populations, and as such, obtaining a higher prediction accuracy is not surprising.
Also, their study had larger sample size than our current study which automatically boosts the
performance of the PRS methods [16].
In other studies, Ge et al. [131] compared the performance of their newly developed method
(PRS-CS) with LDpred, P+T, LDpred-inf, PRS unadjusted and PRS-CS auto. PRS-CS had the best
overall performance in all the comparison criteria. This again highlights the fact that, although
we did not apply the functional PRS methods in our comparison, our conclusion may not change
since the other methods obtained almost similar performance with the PRS-CS, which has been
shown to outperform the functional PRS methods.
Our study shows that the PRS methods have almost similar prediction accuracy when similar
approaches are applied when generating the scores. However, the prediction accuracy of PRS in
Africa populations is still very low and thus necessitates the development of newer algorithms
that may adapt well to all populations, including the Africa populations which bears the greatest
burden of most diseases.
5.6 Application of PRS in Malaria
One of the aim of genetics studies is to understand how the genetic variation contributes to the
phenotypic variations. GWAS has been a tool of choice for more than a decade, and a number of
variants that are associated with complex traits have been identified and replicated. However, the
puzzle that remains for geneticists is that even the strongest genetic associations explain only a
small fraction of the genetic variance and that the genome-wide significant hits explains only a
small variation of the phenotypic variance. In malaria for example, less than half of the genetic
variation is explained by the erythrocyte associated polymorphism, that for a long a long time
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have been hypothesized as the major disorders for malaria susceptibility [47].
Recently, it has been shown that many causal loci whose effect sizes do not reach GWAS
significance threshold explains much of the heritability [15]. In Schizophrenia for example, it
was shown that common variants explain much of the expected heritability than the GWAS
significant hits [78]. The same has been reported in height and subsequent studies, that have
together highlighted the importance of analyzing the small effect SNPs that fail to attain the
genome-wide significant threshold across a wide variety of traits [15, 78]. These findings suggests
that complex traits are driven by the accumulation of weak effects that together drive the disease
susceptibility/protection. In this section, we explore how the non genome-wide significant
variants can predict malaria susceptibility. We use some of the malaria GWAS published data
from African population to estimate the polygenic risk scores using the best predictive polygenic
risk score identified from the previous chapter.
5.6.1 Materials and Methods
We apply the study data and the summary statistics data described in Section 4.2.1 in calculating
the PRS for each of the individual in the study sample from Kenyan population. We chose Kenya
because we obtained the highest number of SNPs from the imputation of summary statistics
by ImpG. The summary statistics had a total of 19,973,364, from which we obtained a total of
7,666,662 common SNPs across the target data and the base data. We then proceeded with the
calculation of PRS by first clumping all the SNPs that were in LD to avoid obtaining an inflated
scores. We applied a clumping P-value of 1.000 and r2 = 0.1 thereby only retaining 381,364 SNPs.
Finally, we calculated PRS at various P-value thresholds using PRSoS, which we identified
in the previous Section 5.2 as the best performing PRS method under P+T PRS methods. Since
PRSoS cannot directly determine the best predicting threshold, we applied PRSice in estimating
the best predictive threshold, which we subsequently applied in generating the score for all
the individuals using PRSoS. The scores were then regressed in a logistic regression with the
phenotypes to determine the relationship between the scores and the phenotypes, and how much
variation on the phenotypes can be explained by the scores.
5.6.2 Results and Discussion
We identified P-value of 0.0246714 as the best predictive threshold value for the generation of
PRS from the Kenyan sample datasets. There were only 1,043 SNPs at this threshold, which we
used in generating the scores.
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To determine the relationship between the scores and the phenotypes, we performed a logistic
regression of the phenotypes and the scores in R. Figure 5.2 shows the results of the logistic
regression.
Figure 5.2: Logistic regression of severe malaria with the individuals Polygenic Risk Scores.
At significant level of α = 0.05, severe malaria was found be to significantly associated with
the scores. The logs of having severe malaria malaria was 2.869, with a unit change in score was
associated with -5.143 change in the odds of having severe malaria. We further calculated the
proportion of variance in the phenotypes that can explained by the scores. For this, we used r2,
which can be calculated by Equation 5.18 from the logistic regression output.
Rˆ2 = 1− Residual Deviance
Null deviance
(5.18)
The scores could only explained 1.28% of the phenotype as determined by the equation.
We then compared the phenotypic variance explained by the GWAS SNPs and that explained
by the PRS scores. For this, we used GCTA to estimate the SNP heritability using the Restricted
Maximum Likelihood (reml) approach. We obtained h2snp = 24.65 of which the GWAS significant
SNPs could explain up-to 10.03% of this variation. By the fact the variation explained by the
GWAS significant SNPs was ten folds higher than the variation explained by the PRS, our study
therefore confirms the low predictive power of PRS methods in non European populations as has
been previously observed [133].
Previously, PRS has been shown to perform best for highly heritable traits like height [15]. For
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example, in Attention Deficit/Hyperactivity Disorder (ADHD) for example, which is known to be
highly heritable ranging from 70-80% (estimated from twin studies), PRS from the largest GWAS
sample (55,374 samples) attained Nagelkerke’s R2 of 5.5% [134]. Similarly, in Autism Spectrum
Disorder (ASD) which has an estimated heritability of 50%, PRS attained a Nagelkerke R2 of 2.5%
[135]. Thus, for malaria, in which the host genes are estimated to accounts for approximately 25%
of the outcome [13] further justifies why we obtained lower PRS scores.
In conclusion, we emphasize the need for better PRS methods that can be generalizable to all
populations and to all traits.
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Chapter 6
Conclusion and Future Work
In conclusion, we evaluated the performance of five imputation methods (BEAGLE4, IMPUTE2,
IMPUTE4, minimac3 and minimac4) in imputing simulated genotypes datasets that mimics
three populations: African, European and admixed populations. We have shown that based on
imputation accuracy, IMPUTE2 should be given more preference when imputing genetic data
from African and admixed populations. However, for the European samples, the imputation
tools gave comparative performance and generally recorded higher accuracy than the African
and admixed samples across all the datasets. Interestingly, we observed that newer versions
of the imputation program recorded higher imputation accuracy that their older versions for
the European datasets. However, for the African and the admixed samples the tools recorded
lower imputation accuracy than their older versions. Our study thus confirms that the current
improvement in imputation programs are no longer focusing on modeling the high genetic
diversity and lower LD of populations like the African but are rather focusing on reducing the
computational complexity and handling large reference panels and samples [60].
We have also shown that more power in association studies can be achieved when imputation
is performed both at raw genotypes level and summary statistics level. As a consequence, we
recommend that if the individual level genotypes data are available, we suggest performing
imputation on the raw genotypes and subsequently on the summary statistics level to maximize
the gains and improve the chance of detecting the associations. Importantly, we have demonstrated
that both imputation via summary statistics and imputation via raw genotypes can be applied to
any population data and have different potentials.
Finally, we evaluated the performance of five PRS (LDpred(p+t), PLINK, PRSoS, PRSice,
PRScS) methods on African populations. We have shown that of the five P+T methods, PRSoS
gives the best prediction accuracy than the other five methods. We have also demonstrated that
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PRS can be applied in predicting the risk of an infectious disease like severe malaria. However,
the prediction rate is very low and may fail distinguish the cases from the controls.
Our future work will be building on the current imputation methods and exploit ways on how
the low LD level and high diversity can be modeled to improve imputation performance. We will
also package all the scripts used in this research in form of a software that can help researchers
select any given imputation tool of their choice and perform imputation on their studies with just
a click.
——————
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Appendix
Relationship Between Minor Allele Frequency and Imputation Accuracy
(a) (b)
(c)
Figure 6.1: Relationship between minor allele frequency and the imputation accuracy at different minor allele frequency bins for 3,000 samples from African population
(a), European population (b) and admixed population (c).
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(a) (b)
(c)
Figure 6.2: Relationship between minor allele frequency and the imputation accuracy at different minor allele frequency bins for 5,000 samples from African population
(a), European population (b) and admixed population (c).
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Meta-analyis
Table 6.1: SNPs with P-value less than 5.0−6 from the meta-analysis of the GWAS data that was imputed with IMPUTE2 prior to performing
association. We considered the SNPs whose either has a Fixed effect P-value (P-FE) or random effect P-Value (P-RE) or binary effect
P-Value (B-PE) or both less than 5.0−6
SNP BP GENE P-FE P-RE P-BE
rs11809587 175128444 TNN 4.68588×06 4.68588×06 1.60938×05
rs1116396 138518857 THSD7B 0.000250746 0.0619837 1.62011×10−06
rs36023051 182180385 LINC00290 0.000845379 0.515529 4.53619×10−06
rs13179872 128149876 FBN2 0.000394406 0.124655 1.85935×10−06
rs9505102 7272006 RREB1 4.96513×06 5.32487×06 2.42561×05
rs9505103 7272069 RREB1 4.72385×06 6.57653×06 2.32246×05
rs17439102 78217826 MAGI2 0.0273898 0.467282 3.22411×10−06
rs112908647 22411637 NEBL 0.000487464 0.154957 1.57679×10−06
rs61744500 131306493 MKI67 2.61506×10−06 0.00812510 2.21348×10−06
rs61859848 131308685 MKI67 3.02920×10−06 0.0106009 2.25074×10−06
rs7098519 131309256 MKI67 3.03723×10−06 0.0106344 2.22169×10−06
rs76175170 131310661 MKI67 2.27526×10−06 0.00720084 2.06792×10−06
rs3837432 205757 SCGB1C1 7.62690×08 7.62690×08 5.04733×07
rs143022364 4617306 OR52K2 0.00217830 0.457040 7.76036×10−08
rs16906303 4830219 OR52R1 2.63212×06 2.63212×06 9.11006×06
rs141935051 4849164 OR52R1 0.00752670 0.169865 6.45535×10−07
Continued on next page
144
Table 6.1 – continued from previous page
SNP BP GENE P-FE P-RE P-BE
rs4290259 5241282 OR51V1 5.37584×10−05 0.0871173 3.20555×10−08
rs12295158 5252794 HBB 2.87576×12 2.87576×12 9.63597×12
rs146674260 5271354 HBG1 0.000130571 0.273425 9.54751×10−07
rs1188152 56423445 KTN1 4.60589×06 6.19290×06 1.55828×05
rs9652671 83365188 CDH13 4.54358×10−06 0.00189990 5.25585×10−06
rs4426340 83365327 CDH13 4.54358×10−06 0.00189990 5.25429×10−06
rs4782771 83366384 CDH13 4.99713×10−06 0.00198876 9.14488×10−06
rs1364298 83367122 CDH13 2.68637×10−06 0.000313878 8.74813×10−06
rs9953918 56005645 NEDD4L 1.10599×10−05 0.0141790 3.94872×10−06
rs4891690 66156630 LOC643542 4.73859×10−06 0.000418924 1.32482×10−05
rs11467740 59815685 LOC284757 2.59144×06 2.59144×06 1.58367×05
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Table 6.2: SNPs with P-value less than 5.0−6 from the meta-analysis of the summary statistics that was imputed by ImpG. We considered the SNPs
whose either the fixed effect P-value (P-FE) or the random effect P-Value (P-RE) or the binary effect P-Value (B-PE) or both was less than
5.0−6
SNP BP GENE P-FE P-RE P-BE
rs7524250 7395704 CAMTA1 0.000317038 0.0525284 5.93874 ×10−07
rs61106622 41967195 SCMH1 1.99278×10−06 1.99278×10−06 1.21338×10−05
rs12750340 75469124 C1orf173 3.37512×10−07 3.37512×10−07 1.51650×10−06
rs74630680 77549114 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.92387×10−06
rs113847753 77553124 ST6GALNAC5 1.15613×10−06 1.15613×10−06 6.38819×10−06
rs77124392 77558424 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.90840×10−06
rs112995621 77559806 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.94666×10−06
rs74741768 77570705 ST6GALNAC5 3.00578×10−06 3.00578×10−06 1.96573×10−05
rs77213925 77579836 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.93160×10−06
rs6661634 77583455 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.96447×10−06
rs111682848 77588467 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.90401×10−06
rs75214944 77589671 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.92406×10−06
rs6686876 77631258 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.93024×10−06
rs145316166 77643355 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.92971×10−06
rs115743261 77645114 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.92288×10−06
rs149115101 77648752 ST6GALNAC5 3.82529×10−07 3.82529×10−07 1.93955×10−06
rs112279760 77669142 ST6GALNAC5 1.21620×10−06 1.21620×10−06 4.56487×10−06
Continued on next page
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rs6695084 77670921 ST6GALNAC5 1.15613×10−06 1.15613×10−06 6.31856×10−06
rs77195732 77676413 PIGK 3.82529×10−07 3.82529×10−07 1.96801×10−06
rs75874098 77682109 PIGK 2.45495×10−06 2.45495×10−06 1.25046×10−05
rs76763532 77692380 PIGK 8.78525×10−07 8.78525×10−07 5.09951×10−06
rs116840202 107904682 NTNG1 4.90251×10−07 4.90251×10−07 2.83702×10−06
rs79377552 107909266 NTNG1 2.16055×10−06 2.16055×10−06 1.09458×10−05
rs116436654 228895380 RHOU 2.34258×10−06 2.30439×10−05 6.50083×10−06
rs6675755 230643364 PGBD5 4.66609×10−06 4.66609×10−06 2.45171×10−05
rs74142924 230652839 PGBD5 4.33178 ×10−06 0.00629534 3.06147×10−06
rs10175893 34253742 LTBP1 0.00540118 0.0845111 1.02977 ×10−07
rs13392908 34258290 LTBP1 0.581972 0.157430 2.80662×10−08
rs76864510 107735018 ST6GAL2 4.64868×10−06 4.64868×10−06 2.81567×10−05
rs75002532 107735966 ST6GAL2 4.64868×10−06 4.64868×10−06 2.81798×10−05
rs13392296 115626894 DPP10 1.65407×10−07 1.65407×10−07 1.15118×10−06
rs10190446 115631727 DPP10 2.87663×10−07 2.87663×10−07 1.92089×10−06
rs76429767 197041698 DNAH7 2.81824×10−06 0.00405477 2.30113 ×10−06
rs73084588 215679061 BARD1 1.90077×10−07 7.88713×10−06 5.92873×10−07
rs60577152 5079600 ITPR1 1.78471×10−08 1.78471×10−08 1.21524×10−07
rs73128543 7036405 GRM7 2.27040×10−06 2.27040×10−06 1.42071×10−05
rs6801701 38868808 SCN10A 2.38864×10−06 2.38864×10−06 9.19238×10−06
Continued on next page
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rs6790184 38869118 SCN10A 2.38864×10−06 2.38864×10−06 9.11948×10−06
rs7644278 38873347 SCN10A 2.38864×10−06 2.38864×10−06 9.07330×10−06
rs113867650 38876770 SCN10A 2.38864×10−06 2.38864×10−06 9.22085×10−06
rs75748123 38881110 SCN10A 2.38864×10−06 2.38864×10−06 9.08303×10−06
rs77023151 38885483 SCN10A 2.38864×10−06 2.38864×10−06 9.01370×10−06
rs78731117 38886084 SCN10A 2.38864×10−06 2.38864×10−06 8.98716×10−06
rs61752574 38888524 SCN10A 2.38864×10−06 2.38864×10−06 8.87832×10−06
rs7629694 38889984 SCN11A 2.38864×10−06 2.38864×10−06 8.94973×10−06
rs74732633 38905642 SCN11A 2.38864×10−06 2.38864×10−06 8.98191×10−06
rs116432495 73943963 PROK2 1.29507×10−07 1.29507×10−07 8.42123×10−07
rs4677367 73944476 PROK2 3.05474×10−06 3.05474×10−06 1.57590×10−05
rs9836886 73944903 PROK2 1.29507×10−07 1.29507×10−07 8.46182×10−07
rs73848574 96923828 EPHA6 4.85690×10−06 5.63185×10−05 1.93300×10−05
rs116320429 152846312 MBNL1 1.00582×10−06 0.000153015 2.04835×10−06
rs76855250 161389107 NMD3 4.32569×10−06 4.32569×10−06 2.58286×10−05
rs12108147 161389695 NMD3 4.32569×10−06 4.32569×10−06 2.59110×10−05
rs16857277 183018012 MCF2L2 2.71795×10−06 7.65299×10−05 8.91227×10−06
rs113612631 188752605 LPP 5.05151×10−08 1.14659×10−05 1.95541×10−07
rs73048763 188764868 LPP 1.88569×10−06 3.32246×10−05 8.91315×10−06
rs141591558 188766723 LPP 1.78999×10−06 0.000206797 7.52236×10−06
Continued on next page
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rs59432893 6905143 PPP2R2C 1.08491×10−06 1.55504×10−06 4.44545×10−06
rs181709025 120611523 FAM170A 5.45164×10−07 5.45164×10−07 2.84954×10−06
rs111660480 125947116 ALDH7A1 2.30888×10−06 2.30888×10−06 1.47310×10−05
rs72798658 133892880 PHF15 3.05338×10−06 0.00175681 4.36424×10−06
rs6859169 133898564 PHF15 3.05338×10−06 0.00175681 4.57340×10−06
rs73790073 137205147 KLHL3 2.86578×10−06 2.86578×10−06 1.83164×10−05
rs79703803 159944078 C1QTNF2 1.80329×10−06 0.000146461 2.80630×10−06
rs80290517 159946431 C1QTNF2 2.81613×10−07 2.81613×10−07 1.40945×10−06
rs78464555 159946738 C1QTNF2 1.80329×10−06 0.000146461 2.78683×10−06
rs111352897 159946930 C1QTNF2 1.80329×10−06 0.000146461 2.84610×10−06
rs11953703 159947961 C1QTNF2 5.85374×10−06 0.00422000 2.01250×10−06
rs74857376 1731779 GMDS 2.67359×10−08 2.67359×10−08 1.93380×10−07
rs114760297 6534810 LY86-AS1 3.24272×10−08 3.24272×10−08 2.23611×10−07
rs56187477 6784474 LY86-AS1 1.64348×10−07 1.64348×10−07 1.02150×10−06
rs116296279 9899074 OFCC1 4.46455×10−06 0.000209404 1.20248×10−05
rs57691377 12087410 HIVEP1 3.68113×10−06 3.68113×10−06 2.14357×10−05
rs77100571 16632468 SOSTDC1 0.000128744 0.0349951 2.56638×10−06
rs143251670 16632910 SOSTDC1 0.000128744 0.0349951 2.66335×10−06
rs75593119 16633320 SOSTDC1 0.000128744 0.0349951 2.69632×10−06
rs149880498 22747569 STEAP1B 3.14753×10−06 3.14753×10−06 1.41378×10−05
Continued on next page
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rs112267225 24321385 STK31 6.92305×10−07 6.07719×10−05 2.87304×10−06
rs59255437 36955957 HERPUD2 2.44041×10−06 2.44041×10−06 1.57665×10−05
rs73455755 127653379 SND1 1.44683×10−06 1.44683×10−06 7.31437×10−06
rs115752921 4116498 CSMD1 9.42619×10−08 9.42619×10−08 5.07114×10−07
rs192443459 3780518 RFX3 1.45649×10−07 1.45649×10−07 9.57891×10−07
rs183731078 3780522 RFX3 8.39562×10−09 8.39562×10−09 4.46842×10−08
rs75676131 14034754 MPDZ 4.74487×10−06 4.74487×10−06 2.73662×10−05
rs71513209 15097606 FREM1 3.59854×10−06 3.59854×10−06 1.48299×10−05
rs7867725 71836731 TJP2 4.29884×10−06 4.29884×10−06 2.29749×10−05
rs118182351 124556385 GSN 1.23932×10−06 8.00207×10−05 3.54347×10−06
rs56101037 53375308 PRKG1 2.25421×10−06 2.25421×10−06 1.46884×10−05
rs114302523 94038690 CPEB3 4.15755×10−06 4.15755×10−06 2.57750×10−05
rs75642696 120233642 FAM204A 1.73933×10−06 0.000379639 4.87215×10−06
rs59104649 129150690 LOC728065 1.13557×10−06 1.13557×10−06 7.33642×10−06
rs78402894 132740552 GLRX3 1.35824×10−06 1.35824×10−06 8.33035×10−06
rs115573913 132758348 GLRX3 1.40427×10−07 1.40427×10−07 9.22566×10−07
rs115084777 132758950 GLRX3 1.40427×10−07 1.40427×10−07 9.16619×10−07
rs79272561 132776876 GLRX3 1.52671×10−07 1.52671×10−07 1.03125×10−06
rs114651413 132777100 GLRX3 1.52671×10−07 1.52671×10−07 1.02525×10−06
rs181397896 132777863 GLRX3 1.52671×10−07 1.52671×10−07 1.01880×10−06
Continued on next page
150
Table 6.2 – continued from previous page
SNP BP GENE P-FE P-RE P-BE
rs76221219 132778067 GLRX3 1.52671×10−07 1.52671×10−07 1.00810×10−06
rs76615755 4262041 NUP98 1.89052×10−06 1.89052×10−06 9.77961×10−06
rs113564957 4329853 NUP98 8.53370×10−07 2.31360×10−05 2.65907×10−06
rs151320773 18795103 LDHA 4.65557×10−06 0.0110859 1.00997×10−05
rs79413720 30805302 FSHB 2.21549×10−06 2.66723×10−05 7.01145×10−06
rs76845508 131001813 ADAMTS15 3.00579×10−06 5.14595×10−05 1.03086×10−05
rs111772662 12974808 DDX47 0.686188 0.159730 1.29569×10−06
rs113092010 12985262 DDX47 0.686188 0.159730 1.35366×10−06
rs35074374 102940479 IGF1 3.20926×10−06 5.96108×10−05 1.48835×10−05
rs61935454 102945889 IGF1 3.20926×10−06 5.96108×10−05 1.46406×10−05
rs73399125 106534519 NUAK1 4.62196×10−06 4.62196×10−06 2.62717×10−05
rs73403013 114424029 RBM19 3.56843×10−06 3.56843×10−06 2.30344×10−05
rs111685758 114426898 RBM19 1.46762×10−08 1.46762×10−08 1.07231×10−07
rs116600250 114428274 RBM19 4.30673×10−07 4.30673×10−07 2.87893×10−06
rs73406439 115255955 TBX3 1.25080×10−07 5.92204×10−06 5.17466×10−07
rs114641714 116114648 TBX3 3.51323×10−06 3.51323×10−06 2.16666×10−05
rs112442238 116123041 TBX3 1.20645×10−06 1.20645×10−06 7.94417×10−06
rs112736328 128188145 LOC440117 1.27092×10−08 1.27092×10−08 9.10594×10−08
rs78970694 128189633 LOC440117 3.09530×10−06 3.09530×10−06 2.01577×10−05
rs143383128 78159614 MYCBP2 7.73814×10−08 7.73814×10−08 5.38455×10−07
Continued on next page
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rs142696984 78161441 MYCBP2 7.73814×10−08 7.73814×10−08 5.48333×10−07
rs143732367 78169793 MYCBP2 3.61018×10−06 3.61018×10−06 2.03343×10−05
rs140567953 78170405 MYCBP2 3.61018×10−06 3.61018×10−06 2.07125×10−05
rs11841309 78172830 MYCBP2 3.61018×10−06 3.61018×10−06 2.03531×10−05
rs4001146 98413112 RAP2A 1.12537×10−06 1.12537×10−06 5.26342×10−06
rs74109414 98416186 RAP2A 1.12537×10−06 1.12537×10−06 5.29779×10−06
rs55666653 98422488 RAP2A 1.12537×10−06 1.12537×10−06 5.19218×10−06
rs75401524 98430416 RAP2A 1.12537×10−06 1.12537×10−06 5.28575×10−06
rs75798371 106625513 LINC00343 1.51209×10−06 1.51209×10−06 1.02336×10−05
rs17115107 44948742 LRFN5 1.56948×10−07 0.000359026 1.80256×10−07
rs111362305 56306095 KTN1 2.09212×10−06 2.09212×10−06 1.25386×10−05
rs147525481 56306157 KTN1 2.09212×10−06 2.09212×10−06 1.26139×10−05
rs113215666 56306969 KTN1 2.09212×10−06 2.09212×10−06 1.25446×10−05
rs112482790 56307284 KTN1 2.96203×10−06 2.96203×10−06 1.84075×10−05
rs16953734 71670073 THAP10 2.94000×10−06 2.94000×10−06 1.94058×10−05
rs148623690 71676470 THAP10 2.92790×10−06 2.92790×10−06 1.77925×10−05
rs139400081 71676639 THAP10 2.94000×10−06 2.94000×10−06 1.93139×10−05
rs115582725 72584085 CELF6 1.81779×10−06 1.81779×10−06 1.18490×10−05
rs114254006 72595098 CELF6 4.59392×10−06 4.59392×10−06 2.94669×10−05
rs60466172 72623423 CELF6 4.59392×10−06 4.59392×10−06 2.92612×10−05
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rs114369106 72625278 CELF6 4.54524×10−07 4.54524×10−07 3.10077×10−06
rs144749334 94395197 CHD2 1.16841×10−06 2.26880×10−05 5.44624×10−06
rs11631144 101339706 ASB7 1.82093×10−06 1.82093×10−06 1.14890×10−05
rs113469389 26047975 HS3ST4 7.78709×10−09 5.64390×10−07 4.60911×10−08
rs113909212 26049230 HS3ST4 3.94124×10−09 1.29372×10−06 2.52969×10−08
rs113604782 26049477 HS3ST4 3.54940×10−08 2.28640×10−06 1.94107×10−07
rs72483415 26060758 HS3ST4 1.38042×10−07 1.38042×10−07 9.77389×10−07
rs41528147 79555485 WWOX 2.33765×10−06 2.33765×10−06 7.11190×10−06
rs7193361 81010343 MAF 1.83405×10−06 3.01221×10−06 5.66695×10−06
rs73264863 86286588 KIAA0513 4.93818×10−06 4.93818×10−06 2.25562×10−05
rs73264899 86294373 KIAA0513 4.93818×10−06 4.93818×10−06 2.26502×10−05
rs8096513 4455491 DLGAP1 1.42909×10−09 1.42909×10−09 1.00692×10−08
rs11876683 58022895 CCBE1 4.69757×10−06 1.94651×10−05 1.38194×10−05
rs75304175 74118555 ZADH2 1.64927×10−06 1.64927×10−06 8.87783×10−06
rs12608785 32796314 TSHZ3 1.89773×10−06 1.89773×10−06 9.81669×10−06
rs144751221 33492965 SLC7A9 4.47657×10−07 4.47657×10−07 2.84429×10−06
rs113748720 33495080 SLC7A9 1.17117×10−07 1.17117×10−07 7.81696×10−07
rs74758634 56755150 ZSCAN5A 2.53343×10−06 2.53343×10−06 1.38622×10−05
rs61484690 5863637 PROKR2 3.71262×10−06 3.71262×10−06 2.47105×10−05
rs77889812 25139678 VSX1 3.43642×10−06 1.03800×10−05 9.57629×10−06
Continued on next page
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rs143241795 40094621 ERG 2.74099×10−06 2.74099×10−06 1.54720×10−05
rs114055013 27526491 CRYBA4 4.37168×10−06 6.36760×10−06 1.55806×10−05
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6.1 Pathway Enrichment Analysis
Table 6.3: Biological pathways that are enriched by the Network of genes identified from IMPUTE2 based
meta-analysis.
Index Name P-value Adjusted P-value Odds
Ratio
Combined
score
African trypanosomiasis 0.00001148 0.003537 67.57 768.55
Malaria 0.00002697 0.004154 51.02 536.77
Nitrogen metabolism 0.02021 1.000 49.02 191.25
Collecting duct acid secretion 0.03192 1.000 30.86 106.31
Prion diseases 0.04119 1.000 23.81 75.94
Glycine, serine and threonine
metabolism
0.04694 1.000 20.83 63.73
Porphyrin and chlorophyll
metabolism
0.04923 1.000 19.84 59.75
Legionellosis 0.06399 1.000 15.15 41.65
Chemokine signaling pathway 0.02160 1.000 8.77 33.64
Antigen processing and presen-
tation
0.08847 1.000 10.82 26.25
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Table 6.4: Biological pathways that are enriched by the Network of genes identified from ImpG based
meta-analysis.
Name P-value Adjusted P-value Odds
Ratio
Combined
score
Glutamatergic synapse 1.311× 10−10 4.038× 10−8 45.48 1035.00
Cocaine addiction 0.00003878 0.005972 45.35 460.66
Amyotrophic lateral sclerosis
(ALS)
0.00004376 0.004492 43.57 437.34
Nicotine addiction 0.001326 0.06808 37.04 245.38
Vasopressin-regulated water re-
absorption
0.001603 0.06172 33.67 216.69
Circadian entrainment 0.0002973 0.02289 22.91 186.05
Arginine biosynthesis 0.02798 0.6630 35.27 126.14
Long-term potentiation 0.003676 0.1132 22.11 123.96
Amphetamine addiction 0.003784 0.1060 21.79 121.50
Protein export 0.03061 0.6734 32.21 112.28
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Table 6.5: Biological pathways that are enriched by the Network of genes identified from both IMPUTE2
and ImpG meta-analysis.
Index Name P-value Adjusted P-value Odds
Ratio
Combined
score
Malaria 0.00001703 0.005244 25.92 284.57
African trypanosomiasis 0.0002144 0.02201 25.74 217.44
Glutamatergic synapse 0.00002975 0.004581 13.92 145.12
Vasopressin-regulated water re-
absorption
0.008484 0.6533 14.43 68.82
Cocaine addiction 0.01044 0.6432 12.96 59.11
Amyotrophic lateral sclerosis
(ALS)
0.01127 0.5788 12.45 55.84
Nitrogen metabolism 0.05224 1.000 18.67 55.12
Arginine biosynthesis 0.06414 1.000 15.12 41.52
Staphylococcus aureus infection 0.01947 0.7495 9.34 36.78
Protein export 0.07003 1.000 13.80 36.70
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